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Marek’s disease (MD) is a T cell lymphoma in chickens and causes high 
mortality and morbidity in productive chickens. Two inbred chicken lines, resistant 
line 63 and susceptible line 72, with the same MHC haplotype, showed distinct disease 
outcomes after MDV infection. The current studies aimed to illustrate the role of 
microRNA (miRNAs) and DNA methylation in MD resistance and susceptibility in 
chickens. First, to ascertain the function of miRNAs, miRNA microarray experiments 
  
were used to identify miRNAs sensitive to MDV infection in the 2 lines. Most 
miRNAs were repressed in line 72 after MDV infection, while their transcription was 
steady in line 63. The miRNA target genes were identified in chickens. Cellular 
miRNA gga-miR-15b and gga-let-7iwere reduced in infected line 72 chickens and 
MD tumors. The downregulation of the two miRNAs increased the expression of 
ATF2 (activating transcription factor 2) and DNMT3a (DNA methyltransferase 3a) in 
infected line 72. These results indicated that miRNAs may play antiviral functions 
through modulating target gene expression. Next, to characterize the role of miRNAs 
in MDV infection, the selected chicken miRNAs were overexpressed in MDV 
infected DF-1 cells. The overexpressions of chicken miRNA gga-miR-15b and gga-
let-7i, by using the retroviral based vector, significantly restricted MDV replications 
in vitro.  MDV oncoprotein was repressed, suggesting that chicken miRNAs may 
limit MDV propagation. Finally, we found deregulation of transcription of DNA 
methyltransfereases (DNMTs) in lines 63 and 72 after MDV infection, which 
coordinated with the methylation alterations in the 2 lines. Infection induced 
differential methylation regions (iDMRs) that were identified through genome-wide 
DNA methylation quantification. Genes overlapping line-specific iDMRs were 
related with pathways of different functions in these two lines, implying the 
involvement of DNA methylation in MD- resistance and susceptibility. An in vitro 
study showed that DNA methylation inhibitor repressed viral spread and viral 
replication. In conclusion, the observed variations of miRNA expression and DNA 
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Chapter 1: Literature Review 
Introduction 
Marek’s disease virus (MDV) is a highly contagious avian oncovirus. MDV 
infection induces Marek’s disease (MD), a neoplastic lymphoproliferative disease in 
domestic chickens, and causes up to 100% mortality rate in productive flock and 
approximately $1 billion losses to the poultry industry in US annually. Although 
vaccines against MD have been developed, vaccination has driven MDV virulence 
upwards. The disadvantages of using vaccines have impelled studies on genetic 
selection of MD resistant chickens. So far, two different MD resistance mechanisms 
have been identified in chickens, either dependent or independent of major 
histocompatibility complex (MHC) haplotype [1]. MHC independent MD resistant 
line 63 and susceptible line 72 have been selected since 1930s; however, the detailed 
molecular basis of MD resistance in these two lines is not clear. 
MDV infection has 4 steps, including early cytolytic stage, latency, late 
cytolytic phase and transformation. The virus targets key components in host immune 
system at each stage of infection [2-6]. Recent studies from MDV and other 
oncovirus revealed that viral infection changed the expression signatures of 
microRNAs (miRNAs) and DNA methylation patterns to induce tumorigenesis [7-9]. 
MiRNAs, a group of short non-coding RNAs, usually negatively regulate target gene 
expression. MiRNAs control numerous biological processes, including development, 





MicroRNA expression profiles differ in healthy and malignant tissues, and some 
miRNAs repress tumor suppressors therefore are defined as oncomirs [9]. DNA 
methylation is an important epigenetic marker for gene silencing, which plays 
important roles in regulating reprogramming, X chromosome inactivation, imprinting 
and tumorigenesis [10, 15, 16].  
Although the critical functions of miRNAs and DNA methylation have been 
delineated in several diseases, little is known about their roles in MD resistance and 
susceptibility, especially at genome-wide scale. Therefore, the characterization of 
miRNA and DNA methylation in MD resistance and susceptibility would provide the 
framework for understanding the genetic and epigenetic effects on disease 
predisposition.    
Marek’s disease resistance in chickens 
Pathogenesis of Marek’s disease virus infection 
Marek’s disease virus (MDV) family consists of three serotypes, MDV1, 
MDV2 and herpesvirus of turkeys (HVT). MDV1 is the only oncogenic serotype that 
causes Marek’s disease (MD). MD is characterized as a T cell lymphoma with serious 
clinical symptoms, such as tumor infiltration, paralysis, and visceral lesions. MDV1 
infection usually results in high mortality rate in high-producing chickens thereby 
causing large economic losses to poultry industry [1]. Vaccines against MD have 
been applied since the 1970s using HTV or attenuated MDV [17]. However, MDV 





nonvaccinated, HVT- and (HVT+SB-1)-vaccinated chickens, MDV was divided into 
4 seroptypes based on their virulence: mild MDV (mMDV), Virulent MDV (vMDV), 
very virulent MDV (vvMDV), and very virulent plus MDV (vv+MDV) [18]. Virulent 
MDV (vMDV) and vvMDV have become predominant and vv+MDV has been also 
isolated from bivalent-vaccinated chickens [1]. The current vaccination provides poor 
protection to chickens. Malignant T cell lymphoma is rapidly developed several 
weeks after MDV infection. New symptoms, for example acute rash, acute brain 
oedema and transient paralysis have been observed in most of susceptible chicken 
population [19].  
MDV genome is linear and double-stranded DNA. The genome size of the 
very virulent strain MDV1 (Md5) is 177,874 bp, with 44.1% GC content, encoding 
103 proteins [20].  According to the genome size and the ability to induce lymphoid 
tumors in chickens, MDV was originally classified as a gamma-herpesvirus, in the 
same subfamily as Epstein-Barr virus (EBV). With the discovery of the DNA 
sequence and genome organization, MDV was finally reclassified as an alpha-
herpesvirus. MDV genome consists of long and short unique regions (UL and US), 
each of which is enclosed by inverted internal and terminal repeats. Two putative 
origins of replication are located at both internal and terminal repeat regions flanking 
the UL region; however, little is known about the initiation and temporal regulation of 
MDV gene expression. The oncogenesis of MDV1 is due to the existence of 
oncogene Meq, located in MDV EcoRI-Q fragment. Meq protein is 339 amino acids 
in length, and carries a basic leucine zipper (bZIP) at N-terminal, structurally 





the expression of both viral and host gene via chromatin remodeling and 
transcriptional regulation in MDV infected birds [21].  
 
Figure 1.1 A schematic representation of the sequential events in lymphocyte 
infected by MDV. MDV infected macrophages carries the virus to immune organs 
(spleen, thymus and bursa), B cells are first infected by MDV, and then the activated 
T cells. Around 7-8 dpi, infected CD4+ T cells enter latency.  In susceptible chickens, 
the latently infected CD4+ T cells are reactivated. Neoplastic transformation and 
proliferation are caused by unknown events, presumably the integration of MDV into 
the host genome. 
 
MD progression includes 4 steps, and each of them is intricately controlled. 
(Figure 1.1) [19]. The initial step of MDV infection in chickens occurs through the 
respiratory tract by inhalation of cell-free virus from the environment. However, the 





yet been identified. Lung-resident macrophages or external macrophages are assumed 
to pick up virus and carry it to lymphoid organs, preferentially in spleen, thymus and 
bursa [22]. In these immune organs, MDV meets the primary target cells: first, B 
lymphocytes and then the activated CD4+ T lymphocytes. In spleen, B cells are 
surrounded by ellipsoid-associated reticular cells (EARCs), where MDV is 
phagocytosed. T cells are activated by the cytolytic infection of B cells. The close 
interaction between T cells and B cells, partially due to immune responses, enhances 
the spread of MDV to T cells, especially activated CD4+ T cells. The expressions of 
viral proteins, such as UL49 and VP22, are essential for cell-to-cell spread of MDV. 
The cytolytic infections of B cells and T cells are semi-productive since no cell-free 
virus but only non-envelope intracellular particles are produced. The rapid viral 
replication in these cells occurs between 3 to 7 days post infection (DPI) [23]. The 
significant feature of the early lytic stage is the sustainable downregulation of MHC I 
molecules on the infected cell surface, which helps virus escape the cytolytic immune 
surveillance by CD8+ T cells [24]. The repressed MHC I representation on the cell 
surface is directly mediated by the expression of viral gene UL49.5, which blocks the 
antigen presentation processing [25, 26].  
At 7-8 DPI or slightly later, MDV infection switches from cytolytic stage to 
latency. During the period of 7 to 14 DPI, MDV undergoes latent phase specifically 
in the target cells. The primary target cells for latency are mainly activated CD4+ T 
cells, along with a minor population of infected B cells. The viral genome is 
maintained in host cells but does not produce infectious progeny viruses. MDV 





in vivo samples, latent infected cells usually coexist with transformed cells. During 
latency, transcription is restricted to latency-associated transcripts (LATs) in MDV. 
The activation of LATs and the repression of other viral genes are associated with the 
epigenetic markers, including DNA methylation, histone acetylation and histone 
methylation [4]. The presence of LATs help MDV to establish latent phase and keep 
the balance between latency and lytic infection in host cells [19, 27]. Some small non-
coding miRNAs located upstream of LATs, are also expressed during latency, and 
may regulate the transition between latent and cytolytic infection [28]. In the latent 
infected cells, MDV genome exists either as the episomal, the isolated from or 
integrated into host chromosomes [29, 30]. The hot spots for viral integration have 
been found. Some evidence suggested that integration sites were different among 
integration events, and were generally near telomeres of the macro- and intermediate- 
chromosomes. Very few copies of viral genome are detected in the non-transformed 
T cells and peripheral blood lymphocytes (PBL) during this phase, i.e. around 5 
copies/cell [31]. In resistant chickens, latent infection persisted at a low level in 
spleen and blood lymphocytes, while the infected PBLs delivered virus to other 
organs and propagate in kidneys, skin and nerves of susceptible chickens [31].    
The reactivation from latency to late cytolytic infection and transformation 
occur around 2-3 weeks post infection in susceptible chickens. Immunosuppression in 
susceptible chickens is usually coincident with late cytolytic infection. MDV 
provokes the reactivation and the transformation by expressing viral oncogene Meq. 
As a transcriptional factor, Meq represses or activates host and viral gene expression 





changes and the growth of cells [32, 33]. Due to its similarity to the Jun/Fos family, 
Meq forms a heterodimer with members of the Jun/Fos family, and binds to AP-1 
sites leading to the activation of oncogenic pathway [34, 35]. In vitro study shows 
that cells overexpressing Meq has strong antiapoptotic properties with the 
downregulation of apoptotic genes Fas and DAP5 [33]. In vivo analyses demonstrate 
that the transcription of some immune responsive genes is time-dependent, and is 
likely activated during the transition from latency to late cytolytic stage [36-38]. For 
example, proto-oncogene Bcl-2 was upregulated in the transformed cells, indicating 
its critical role in the transformation process by MDV [39]. The overexpression of 
CD30, a tumor necrosis factor receptor II family member, was found in MD tumors, 
which was similar to Hodgkin’s lymphoma disease in human. This fact makes 
MDV/Chicken a natural model to study virus-induced lymphoma and Hodgkin’s 
disease [19, 40].  
Immunity to Marek’s disease  
 MDV infection triggers innate and acquired immune responses during 4 
infection stages. Some of the lymphocytes are the effecter cells, eliciting immune 
functions to protect the host from viral infection and disease development, and some 
of them are the targets for the MDV infection, resulting in cell death or malignant 
transformation. The spread of virus and viral replication are impaired by effective 
immune responses. Meanwhile, viral infection induces tumorigenesis and 
immunosuppression, which restricts the efficiency and the effectiveness of immune 





between protections elicited by the immune responses and MD tumors provoked by 
MDV infection.  
 Innate immunity is the first host response to MDV infection. MDV can be 
detected within 2 dpi in the spleen of infected chickens, and the innate immune 
response is stimulated at 3 dpi. Macrophages, natural killer (NK) cells, and other 
factors such as cytokines and chemokines, are rapidly activated after MDV entering 
into cells. The mRNA level of interferon (IFN)-γ is upregulated in splenocytes, which 
triggers MHC class II expression and inhibits MDV replication in vitro and in vivo 
[41, 42]. NK cells are the other population of effecter cells in the MDV induced 
innate immune responses, and provide protection against MDV by producing an 
additional source of IFN-γ in the early cytolytic phase. The increased IFN-γ provokes 
the immune responses by stimulating the transcription of inducible nitric oxide 
synthase (iNOS) and interleukin (IL)-1β in macrophages [43, 44]. Macrophages 
recognize viral antigens via the pattern recognition receptors.  It has been reported 
that the inhibition of MDV replication in vitro is much more effective by the 
macrophages collected from MDV infected chickens than from uninfected chickens 
[45]. Depletion of macrophages or their repressed activity in infected chickens 
increase MD incidence and reduce the survival time [46]. The activated macrophages 
produce soluble mediators such as nitric oxide (NO) through the upregulation of 
iNOS (inducible nitric oxide synthase). The increased level of circulating NO and that 
generated by spleen cells are probably responsible for the reduction of the viral 
replication [38]. In addition, IFN-γ also plays a role in the establishment and 





receptor on the activated T cells which allows the establishment of latency [1]. Some 
undiscovered soluble factors may also contribute to the induction of acquired immune 
responses, especially released by the cytotoxic T lymphocytes (CTLs). 
  CTL is the major component of acquired immunity. Its particular importance 
in immune responses to MDV is to kill infected cells and prevent the development of 
the secondary lytic infection and tumor formation. The acquired immune response is 
detected as early as about 6-7 dpi with the emergence of antibodies and antigen-
specific CTL. MDV genome encodes 103 viral proteins, including structural proteins 
such as glycoproteins gB, gE, and gI. Given the complexity of MDV infection, it is 
reasonable that antibodies are generated in response to MDV infection. Sera from 
MDV vaccinated birds provide the protection to chickens, which decreases early 
mortality rate [47]. Cell lines overexpressing viral antigen pp38, meq and gB were 
lysed by MDV vaccinated splenocytes, but cells overexpressing other viral genes 
were not recognized [48]. Among the purified MDV antibodies, gB and gE 
homologous antibodies were able to neutralize herpes simplex virus [49, 50]. The 
maternal antibodies transmitted from vaccinated hens to their offsprings decrease the 
severity of MD regarding mortality, morbidity and tumor formation. In  contrast, it 
has been observed that the presence of maternal antibodies has deleterious influences 
on the vaccine efficiency [1]. Depletion of CD8+ or T cell receptor (TCR) alpha beta 
1+ cells significantly reduce the amount of MDV released from the cells [48]. It is 
likely that CTL is essential for preventing the reactivation and transformation of virus 





Marek’s disease resistance and susceptibility  
 MD resistance is observed in natural chicken populations, and numerous 
studies have used different populations to estimate the heritability of MD resistance in 
chickens. Heritability estimates range from 0.1 to 0.61 [51, 52]. The inconsistent 
estimation of MD resistance heritability is likely due to different populations, chicken 
lines, ages, virus strains and routes of MDV exposure. These studies also reported 
negative correlations between MD incidence and egg production or egg weights, and 
positive correlation between MD incidence and age of the first egg or egg gravity. 
Like other complex traits, it is a challenge to identify exact genes that control MD 
resistance or susceptibility and balance the MD resistance and production traits. 
 MD resistance is classified as either MHC dependent or MHC independent. 
MHC (B system of haplotype) gene is the determining factor for MD resistance [53]. 
Cell-mediated or humoral immune responses are thought to contribute to MHC linked 
MD resistance. The genomic structure of the MHC locus is shown in Figure 1.2. MD 
resistance is attributed to genes located in BF/BL region of the B locus [54]. The most 
famous MHC associated resistant and susceptible chickens are the N and P chicken 
lines, with B21 and B19 haplotypes, respectively. B21 haplotype shows the strongest 
MD resistance regardless of the strains or genetic origins (white leghorn, broiler or 
red jungle fowl). Besides B21 and B19, haplotypes such as B1, B4/B13, B5, B12 and B15, 
are related with moderate susceptibility, and haplotypes B2, B6 and B14 shows the 
moderate resistance. Chickens of different haplotypes, when crossed, produce MHC 





incidence); chickens with B2/B13 and B2/B14 hapotypes were moderately susceptible 
(42-43% MD incidence) [55]. Therefore, crossing chickens with different MHC 
hapotypes can improve MD resistance. However, MHC associated MD resistance 
cannot fully explain the differences in disease incidence observed in commercial 
flocks [1].  
 
Figure 1.2 A schematic of chicken MHC locus. Open boxes denote the genes with 
gene names above the line (transcription from left to right) or names below the line 
(transcription from right to left). 
 
Despite the contribution of MHC haplotpyes, it is clear that other genes also 
have strong influences on the overall level of MD resistance. Chicken line 6 and line 
7 are MD resistant and susceptible inbred chickens developed by the Avian Disease 
and Oncology Laboratory (ADOL) [56]. These two lines share the same B2 MHC 
haplotype, showing moderate resistance to MD. Studies showed that about 99% of 
line 72 chickens generated tumors after infection with vv+MDV whereas almost none 
of line 63 chickens developed MD. MD phenotypic difference between these two 
lines results from differences in MDV replication and spread as well as the way of 
infected cells being transformed in hosts. MDV replicated faster in line 6 than in line 
7, and the different viral load was detected at 10 dpi [31]. Spleen cells from line 7 had 





[57]. The transplantation of thymus from line 7 to line 6 raised the level of 
susceptibility in the line 6 recipient chickens, and grafting of line 6 thymus to line 7 
did not diminish the susceptibility of the recipients [58]. To investigate the 
mechanism of non-MHC associated MD resistance, a number of approaches were 
applied to compare the difference between line 6 and line 7 chickens. Quantitative 
trait loci (QTL) analysis identified genes or regions outside MHC locus were linked 
with MD phenotypic variations. The most striking association was between 
polymorphisms in growth hormone (GH) and MD resistance [59]. Genomic 
approaches, such as microarray, also uncovered several non-MHC genes that were 
related to MD resistance and susceptibility [37, 38, 60-64]. Cytokines, some immune 
related genes and unknown genes showed significant transcriptional variations 
between line 6 and line 7 before and after MDV infection. The expression of IL-6 and 
IL-18 was significantly higher in splenocytes from infected line 7 than those from line 
6. The higher transcriptional level of IL-2 in line 7 rather than in line 6 was only 
observed at 21 dpi. IFN-γ mRNA was expressed by all infected chickens from 3 to 10 
dpi, with the increased MDV loads. No significant differences were observed in 
transcription of IL-8 and IL-15 [65]. Genes, such as T cell receptor beta chain (TCR-
β), MHC class I and immunologically light chain had two-fold or greater differences 
in expression in two lines [36]. These results suggested that non-MHC genes may 
play essential roles in MDV driven immune responses, which causes lymphoma in 
the susceptible chickens but maintains latency in the resistant birds. However, the 
important question about how these genes are regulated to modulate MD resistance 





MicroRNAs in Animal Health 
MicroRNAs Biogenesis 
MicroRNAs (miRNAs) are a newly identified class of single-stranded RNA 
(ssRNA) molecules ~22 nucleotides in length. They do not encode proteins but 
regulate gene expression at the post-transcriptional level. The biogenesis of miRNAs 
is well studied. Basically, miRNAs are generated by RNA endonuclease cleavage of 
endogenous transcripts with a stem-loop structure. MiRNA genes are transcribed by 
RNA polymerase II (PolII) or polymerase III (PolIII) into long primary microRNAs 
(pri-miRNAs) in the nucleus [66]. Same as other PolII transcripts, pri-miRNAs are 
also capped with 7-methylguanosine at the 5’ UTR and polyadenylated at their 3’ 
end, which are the marks of PolII transcription. Lee et al. reported that pri-miRNA 
levels decreased in cells treated with PolII inhibitor α-amanitin, and the 
immunoprecipitation analysis demonstrated that PolII physically interacted with 
miRNA promoters [67]. Pri-miRNAs are trimmed by a microprocessor complex 
formed by RNase III Drosha and GGCR8/Pasha to precursor microRNAs (pre-
miRNAs). Typical pri-miRNAs consist of approximately 33 bp stem terminal and 
ssRNA flanking sequences at both up- and down-stream of the loop. The flanking 
ssRNAs of pri-miRNAs are essential for the processing, since the flanking regions 
directly and specifically interact with GGCR8. The cleavage sites depend on the 
distance from the ssRNA-stem junction [68]. Upon nuclear cleavage by Drosha, one 
end of the mature miRNA is defined [69]. Pri-miRNAs can be modified by ADAR 





adenosine (A) to inosine (I). It has been reported that some miRNAs such as mir-22 
[70], mir-142, mir-143 and mir-151[71] as well as mir-99 [72] are edited by ADAR1 
and ADAR2. A-to-I editing in pri-mir-142 is likely to interfere with miRNA 
processing, specially the cleavage function of Drosha, and results in the reduction of 
mature mir-142 [71].  The processing for some intron-derived miRNAs occurs in a 
Drosha independent manner, and splicing replaces Drosha cleavage, which indicated 
that these pre-miRNAs are released from their host transcripts after splicing [66]. 
After transcription and processing, pre-miRNAs are formed, around 70 nt in length 
with the imperfect hairpin structure, and exported to the cytoplasm by nuclear 
transporter receptor complex exportin-5-RanGTP [73] (Figure 1.3.). 
Inside the cytoplasm, pre-miRNAs are further cut by another RNase III Dicer 
to generate ~22 nt miRNA:miRNA*duplex. Dicer was first identified to play an 
important role in the RNAi pathway, and performs a similar activity in miRNA 
synthesis. It was proposed that Dicer had particular affinity to 5’ phosphate and 3’ 
overhang at the base of hairpin precursors, and cut pri-miRNA to form an imperfect 
double-stranded RNA (miRNA:miRNA*) [69]. The double-stranded RNA (dsRNA) 
duplex contains both the mature miRNA strand called the guide strand and the 
complementary fragment from the opposing arm, called miRNA* or the passenger 
strand. In principle, two different mature miRNA could be produced from the dsRNA 
duplex, and load on the RNA-induced silencing complex (RISC). However, RISC 
incorporation rate of miRNA versus miRNA* is roughly 100-fold due to the different 
stabilities of the 5’ ends [74]. MiRNA and miRNA* selection is based on the 





determine the duplex unwinding, molecule’s longevity, and function [75]. The 
passenger strand, with a more stable 5’ end compared to the miRNA guide strand, is 
usually released and decayed rapidly, but it is not always the byproduct of miRNA 
synthesis. It also can associate with RISC and function as the guide strand [76-78]. 
The guide strand (miRNA) with a relatively less stable 5’ end preferentially loads into 
RISC to control target gene expression [76, 79] (Figure 1.3).  
 
Figure 1.3. MicroRNA Biogenesis. Pri-miRNA is transcribed by Pol II from the 
genome. Drosha and other processor proteins cleave the pri-miRNA into ~ 70 nt long 
pre-miRNA. The hairpin structured pre-miRNA is transported from nucleus to 
cytoplasm in a RanGTP/Exportin dependent manner. In the cytoplasm, pre-miRNA is 
further cut by Dicer to release stem-loop structured mature miRNA (~ 22 nt).  The 
miRNA is incorporated into an RNA-induced silencing complex, and represses gene 
expression by translational inhibition, mRNA destabilization or mRNA degradation.  
 





pathway to interact with messenger RNAs (mRNAs) (Figure 1.3). Argonaute (AGO) 
proteins are the core components in RISC, and are an evolutionarily conserved 
protein family. Proteins from this family contain PIWI domain and PAZ domain, 
providing endonucleolytic RNase H activity, which implicates AGO as the slicer 
[80]. Among AGO proteins, the deletion of AGO2 reduces miRNA expression and 
activity, suggesting that AGO2 serves as the regulator to coordinate miRNA 
biogenesis and function [81]. MiRNA target recognition largely depends on sequence 
complementarity. The seed sequence of miRNAs refers to nucleotides 2~8 that 
perfectly match to mRNA, and is crucial for target recognition. The less important 3’ 
end of miRNA also contributes to miRNA-mRNA interaction, particularly when the 
seed sequence match is weak [82]. Most miRNA target prediction methods rely on 
the base pairing information of the seed sequence to mRNA interacting sites. 
Meanwhile, it has been found that mRNA fragments that pair to miRNAs and seed 
regions in miRNAs are conserved among different species, and now are a vital 
criterion for bioinformatic prediction of miRNA targets [83, 84].  
Post-transcriptional repression by miRNAs 
MiRNAs usually reduce gene expression at post-transcriptional level. Several 
models have been proposed to explain miRNA-induced gene repression [76]. 
MiRNAs direct mRNA destruction when miRNAs perfectly matching to mRNAs, 
which is common in plants. The molecular basis of the repression in animals is less 
clear. Generally, early studies reported that miRNAs negatively regulated gene 





imcomplementary match to 3’ UTR of target mRNA. It is a rare phenomenon in 
animal kingdom that miRNA causes mRNA degradation via perfectly base-pairing. 
Mouse mir-196 was the first example of an animal miRNA resulting in target mRNA 
cleavage [85]. However, some new evidence has shown that, like in plants, miRNA 
also reduces mRNA levels by promoting mRNA deadenylation, which is followed by 
decapping and rapid degradation of mRNA [86, 87]. An alternative possibility is 
miRNA-dependent mRNA accumulation into processing bodies (P-bodies) for 
translation repression [76, 78, 88]. Recently, miRNA induced gene expression has 
been reported. In quiescent cells, AU-rich elements (ARE) in the 3’ UTR of TNF 
recruited AGO and fragile X mental retardation-related protein 1 (FXR1), which are 
associated with the upregulation of TNFα expression by microRNA mir-369-3  [89]. 
Another example was that miRNA let-7i was shown to activate translation on cell 
cycle arrest by serum starvation, but it inhibited translation in the proliferative cells 
[90].  
MiRNA recognition sites are not restricted to the 3’ UTR of mRNA. In vitro 
studies suggested that 5’ UTR miRNA-binding sites were as effective for translation 
inhibition as those in the 3’UTR [91]. A recent study showed that human mir-148 
decreased DNA methyltransferase 3b (DNMT3b) expression through the interaction 
with the coding region. Dnmt3b has 4 different transcript variants, and this miRNA 
binding region is conserved and present among the other 3 DNMT3b splice variants, 
but absent in DNMT3b3 transcript [92]. Due to the lack of a putative binding site, 
DNMT3b3 was resistant to mir-148-mediated translation inhibition. This discovery 





challenge the current miRNA target searching algorithms since most tools confine the 
search to the 3’ UTR regions [93], but ignore the possibility that miRNA target sites 
may be in other regions of mRNA sequence.  
Functions of MicroRNAs in immunology 
So far, miRNA control has emerged as essential in regulation of animal 
development, metabolism, homeostasis, and especially the immune system. 
Mammalian immune cells are generated from hematopoietic stem cells (HSCs), 
including a series of ordered events of lineage commitment, differentiation, 
proliferation and migration [94]. Chen et al. reported HSC specific miRNAs, and 
their dynamic expression was associated with cell commitment [95]. For example, 
mir-181 was involved in the differentiation of hematopoietic cells to B lymphocytes. 
Its expression was detectable in undifferentiated progenitor cells, and upregulated in 
B lymphocytes. The ectopic expression of mir-181 in progenitor cells increases the 
proportion of B-lineage cells both in vitro and in vivo [95]. The depletion of Dicer in 
the early stage of B cell development almost completely obstructs the transition from 
progenitor B (pro-B) to precursor B (pre-B) cells [96]. Gene expression analysis in 
Dicer-deficient and sufficient pro-B cells revealed that Bim and Pten are upregulated 
in Dicer-deficient pro-B cells and contain miRNA seed motifs in their 3’ UTRs. Six 
miRNAs (miR-17, mir-18a, mir-19a, mir-20a, mir-19b and mir-92) encoded by mir-
17~92 were identified to modulate the expression of the proapoptotic molecule Bim 
and the tumor suppressor Pten. B cell development was also impaired in mir-17~92 





demonstrate that miRNAs are an important modulator in B lymphocyte development.  
In addition to B cell development, recent studies have also elucidated that 
miRNAs  were linked to T cell selection and differentiation [98]. MiRNA expression 
patterns were similar among naïve, effector and memory T cells while several 
miRNAs showed significant expression variations in different cell populations. 
Compared to the naïve cells, most of miRNAs were downregulated in the effector 
cells, and tended to be upregulated in the memory cells [99]. MiRNA mir-181 plays 
important function in T cell function. The increasing mir-181 expression augmented 
mature T cell sensitivity to peptide antigens and downregulated multiple phosphatases 
to reduce T cell receptor signaling threshold [100]. Two essential components in TCR 
signaling, Lck and ZAP70, were inactivated by protein tyrosine phosphatase PTPN22, 
whose expression was repressed by mir-181. Overexpression of mir-181 increased 
ERK1/2 activity by inhibiting dual specific phosphatases DUSP5 and DUSP6. 
Thymocytes treated with the antagonist of mir-181 decreased ERK1/2 activity and 
disrupted positive selection. T cell tolerance is mediated through Dicer-dependent 
miRNA pathway. In disease-free mice, the Dicer-deficiency repressed the regulatory 
T cells (Treg) and homeostatic potential of Treg was weakened. In mice with 
autoimmune disease, Dicer-deficiency lead to the complete loss of suppressive 
function of Treg [101].    
Cancer is a complex disease, associated with the aberrant expression of coding 
and non-coding RNAs, and it has become evident that miRNAs are involved in 
tumorigenesis [102]. To address the contribution of miRNAs to cancer, Volinia et al. 





tumors [103]. Twenty one miRNAs showed commonly differential expression in at 
least 3 types of tumors. At the top of the list was mir-21, which was upregulated in all 
six types of cancers, and directly targeted tumor suppressor PTEN [104]. Moreover, 
the depletion of mir-21 stimulated the activation of caspase dependent apoptosis and 
resulted in enhanced cell death, indicating the role of mir-21 as an anti-apoptotic 
factor. Taken together, the evidence pertaining to abnormal expression of mir-21 in 
tumor samples implies it may be involved in the malignant phenotype via diminishing 
apoptosis-related gene expression [105]. The miRNA let-7 family is the first 
identified group of miRNAs that regulate oncogene expression [106]. Members of the 
let-7 family also direct oncogene RAS expression in both C. elegans and humans [76, 
107]. Recent studies showed that the reporter constructs that contained RAS 3’UTR 
were downregulated by let-7, and let-7 inhibitors could reverse this suppression [76, 
107]. In addition, it has been reported that let-7 expression is low in lung tumor 
tissues compared to normal and adjacent tissues, and Ras oncoprotein is highly 
expressed in tumors, suggesting the potential mechanism of let-7 in cancer [106]. The 
repression of let-7 is a unique phenomenon observed in lung cancer development. 
MiRNA analysis in lung cancer revealed that let-7 was dramatically reduced, and 
other 167 miRNAs were not remarkably changed. However, the function of miRNAs 
as tumor suppressors or oncogenes is not absolute. For example, the mir-17~92 
cluster was implicated as oncogenes in B cell lymphoma which coordinated with 
MYC to block the apoptosis [108]. The another study using human B cell line showed 
that mir-17-5p and mir-20a, from miRNA-17~92 cluster, decreased the translation of 





their role as tumor suppressors [109, 110]. The expressions of both mir-17~92 and 
E2F1 were elevated by MYC at transcription level, forming a feedback loop, and 
allowing the accurate and robust control of cell proliferative signals. 
The defensive role of miRNAs in viral infections was uncovered recently by 
several studies. In Arabidopsis, the dicer mutants sufficiently elicited the 
susceptibility to single strand RNA virus and the accumulation of viral miRNAs 
[111]. A similar phenomenon was observed in vertebrates. Mice with inactivated 
Dicer became hypersusceptible to vesicular stomatitis virus infection following the 
downregulation of two cellular miRNAs mir-24 and mir-93 [112].  In another study, 
cellular miRNAs were induced by interferon-β to repress hepatitis C virus (HCV) 
replication through targeting HCV genomes [113]. In humans, miRNA hsa-mir-32 
limited the proliferation of primate foamy virus type 1 (PFV-1) in human cells [114]. 
Several human miRNAs were upregulated after HIV infection which targeted the 
viral genome to inhibit HIV replication [115]. The discovery of antiviral functions of 
miRNAs adds new information to the host-virus interaction, however, it is far from 
complete. Further elucidation of miRNA functions during infection of particular 
viruses is required.  
Chicken and MDV microRNAs 
As mentioned above, miRNAs are conserved among many animal species, but 
miRNAs from viruses do not show sequence similarity between each other, even 
within in the same family [116]. The identification of miRNAs in the Epstein-Barr 





miRNAs [117]. Presently, 20 viruses have been found to encode at least one 
miRNAs, and most of them are from herpesviruses [118]. By using the MDV 
transformed T cell line and MDV infected chicken embryo fibroblasts (CEF), 26 
mature MDV-1 miRNA sequences and 14 pre-miRNA sequences have been 
identified [119, 120]. Most of MDV miRNAs are clustered together, at the terminal or 
internal repeat regions of UL and US. Five of  MDV miRNAs have been mapped to 
LAT region, and are antisense to viral immediate-early gene ICP4, suggesting that 
viral miRNAs may regulate the switch to latent stage in MDV infection [120].  
MDV1-miR-M4, the ortholog of gga-mir-155, shares targets with gga-mir-155. The 
deletion of this viral miRNA or mutations in its seed sequence inhibits the induction 
of lymphoma [121, 122]. MDV1-miR-M4 was found to inhibit the expression of host 
genes, such as c-Myb and C/EBP, as well as viral genes UL28 and UL32. MDV1-miR-
M3 suppresses apoptosis by directly downregulating Smad, a key component in 
TGFβ pathway [123, 124]. These results demonstrated that viral-encoded miRNAs 
plays a direct role in inducing tumors in vivo.  
Recently, chicken miRNAs were profiled in different tissues and cells during 
development [119, 125, 126]. The current version of the miRNA database (miRbase 
version 18 http://www.mirbase.org/) contains 499 chicken miRNAs, including 
bioinformatically predicted and experimentally confirmed miRNAs. By using deep 
sequencing technique, Burnside et al. identified chicken miRNAs in CEF, and also 
compared miRNA expression between MDV infected CEF and uninfected CEF. 
MDV infection did not significantly disrupt miRNA biosynthesis, and the 





CEF. Several chicken miRNAs showed lower expression levels in the infected CEF 
than in MDV free CEF, including let-7, mir-199a-1 and mir-26a, implying that 
miRNAs probably play regulatory roles after MDV infection [119]. Other studies 
have also reported dynamic expression patterns of chicken miRNAs in the 
development of the immune organs, such as embryonic spleen and bursa. These 
results indicate that miRNAs may be the key regulators in immune system 
development and maturation [126]. For example, gga-mir-10a was highly expressed 
during the development of spleen in embryonic chickens, and regulated the 
expression of genes in Ras signaling [127]. It also has been proven that c-Myb, a gene 
controlling hematopoiesis and tumorigenesis, was the target of gga-mir-150 [128]. 
The function of miRNAs in MDV infection has been revealed. In MDV-transformed 
cell line MSB-1, gga-mir-221 and gga-mir-222 were significantly upregulated. This 
upregulation directly contributed to the repression of cell cycle regulator p27Kip1 
through the interaction between miRNAs and the 3’ UTR of the gene. Inhibition of 
these two miRNAs partially alleviated the miRNA mediated suppression. These data 
suggested that MDV is able to take advantage of the miRNA pathway for T cell 
lymphoma development and progression through controlling cell cycle regulators in 
vitro [129]. However, the relationship between miRNAs and MDV infection in vivo 






The regulation of DNA methylation 
 DNA methylation is an epigenetic process of transferring the methyl group 
from the methyl donor S-adenosylmethionine (SAM) to the 5 position of cytosine. 
This process is catalyzed by DNA methyltransferases (DNMTs), which include 3 
major members, DNMT1, DNMT3a and DNMT3b. The task of DNMT1 is to 
maintain DNA methylation during cell division when DNA is duplicated. DNMT3a 
and DNMT3b establish de novo methylation, which introduce new 5’-methylcytosine 
(5mC) to the genomic positions that were not previously methylated. Methylation 
primarily occurs at CG dinucleotide (CpG) sites in mammals and other vertebrates. 
Non CG methylation is observed in plants, and recently it was  discovered in human 
embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells, but the 
enzymes that catalyze the non CG methylation have not yet been identified in 
mammals [130]. 
 Methylation is not equally distributed within the genome. In mammals, about 
70% of all CpG sites are methylated, including repetitive DNA, intergenic non-
repetitive DNA and exons of genes, while genome regions called CpG islands (CGIs) 
are one exception [131]. CGI is defined as a region at least 200 bp in length, 
containing a (C+G) content greater than 50%, and that has an observed-to-expected 
CpG ratio greater than 60% [132]. CGI is one of the markers for gene promoters, and 
about 60% of human genes have CGIs in the promoter regions. Two possible 





other DNA binding proteins are recruited to CGIs, which exclude the binding of 
DNMTs [133]. Second, DNA demethylation pathways may remove the methyl group 
from the methylated CGIs. It has been reported that both 5’-hydroxymethylcytosine 
(5hmC), the intermediate of demethylation, and TET1, the enzyme responsible for 
hydroxymethylation of 5mC, were enriched in the CG-rich promoters in the ESC, 
suggesting that the methylation free zone at CGIs was established from the early 
developmental stage [134].  
Two mechanisms, active and passive processes, are involved in DNA 
demethylation at a genome-wide scale or at specific loci. Passive demethylation 
occurs through DNMTs. If the activities of DNMTs are inhibited, methylation is 
reduced after several rounds of cell divisions, due to the loss of methylation on the 
newly synthesized strand. Hydroxymethylation by TET family, glycosylation and 
DNA repair pathways, as well as other DNA binding proteins are involved in the 
active demethylation [135]. Methylcytosine is oxidized by Tet to 5hmC, which can be 
converted to T by deamination and then replaced by C via a base excision repair 
pathway.  Hydroxymethylcytosine can be further converted to 5’formylcytosine (5fC) 
and 5’carboxylcytosine (5caC), and decarboxylase and DNA repair mechanisms can 






Figure 1.4. Proposed mechanisms for DNA demethylation. C is methylated to 
5mC by DNMTs. Demethylation is achieved through the oxidation of 5mC by Tet, 
DNA glycosylase, decarboxylase and DNA repair pathways. 5hmC, 5fC and 5caC are 
all intermediates of demethylation.  
  
DNA methylation can also be influenced by its chromatin structure. For 
example, the lack of  methylation on histone 3 lysine 9 (H3K9) causes the loss of 
DNA methylation in the heterochromatic repeat region [136]. By applying a newly 
developed method, bisulfite sequencing of immunoprecipitated DNA (BisCHiP-seq), 
the crosstalk between DNA methylation and histone modifications was directly 
studied. The results showed that DNA methylation and histone 3 lysine 27 
trimethylation (H3K27me3) were compatible at most genome regions except at the 





global H3K27me3 pattern, and depletion of histone lysine methyltransferase (HKMT) 
also caused the loss of DNA methylation at specific loci [137, 138].  Plants and fungi 
exploit RNA interference (RNAi) pathway to direct DNA methylation at transposons 
and repetitive DNA regions. A similar phenomenon was observed in cultured 
mammalian cells, but the mechanism was not elucidated [139]. Environmental 
stimulation, such as nutrients, triggers DNA methylation alterations. The methyl 
supplement in the diet of female adult mice changed the DNA methylation patterns in 
their offsprings. Adult females fed with methyl donor tended to have offsprings with 
brown coats, which resulted from DNA methylation at the coat color gene, agouti 
[140, 141]. Prenatal exposure to the endocrine disrupters changed the DNA 
methylation pattern in the germ line, and had a transgenerational influence on the 
reproduction system in offsprings [142].  
The biological functions of DNA methylation 
 DNA methylation at promoter regions is a repressive mark for gene 
expression. Methylated CpGs recruit methyl-binding proteins, which mediate the 
binding of repressor complex to promoters and inactivate gene transcription. Methyl 
binding protein MeCP2 interacts with methylated CpGs and attracts corepressors, 
polycomb group proteins, HKMT or histone deacetylase (HDAC). Some evidence has 
suggested that MeCP2 is able to directly block transcription by the contact with the 
transcription initiation complex [143]. Methylated CpGs also interfere with the 
interaction between transcription factors and gene promoters. In the imprinting gene 





activation of Igf2. In the paternal copy, CTCF binding site is methylated, preventing 
the interaction between CTCF and the enhancer, which silences the paternal gene 
expression [144].  
 DNA methylation is involved in numerous biological processes, including 
genomic imprinting, X chromosome inactivation, germ cell reprogramming, immune 
responses and carcinogenesis [145]. Several studies have discovered that DNA 
methylation regulates cell differentiation and maintained the cell type identity. 
Differential methylation regions (DMRs) were found in mouse ESCs before and after 
differentiation as well as in sperm and somatic tissues, indicating that DNA 
methylation was altered in a specific way according to the cell lineage, tissue type 
and during cell differentiation [16]. Bibikova et al. compared genome-wide DNA 
methylation profiles between human ESCs and 24 other cell types, including cells 
derived from different cancers and normal human tissues [146].  The results 
demonstrate that the DNA methylation signatures clearly distinguish human ESCs 
from different cell types, and could be markers for the cell differentiation. They also 
suggest that DNA methylation contributes to maintenance of the pluripotency in the 
ESCs, and is engaged in the cell differentiation process. In another study, DNA 
methylation variations occur during the development of B cells. In B cell early 
development stage, Pax5 was activated due to the hypomethylation at its promoters; 
and later on this region was remethylated and the transcription was turned off during 
B cell maturation [147].    
 It is also clear that DNA methylation plays a role in immune disorders, such 





causes T-cell autoreactivity in vitro and autoimmunity in vivo [148]. DNA 
methylation discordance between monozygotic twins is associated with systemic 
lupus erythematosus (SLE), with the loss of methylation in CD4+ T cells from SLE 
patients [149]. Hypomethylation reduced the specificity of antigen presentation and 
induced T cell proliferation and activation. From genome-wide analysis, about 49 
genes were found to be differentially methylated between healthy and sick twins. 
These genes are enriched in gene ontology (GO) categories in relevant to defense 
response, cell activation and cytokine production.  
 DNA methylation is a dynamic process throughout life time [150]. After 
fertilization, methylation on the prenatal and maternal DNA in a zygote is eased, and 
then the pattern is rebuilt following implantation by de novo DNMTs, especially 
DNMT3b [151]. During remethylation, genes expressed in the germ line stage are 
switched off due to the hypermethylation, and promoters of lineage-specific genes are 
demethylated until terminal differentiation. The expression of pluripotency associated 
genes, such as Oct4, are controlled by DNA demethylation and remethylation during 
reprogramming. Global methylation alterations are also observed during the aging 
process. The DNA methylation levels are reduced in human aging-related diseases. 
From the 8-year observation of people from 55- to 92-years-old, a significantly 
declined DNA methylation level was observed in repetitive DNA, Alu elements 
[152]. The loss of DNA methylation in Alu elements was linear and time-dependent. 
DNA hypomethylation in another DNA repeat element, long interspersed nuclear 
element 1 (LINE-1), also demonstrated the weaker correlation with aging. Therefore, 





characteristic of aging.               
DNA methylation and miRNAs in diseases 
Cancer is both an epigenetic and a genetic disease, and DNA methylation 
variations in cancer are recognized, including the hypomethylation at the promoters 
of oncogenes and the hypermethylation of the tumor repressor genes [12]. Tumor 
development is associated with the gain of DNA methylation at CGIs, and the loss of 
imprinting and DNA methylation fluctuations at repetitive genomic regions [153].  
Infective agents belong to the environmental stimulus, and influence DNA 
methylation patterns in the hosts as well as in pathogens. The manipulation of host 
methylome by viruses is achieved by the interaction between viral proteins and DNA 
methylation modifiers. Several viral oncoproteins, such as E1A from Adenovirus, 
LMP1 from EBV, LANA from KSHV, and HBx from Hepatitis B virus as well as E7 
from Papillomavirus, have been discovered to interact with DNMTs, which 
consequently induce oncogenic cell signaling [8]. Infection with bacteria C. rectus 
promoted the methylation level of Igf2 in murine placenta and inhibited the gene 
expression [154]. Herpes simplex virus infection causes hypomethylation in the host 
cells although the mechanism is unclear. EBV infection in human B cells inhibits the 
expression of apoptotic Bcl-2 family member Bim, which is rescued by a methylation 
inhibitor. The promoter region of Bim is highly methylated in all EBV positive cells, 
and unmethylated in EBV negative cells [155]. DNA methylation causes chronic 
infection by silenceing viral gene transcription to escape from the host immunity. In 





in hosts, and is associated with the immunosuppression and tumors. DNA 
methylation controls the switch from latency to lytic phase in EBV infected human B 
cells. Viral gene BZLF1, a transactivator, preferentially binds to methylated CpGs, 
and induces the productive life cycle of EBV from latency. In the newly infected 
cells, the unmethylated viral DNA prevents the interaction from BZLF1 and 
establishes the non-productive infection [156]. With the progresses of the infection, 
EBV genome becomes methylated, and BZLF interacts with the methylated 
promoters of EBV genes and reactivates the EBV. MDV infection also changes 
methylation patterns of several genes in the chicken spleens probably via regulating 
the expression of DNMTs [3]. Moreover, DNA methylation is present in some 
intergenic regions in MDV genome but reduced at the region containing LATs and 
some active genes [4].  
Similar to coding genes, miRNA expression is directed by DNA methylation 
at promter CpGs [157, 158]. Han et al. (2007) compared miRNA expression and 
miRNA gene methylation in colon cancer cell line HCT 116 and its derivative, 
DNMT1 and DNMT3b double knockout cell lines (DKO) [159]. They found that the 
majority of CpG islands upstream of miRNA genes were hypermethylated in HCT 
116 cell line, but unmethylated in the DKO cells. Out of 135 miRNAs, 13 miRNAs 
were upregulated in the DKO cells than in the HCT116 cells, and 7 of them had CpG 
sites in the close vicinity to the promoter regions.  This result indicated that the 
transcription of some miRNAs was probably dependent on the methylation status in 
the promoters. Works done by Saito Y et al. (2006) demonstrated that DNA 





expression more than 3-fold in T24 human bladder cancer cells [160]. Among the 
upregulated miRNAs, mir-127 expression was 49 times higher than in the untreated 
cells, which was embedded in a CpG island and highly methylated in the primary 
tumors. Mir-127 target gene BCL6 was repressed when the cancer cells were treated 
with 5-aza-CdR, which reactivate mir-127 [161]. On the other hand, miRNA is 
another regulator for DNA methylation by targeting the DNMTs. Three members of 
mir-29 family, mir-29a/b/c, interact with the coding regions of DNMT3a/b to 
negatively control protein yield [162]. This miRNA family is repressed in patients, 
and inversely correlates with elevated DNMT3a/b expression. Forced expression of 
mir-29a/b/c restores the normal DNA methylation patterns in the lung cancer cell 
lines, and reactivates the previously silenced tumor suppressor genes FHIT and 
WWOX. The anti-tumor effect of mir-29 family is also observed in vivo, by limiting 
tumor growth. MiRNA transfection reduces cell growth and induces apoptosis in the 
cancer cell line A549.  
DNA methylation and miRNA work together to control cancer metastasis 
[163, 164]. The regulation of miRNAs by DNA methylation is uncovered by the 
study that showing the deregulation of miRNA in the cancer line treated with DNA 
methylation inhibition agent 5-aza-CdR. Altogether, 57 miRNAs were upregualted at 
least 2-fold upon the treatment, including 27 of them residing in the CpG sites. After 
excluding the tissue-specific DNA methylation, mir-34b/c, mir-148a, and mir-9-1/2/3 
were identified as candidate metastasis suppressor miRNAs, which were 
unmethylated in normal tissues but highly methylated in tumors. Overexpression of 





formation in mice.   
Rationale and significance 
 Marek’s disease outbreak is one of the major health problems causing large 
economic losses to the poultry industry due to the high mortality rate. The frequent 
unexpected outbreaks of MD reveal severe limitations in current MD control system. 
Therefore, it is necessary to develop new strategies in order to better protect chickens 
from the disease. Understanding the mechanisms of MD resistance/susceptibility is 
the essential step towards the development of effective defenses to MD. This goal 
could be achieved by identifying molecular basis of MDV-host interaction and the 
association between MD resistance/susceptibility and microRNAs as well as DNA 
methylation. Although some studies described the variations of miRNAs and DNA 
methylation induced by MDV infection, the global scenarios have not been 
characterized. The goals of the project were to identify viral-induced miRNA 
expression profiles and DNA methylation patterns at a genome-wide scale, as well as 
to determine how these virally-induced changes exert a physiological or pathological 
action during MD progression in MD resistant and susceptible chickens. The outcome 
of the research will improve our understanding of how genetic and epigenetic 
differences in chickens influence MDV infection and provide clues to develop new 
strategies to enhance immune response to MDV infection and to eliminate viruses 
through the host itself; moreover, the implications of this project will advance our 
knowledge of the roles of microRNAs and DNA methylation in virus induced 





1. To explore the miRNA expression signatures in MD resistant and susceptible 
chickens after virus infection; 
2. To investigate the function of selected miRNAs on MDV infection;  
3. To characterize the genome-wide DNA methylation profiles in MD resistant 





















Chapter 2: MiRNA Expression Signatures Induced by Marek’s 
Disease Virus Infection in Chickens 
Abstract 
MiRNAs are small, non-coding RNAs that regulate gene expression at the 
post-transcriptional level. Emerging evidence suggests that differential miRNA 
expression is associated with viral infection and cancer. MDV infection induces 
lymphoma in chickens. However, the host defense response against MD progression 
remains poorly understood. Here, we utilized microarrays to screen miRNAs that 
were sensitive to MDV infection. QRT-PCR analysis confirmed the microarray data 
and revealed expression patterns of some miRNAs in tumor samples. Chicken 
miRNA gga-miR-15b and gga-let-7i, which was reduced in infected susceptible 
chickens and splenic tumors, controlled the expression of ATF2 (activating 
transcription factor 2) and DNMT3a (DNA methyltransferase 3a). The expressions of 
ATF2 and DNMT3a were significantly increased in infected susceptible chickens. Our 
results indicated that differential expression of miRNA in resistant and susceptible 
chickens was caused by MDV infection, which effectively influenced protein 
expression of ATF2 and DNMT3a. This latter result might be related to Marek’s 
disease resistance/susceptibility.   
Introduction 





length) that govern post-transcriptional repression of target genes by binding to 3’ 
UTRs or gene bodies [76].  It has been shown that miRNAs are involved in a broad 
range of biological processes, including development, metabolism and cell 
differentiation [9, 76]. MiRNAs have been specifically implicated in tumorigenesis 
and pathogen infection [9, 165]. Functional evaluations of differentially expressed 
miRNAs have uncovered their abilities to elicit diverse immune responses, mainly 
through the regulation of immune cell differentiation and their association with 
immunity and inflammation [98, 165, 166].  
MD is a chicken lymphoma caused by MDV1, which is an α-herpesvirus that 
is closely related to human herpesvirus 1 (herpes simplex virus type 1, HSV-1) and 
human herpesvirus 3 (varicella-zoster virus, VZV) [19]. MDV infection exhibits an 
early cytolytic phase between 3 to 7 days post infection (dpi) and then enters into the 
latent phase within 2 weeks. During this period, the MDV genome is maintained in 
host cells without the production of infectious progeny viruses [19]. Reactivation of 
MDV to the late cytolytic phase occurs between 14 to 21 dpi in MD susceptible 
chickens, which coincides with permanent immunosuppression [19, 167]. Here, we 
analyzed miRNA expression profiles in MD-resistant and MD-susceptible chickens to 
elucidate the function of miRNA in the regulation of Marek’s disease (MD) 
resistance.   
To date, 499 predicted and confirmed chicken miRNAs as well as 14 MDV-1 
miRNAs have been released from miRBase (http://miRNA.sanger.ac.uk/sequences/). 
A portion of chicken miRNAs were repressed in MDV-infected chicken embryo 





development of chicken immune organs [126]. Several MDV-1 miRNAs, including 
MDV1-M2, MDV1-M3 and MDV1-M5 have been physically mapped to the regions 
flanking the MDV oncogene Meq [28].  However, the differences in miRNA 
expression between MD-resistant and MD-susceptible chickens, especially before and 
after MDV infection, are still unknown. These variations appear to be important for 
understanding host-virus interactions. In this study, we used two highly inbred 
chicken lines (line 63 and line 72) to evaluate the hypothesis that MDV infection 
induces distinct miRNA expression signatures in MD-resistant and MD-susceptible 
chickens that modulate target gene expression.  MDV can enter target cells in line 63 
and line 72 chickens, but line 63 chickens survive after infection and most of them do 
not develop tumors. In contrast, line 72 is susceptible to MD, which leads to the 
development of lymphoma. Using this model, we identified 64 candidate miRNAs 
that were differentially expressed in the spleens of MDV-infected and noninfected 
line 72 chickens. Among these miRNAs, gga-miR-15b deregulation in infected line 72 
was shown to control the expression of activating transcription factor 2 (ATF2) and 
DNMT3a (DNA methyltransferase 3a), which were both increased in infected line 72 
chickens. Collectively, our data demonstrated that MDV infection caused distinct 
miRNA expression patterns in MD resistant and MD susceptible chickens, which 
effectively influence the protein levels of target gene in the infected samples. Taken 
together, these results provide clues for future exploration of how miRNAs are 





Materials and Methods 
Experimental animals and sample preparation 
Line 63 and line 72 (USDA-ARS Avian Disease and Oncology Laboratory, 
East Lansing, Michigan, USA) are two highly inbred lines of specific-pathogen-free 
white leghorn chickens that are resistant and susceptible, respectively, to MD tumors. 
Chickens from each line were separated into two groups. One group was infected 
with a very virulent (vv+) strain of MDV (648A passage 40) at day 5 after hatching, 
while the other group did not receive MDV. Four chickens were selected from each 
group at 5, 10 and 21 days post infection (dpi), and none of them developed tumors 
during the experiment period. Besides the infected spleen samples from line 63 and 
line 72, we received 4 spleen tumor samples of MDV infected chickens and 4 spleen 
samples of uninfected control birds from Avian Disease and Oncology Laboratory 
(ADOL, USDA). The tumor diagnosis and tumor sample collection were done by the 
veterinary medical officer in ADOL. Fresh spleen samples were harvested 
individually and stored in RNAlater solution (QIAGEN) at -80°C for DNA or RNA 
extraction. The entire animal experiment was conducted following the procedures and 
guidelines described in the “Guidelines for Animal Care and Use” manual approved 
by the Animal Care and Use Committee, the USDA-ARS, and the Avian Disease and 
Oncology Laboratory (Approval ID 111-26). 
Quantification of MDV genome DNA loads in spleen samples 





viral genomic DNA at 5, 10 and 21 dpi. Quantitative PCR of viral copy number was 
performed on genomic DNA (100 ng/µl) with the iCycler iQ PCR system (Bio-Rad, 
USA) and QuantiTect SYBR Green PCR Kit (Qiagen, USA). Relative MDV loads 
were determined after normalization to a single-copy gene VIM (vimentin) [169].  
MiRNA array profiling and data Analysis 
Total RNA was extracted from three spleen samples using the miRNeasy Mini 
Kit (QIAGEN). Total RNA quality was verified with Agilent 2100 Bioanalyzer chips 
(Agilent, Santa Clara, CA, USA). Three of the samples from each of the treatment 
groups from two chicken lines were processed for miRNA microarray analysis.  
Microarray analysis was done by Exiqon (Exiqon, Denmark). Briefly, total RNA (1 
µg) from each of the samples and the common reference sample were labeled with 
Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY™ LNA Array 
power labeling kit (Exiqon, Denmark) following the manufacturer’s specifications. 
The Hy3™-labeled samples and a Hy5™-labeled reference RNA sample were mixed 
pair-wise and hybridized to the miRCURY™ LNA array (Version 9.2; Exiqon, 
Denmark), which contained capture probes targeting all of the miRNAs for all the 
species registered in the miRBASE (Version 10.1) at the Sanger Institute. One 
hundred and sixty-two of these probes were chicken-related miRNAs. Hybridization 
was performed according to the miRCURY™ LNA array manual with a Tecan 
HS4800 hybridization station (Tecan, Austria). After hybridization, the microarray 
slides were scanned and stored in an ozone free environment (ozone level below 2.0 





array microarray slides were scanned using the Agilent G2565BA Microarray 
Scanner System (Agilent Technologies, Inc., USA) and image analysis was 
performed with ImaGene 8.0 software (BioDiscovery, Inc., USA). Microarray data 
were analyzed in R using the Limma package [170, 171]. Quantified signals within 
arrays were averaged and normalized using the global LOWESS (LOcally WEighted 
Scatterplot Smoothing) regression algorithm. Contrasts were made to compare 
noninfected and infected groups in both lines. Differentially expressed miRNAs were 
selected to perform cluster analysis with CLUSTER/TreeView software [172]. The 
target genes for miRNAs were predicted by RNA22 
(http://cbcsrv.watson.ibm.com/rna22.html).  
Quantification of miRNA and mRNA Levels using real-time PCR 
MiRNAs and mRNAs were extracted from four chicken spleen samples per 
treatment group using the miRNeasy Mini Kit (QIAGEN) and RNeasy Mini Kit 
(QIAGEN) according to the standard protocol by manufacturer. The on column 
DNase digestion was done for miRNA and mRNA purification to remove DNA. 
MiRNA samples were reversely transcribed and quantified with a miScript Reverse 
Transcription Kit (QIAGEN), a miScript SYBR Green PCR Kit (QIAGEN), and 5 
miScript Primer assays (QIAGEN). Reverse transcription and quantification of 
mRNA were performed with SuperScript™ III Reverse Transcriptase (Invitrogen) 
with oligo (dT)12-18 primers (Invitrogen), and the QuantiTect SYBR Green PCR Kit. 
In the reverse transcription control, PCR water (Invitrogen) was used to replace 





The primers were designed using NCBI/Primer-BLAST tool from NCBI web 
site (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The melting temperatures 
were between 55-65 ˚C, and the length of the amplicons was between 100-200 bp. 
The primer pairs were designed to separate by one intron, and were specific to Gallus 
gallus. The forward and reverse primers for ATF2, GAPDH and Meq quantification 
are listed in Table 2.1. 
Briefly, 1µg of purified miRNA or total RNA was used for reverse 
transcription, respectively, and 2 µl of RT products (1:5 dilution) were used for real-
time PCR quantification. Two types of controls were applied in real-time PCR, 
including reverse transcription control and blank using PCR water. No amplicon was 
observed in the controls. A final volume of 20 µl real-time PCR product was 
incubated in an iCycler iQ PCR System (Bio-Rad), and each was performed on four 
biological replicates from the treatment per line in each experiment. Four biological 
replicates were carried out for each gene and miRNA, and each biological replicates 
were technically repeated 3 times. U6 or GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) were used as normalization controls for the data [120].  After 
normalization, ANOVA and Tukey test were used to compare the miRNAs or genes 












Table 2.1 Real time-PCR  
GeneA Sequences 
ATF2B Forward 5’-CCTCCCCACAGCCAGTGCAG-3’ 
Reverse 5’-TGAGCTGGTGATGCCGGTGT -3’ 
DNMT3aB Forward 5’-ATGAACGAGAAGGAAGACATC-3’ 
Reverse 5’-GCAAAGAGGTGGCGGATCAC-3’ 
MeqB Forward 5’– AAGTCACGACATCCCCAACAGC-3’ 
Reverse 5’-TACATAGTCCGTCTGCTTCCTGCG-3’ 
GAPDHB Forward 5'- GAGGGTAGTGAAGGCTGCTG-3' 
Reverse 5'-ACCAGGAAACAAGCTTGACG-3' 
VimB Forward 5’-CAGCCACAGAGTAGGGTAGTC-3’ 
Reverse 5’-GAATAGGGAAGAACAGGAAAT-3’ 
ATF2C Forward 5’- GTTTAAAC TCCAGGCCCGTTTCCTCTGCT -3’ 
Reverse 5’-TCTAGA AGCTTCCGTGTGTGGGCTGC -3’ 
DNMT3a_1C Forward 5’- GTTTAAAC  CATGAAGCACGGCCCAAG-3’ 
Reverse 5’-TCTAGA TGTGCCGCAGACACCTCT -3’ 
DNMT3a_2C Forward 5’- GAGCTC  AAGATTGGCCGTCGCGCCTC -3’ 
Reverse 5’-TCTAGA AGGTCGAAGGGGCCCCACT -3’ 
A: Gene name. B: Primers for real time-PCR. C: Primers for amplifying ATF2 and 




Total protein was extracted by lysis of ~20 mg of tissues with RIPA buffer 
(150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 
50 mM Tris, pH 8.0) containing a protease inhibitor cocktail (Sigma). Approximately 
20 mg of splenic tissue was homogenized in RIPA buffer, and the lysate was 
incubated at 4 °C for 2 hours with constant agitation and subsequently centrifuged at 





assay (Thermo Scientific). For the western blotting, 30 µg of extracted protein was 
heated at 95-100°C for 5 min and loaded on 10% SDS-PAGE for electrophoresis. 
After separation, proteins were transferred onto polyvinylidene fluoride (PVDF) 
membrane and blocked with 5% nonfat milk in TBST containing 0.1% Tween 20. 
Primary antibodies against ATF2 (Santa Cruz), DNMT3a (Abcam) and β-actin 
(Abcam) were prepared at 1:500 and 1:1000 dilutions, respectively. Membranes were 
incubated with primary antibodies overnight at 4°C. Membranes were washed quickly 
3 times (less than 1 min) and 3 more times for 5 min. Membranes were then 
incubated with anti-rabbit IgG and anti-mouse IgG secondary antibodies (Santa Cruz) 
diluted in TBST (1:5000 or 1:10,000) for 1 hr at room temperature. The membranes 
were quickly washed 3 times and then washed 3 more times for 5 min each.  
Membranes were developed with ECL (Amersham) and measured using ChemiDoc 
XRS (Bio-Rad). To quantitate the amount of protein, the signal volume was measured 
with Quantity One software using volume analysis. The band signals were measured, 
and background correction was applied. The background-adjusted volume singals of 
each band were export to excel. The relative protein expression was calculated as the 
ratio of the adjusted volume signals between protein of interest and β-actin.  Four 
independent experiments were done for each antibody.  
Cell culture, Plasmid constructs, Transfection and Luciferase Reporter 
Assay 
Hela cells were grown in Dulbecco’s modified Eagle’s medium supplemented 





(Invitrogen). Cells were maintained at 37°C in humidified 5% CO2 conditions. ATF2 
cDNA fragments containing miRNA target sequences were amplified by PCR (Table 
2.1), and cloned into pmirGLO Dual- Luciferase miRNA target expression vector 
(Promega) to create plasmid constructs. For transfection, cells were plated in 24-well 
plates and were ~25% confluent 24 hrs before transfection. Before transfection, the 
medium was replaced with growth medium without antibiotics. Chicken miRNA 
mimics (QIAGEN) were diluted to working concentration (3 pmol/µl), and were co-
transfected with plasmids (500 ng) harboring miRNA target sites using Lipofectamine 
2000 transfection reagent (Invitrogen), and the medium was replaced with normal 
growth medium 4-6 hrs later. Cells were harvested after 24 hrs, and Renilla and 
firefly luciferase activities were measured using Dual-Luciferase Reporter Assay 
System (Promega).  
Results 
Validation of MDV infection in resistant and susceptible chickens  
MDV successfully infected chickens from line 63 and line 72, but this 
infection had discordant behavior in the two lines. By measuring the copies of two 
important viral genes (Meq and ICP4), virus copy number was estimated and was 
similar between infected line 63 and infected line 72 chickens at 5 dpi, but was much 
higher in infected line 72 chickens than in infected line 63 chickens at 10 and 21 dpi 






Figure 2.1 Quantification of viral gene copy number and viral gene expression. 
(A) Virus copy number, based on Meq and ICP4, in MDV-infected line 63 and line 72 
chickens were measured (5, 10 and 21 dpi) and normalized to a single copy gene, 
Vim. (B) Meq transcription levels were measured in MDV-infected line 63 and line 72 
chickens (5, 10 and 21 dpi) and normalized to GAPDH. Quantitative results are 
represented as Mean ± SEM (n=4). L63: infection line 63 and L72: infected line 72.  
MiRNA expression profiles  
Based on our criterion (p-value less than 0.05 and false discovery rate (FDR) 
smaller than 0.1) using in microarray analysis, 64 out of the 162 miRNAs had 





spleen at 21 dpi, including the downregulation of 58 miRNAs and the upregulation of 
6 miRNAs in the infected line 72 group (Table 2.2 and Appendix I.). Notably, using 
the same criteria, none of the miRNAs were expressed differently between the 
infected and noninfected line 63 chickens (Table 2.2). Sixty-two miRNAs were 
expressed differently when  infected line 63 and line 72 chickens were compared, 
including 50 downregulated and 12 upregulated miRNAs in the infected line 72 group 
(Appendix II.). In total, 73 miRNAs showed differential expression. By using the 
cluster analysis that included all of the significantly expressed miRNAs, we found 
that the experimental birds were categorized into two groups (Figure 2.1). The 
infected line 72 birds were in one subgroup. In the other subgroup, noninfected line 72 
chickens were associated with line 63 chickens that were both infected and 
noninfected, indicating that their microRNA profiles were less varied (Figure 2.1). 
Additionally, we also found that the abundance of 10 MDV1 miRNAs dramatically 
increased in infected line 72 chickens but not in infected line 63 birds (Appendix III.).   
Table 2.2 Numbers of chicken microRNAs differentially expressed between 
chicken lines and MDV treatment groups  








Downregulated 0 58A 0 50C 
Upregulated 0 6B 0 12D 
Total 0 64 0 62 
A and C: MicroRNA levels were downregulated in the infected line 72  chickens 
compared to  noninfected line 72 or infected line 63 chickens, respectively, based on 
p<0.05 and FDR<0.1. 
B and D: MicroRNA levels were upregulated in the infected Line 72 chickens 
compared to noninfected line 72 or infected line 63 chickens, respectively, based on 












clustering analysis classified the samples based on significantly differentially 
expressed miRNA in the normalized data. Green or red bars denote that the level of 
specific miRNA was decreased or increased in samples. Black bars indicate that the 
levels of miRNA were similar between samples and the common reference sample. 
Gray indicates data that are not available. The scale of the color bar represents fold 
changes of miRNA expression relative to the common reference. L72.inf.1-3: 3 
samples from infected line 72; L72.non.inf.1-3: 3 samples from noninfected Lines 72; 
L63.non.inf.1-3: 3 samples from noninfected line 63; L63.inf.1-3: 3 samples from 
infected line 63. 
 
Based on the results from the microarray analysis, 3 gga-miR-15b, gga-miR-
456 and gga-let-7i miRNAs, which potentially regulate ATF2 and DNMT3a,  were 
chose to verify the results from the microarray analysis. The expression of gga-miR-
15b, gga-miR-456 and gga-let-7i were all significantly downregulated in infected line 
72 samples compared to MDV-free chickens (p<0.05) (Figure 2.3 A). Significantly 
reduced expression of gga-miR-456 and gga-let-7i were observed in infected line 72 
chickens compared to infected line 63 chickens (p<0.01 and p<0.05 respectively). 
Transcription of gga-miR-15b was decreased in infected line 72 samples relative to 
infected line 63 samples, although this difference was not statistically significant 
(Figure 2.3 A). These 3 miRNAs did not show significant variance between infected 
and noninfected in line 63 samples. Additionally, these 3 miRNAs were also repressed 
in splenic MD tumors compared to healthy spleen (p<0.05), which was consistent 
with the microarray results (Figure 2.2 B). Besides chicken miRNAs, the expression 
levels of MDV-miR-M2 and MDV-miR-M5 were significantly higher in the infected 







Figure 2.3 Expression of chicken and MDV miRNAs in MDV. Expression of gga-
miR-15b, gga-miR-456 and gga-let-7i was measured by qRT-PCR in spleen samples 
from noninfected and infected line 63 and line 72 chickens as well as in the normal 





levels of MDV1-miR-M2 and MDV1-miR-M5 in infected line 63 and line 72 chickens 
were detected using qRT-PCR and normalized to U6.  The quantitative results are 
represented as mean ± SEM (n=4). A single asterisk (p-values <0.05) and double 
asterisks (p-values < 0.01) indicate the transcription level in the specific group was 
significantly different when compared to the adjoined group.  L72.inf: infected line 72; 
L72.non.inf: noninfected line 72; L63.non.inf: noninfected line 63; L63.inf: infected 
line 63. 
 
MiRNA Target Identification 
To further understand the potential functions of miRNAs in MDV resistance 
and susceptibility, we examined the protein and mRNA levels of several genes that 
were reported to interact with MDV oncogene Meq. The protein level of activating 
transcription factor 2 (ATF2) was significantly increased in infected line 72 chickens 
compared to MDV-free chickens, whereas its expression was stable in line 63 birds 
before and after MDV challenge (Figure 2.4 A). Comparably, qRT-PCR revealed that 
the mRNA levels of ATF2 were slightly decreased upon MDV infection in the two 
lines but were not significantly different (Figure 2.4 B), indicating that miRNAs 
might be regulating ATF2 expression. By using a bioinformatic tool (RNAhybrid), 3 
chicken miRNAs (gga-miR-15b, gga-miR-456 and gga-let-7i) were found to be 
among those differentially expressed and predicted to interact with ATF2 mRNA in 
its coding regions (Figure 2.5 A). The speculation that ATF2 translational regulation 
requires chicken miRNAs was verified by the observation that induction of gga-miR-
15b inhibited luciferase activity by ~20% compared to negative control (p<0.05) 
(Figure 2.5 B). However, the presence of gga-let-7i silenced firefly luciferase activity 
by ~15% although this difference was not statistically significant. We also found that 





Since MDV infection was reported to induce DNA methylation alterations, 
the same bioinformatic tool was applied to investigate if miRNAs were involved in 
the regulation of DNMTs.  The protein expression was significantly upregulated line 
72 infected chickens, and the no transcriptional changes were observed among the 4 
samples (Figure 2.6). DNMT3a was predicted to contain binding sites for gga-let-7i 
and gga-miR-15b at the gene body regions (Figure 2.7 A). The reporter assay showed 
that gga-let-7i and gga-miR-15b significantly repressed the luciferase activities by 






Figure 2.4 Protein and mRNA quantification of ATF2. Western blot (A) and qRT-
PCR (B) of ATF2 were measured in the spleen samples from the two lines before and 
after MDV infection at 21 dpi. The quantitative results are represented as mean ± 
SEM. A single asterisk (p-values <0.05) and double asterisks (p-values < 0.01) 
indicate the expression level in the specific group was significantly different when 








Figure 2.5 The validation of miRNA-ATF2 interaction. (A) Schematic of gga-mir-
15b, gga-let-7i and gga-mir-456 binding sites in chicken ATF2 mRNA. (B) 
Luciferase reporter assay was used to measure the interaction between microRNAs 
and the plasmid construct containing microRNA target sites. Firefly luciferase 
activity was normalized to Renilla luciferase activity for each treatment. A single 
asterisk indicates a significant difference (p<0.05) between microRNA-mimicked 







Figure 2.6 Protein and mRNA quantification of DNMT3a. Western blot (A) and 
qRT-PCR (B) of DNMT3a were measured in the spleen samples from the two lines 
before and after MDV infection at 21 dpi. The quantitative results are represented as 
mean ± SEM. A single asterisk (p-values <0.05) and double asterisks (p-values < 
0.01) indicate the expression level in the specific group was significantly different 








Figure 2.7 The validation of miRNA-DNMT3a interaction. (A) Schematic of gga-
mir-15b and gga-let-7i binding sites in chicken DNNMT3a mRNA. (B) Luciferase 
reporter assay was used to measure the interaction between gga-mir-15b and the 
plasmid construct containing microRNA target sites. (C) Luciferase reporter assay 
was used to measure the interaction between gga-let-7i and the plasmid construct 
containing microRNA target sites. Firefly luciferase activity was normalized to 
Renilla luciferase activity for each treatment. A single asterisk indicates a significant 






MDV has been reported to be replicated relatively faster in line 72 than in line 
63 [58, 173]. This phenomenon may be caused by the differential expression of 
microRNAs or may lead to the distinct microRNA expression in these two lines; 
however, this requires further investigation. The highest virus copy number was 
found at 21 dpi in both lines, and virus induced or repressed microRNAs could be 
detected at this time point for microarray analysis.  Compared to high-throughput 
sequencing, microarray relies on the prior sequence information for probe designs, 
and focuses only on the well-studied miRNAs which were printed on the array, 
therefore, was inadequate to identify novel miRNAs. Despite of these limitations, 
array-based approach is a feasible and cost-efficient method to identify differentially 
expressed miRNAs. Therefore, to generate a global view of differentially expressed 
microRNAs, microarray analysis was conducted on samples from 21 dpi. 
The spleen is an important immune organ that provides a niche for MDV to 
reach its primary targets (B cells and CD4+T cells) during infection [19]. Because of 
the absence of classical transforming genes in MDV, the environment provided by the 
spleen is critical for viral replication [174]. Therefore, all the experiments were 
carried out using splenic samples. To gain insights into MDV-induced microRNA 
expression variations in the immune system, this study profiled microRNA 
expression in resistant and susceptible chickens in vivo, which will improve our 
knowledge of the MDV-chicken interaction. 





identified in chicken embryo fibroblast (CEF), including some miRNAs that also 
showed differential expression in our study [119]. Based on the current microarray 
cutoff for differential expression (p<0.05 and FDR<0.1) in the microarray, miRNA 
expression was only significantly different between infected and noninfected line 72 
groups, and between the infected line 63 and line 72 groups. This finding suggested 
that potential functions of these miRNAs were related to MD resistance and 
susceptibility. However, we did observe significant miRNAs between line 63 infected 
and uninfected chickens or between line 63 and line 72 if with p<0.05 only, but none 
of these miRNAs were confirmed by qRT-PCR. Because microRNA expression 
signature following MDV infection in line 63 and line 72 has not been studied, we 
compared our results with cDNA microarray analysis in the two lines. Previous 
studies [36] examined gene expression in peripheral blood lymphocytes (PBLs) in 
two chicken lines and revealed that the expression of some genes show at least two 
fold changes between infected line 63 and line 72 chickens, while the transcriptional 
profiles of uninfected birds were similar, which was consistent with our findings. 
Collectively, our results demonstrated that differential expression of miRNAs was 
driven by MDV infection in line 63 and line 72. Results from qRT-PCR were 
consistent with the microarray analysis for both cellular and viral miRNAs. These 
data demonstrated significant inactivation of cellular miRNA production and the 
increased MDV miRNA transcription in infected line 72 at 21 dpi. Moreover, we 
found a set of miRNAs (gga-miR-15, gga-miR-456 and gga-let-7i) that were 
deregulated in MD tumors, similar to infected line 72, which implied their potential 





miRNAs had different transcriptional levels between tumor samples and infected line 
72 (data not shown), suggesting different functions in viral infection and 
tumorigenesis. In contrast to cellular miRNAs, all of the MDV miRNAs were 
significantly upregulated. For example, MDV1-miR-M2 and MDV1-miR-M5, located 
at the 5’ upstream of Meq [28], were overexpressed in the infected line 72 at 21 dpi 
compared to the infected line 63. This result is consistent with the higher DNA copy 
number and activated transcription of Meq, and highlighted increased viral replication 
in infected line 72.  
The candidate target genes that may be regulated by differentially expressed 
miRNAs were predicted using bioinformatic tools miRDB and MDV MicroRNA 
Target Prediction. The pathway analysis was done using IPA (Ingenuity systems 
pathway analysis) to further clarify the molecular functions that miRNAs may be 
involved in (Appendix IV.). Several immune related pathways, such as NF-κB 
signaling and T cell and B cell receptor signaling were included, implying that 
miRNAs may influence MD resistance or susceptibility through controlling the 
immune responses.  
The discovery of the miRNA gga-miR-15b target, ATF2, is valuable for 
understanding the etiology of MD. ATF2 is a sequence-based DNA binding protein 
that belongs to the cAMP-response element (CRE)-binding protein (CREB) family, 
which regulates proliferation and apoptosis by altering downstream gene expression 
[175]. The mRNA level of ATF2 was only slightly reduced (20 % and 10 %, 
respectively) after MDV infection in line 63 and line 72, suggesting MDV infection 





protein increased significantly compared to non-infected birds.  Interestingly, in the 
same line, the increase of ATF2 was coincident with the decrease of gga-miR-15b 
level. Bioinformatics analysis predicted that ATF2 was one of direct targets for gga-
miR-15b.  The luciferase reporter assay showed that gga-miR-15b indeed depressed 
ATF2.  This information suggested that MDV infection resulted in the 
downregulation of gga-miR-15b thus released its inhibition on ATF2 translation in 
line 72.  The coexpression of ATF2 and gga-miR-15b was observed in line 63. 
Traditionally, it is believed that because of its inhibition effect, miRNA and its target 
show mutually exclusive pattern. However, this classic view has been disputed by 
recent publications that show miRNA and its target can be coexistent  to maintain the 
balance of translational network [176-179]. It appeared that the abundance of ATF2 
protein was similar in line 63 chickens regardless of MDV infection; however, this 
observation was not surprising because it was well possible that in this resistant line, 
some unknown mechanisms prevent MDV from reducing gga-miR-15b expression to 
increase ATF2 translation. The mechanisms that inhibit MDV-mediated reduction of 
gga-miR-15b in line 63 remained unclear. The distinct genetic backgrounds, such as 
SNPs and gene expression variations between two lines may contribute to the 
different regulatory mechanisms. The unique expression pattern and distinctive 
regulatory mechanism may suggest that ATF2 plays different roles in line 72 and line 
63. As far as the biological function of ATF2 is concerned, several lines of evidence 
suggest that ATF2 may work as an oncogene or tumor suppressor dependent on the 
cellular systems. For example,  it has been reported that ATF2 elicited tumor 





tumor suppressors or oncogenes [34, 180, 181].  Chicken ATF2 was documented to 
form a heterodimer with c-Jun, MDV oncogene Meq and other b-ZIP proteins [19, 
34, 35]. In line 72, we found ATF2 protein level was higher in MDV infected birds 
than uninfected ones. Since MDV oncogene Meq was highly expressed in line 72 after 
MDV infection, ATF2 probably formed a heterodimer with Meq and favor MD 
development. In the line 63, due to the absence of Meq after MDV exposure, ATF2 
may be in cooperation with c-Jun and perform distinct functions as in line 72. 
Considering the dramatic difference in Meq expression between infected line 72 and 
infected line 63, it is likely that ATF2 may have different partners and play distinct 
roles in two chicken lines after MDV infection even though the expression was 
similar between infected line 72 and infected line 63. The other chicken miRNA gga-
let-7i, which was also deregulated in line 72 after MDV challenge, may have negative 
effects on ATF2 translation since it slightly suppressed luciferase activities, but might 
not control ATF2 translation alone. In general, miRNA regulation of gene expression 
is largely dependent on binding at the 3’ UTR. However, miRNA target sites in the 
coding regions of genes have recently been reported in humans [92]. The validation 
that gga-miR-15b reduced ATF2 expression provided further evidence that the 
miRNA regulation of gene expression could depend on the binding at the coding 
region. 
DNA methylation variations were induced by MDV infection in chicken [3], 
therefore,  it was reasonable to speculate the expression of DNMTs was changed after 
MDV exposure. In chickens, there are 3 different DNMTs, including DNMT1, 





protein expression without the mRNA alterations, suggesting its expression may be 
regulated by miRNAs. The manipulation of DNMTs by miRNAs was discovered, 
such as DNMT3a and DNMT3b directly targeted by has-mir-29b as well as the 
regulation of DNMT1 by has-mir-148a and has-mir-152 in human [182, 183]. The 
interaction between chicken DNMT3a and miRNAs was confirmed by luciferase 
report assay. Before MDV infection, DNMT3a expression was similar between line 
63 and line 72, and the MDV infection activated DNMT3a expression in line 72, which 
was controlled by the downregulation of gga-mir-15b and gga-let-7i.  
In summary, MDV challenge in resistant and susceptible chicken lines 
resulted in differential miRNA expression signatures in the spleens of infected 
chickens. The expression of most cellular miRNAs was dramatically decreased, but 
viral miRNAs were overexpressed in the MDV-infected susceptible line. In contrast, 
chicken miRNA transcription was relatively stable while MDV miRNA expression 
was suppressed in infected resistant lines. The repression of miRNA results in distinct 
target gene expression in the two lines after MDV infection. ATF2 and DNMT3a were 
identified as direct targets for gga-miR-15 and bgg-let-7i, and the biological 
consequences of activation of ATF2 and DNMT3a and on MD resistance and 








Chapter 3: The Functional Analysis of Selected Chicken 
MicroRNAs on Marek’s Disease Virus Infection 
Abstract 
 MicroRNAs (miRNAs) are a class of short, noncoding RNA, which are 
emerging as major regulators for the antiviral mechanism. Marek’s disease (MD) is 
an aggressive T-cell lymphoma in chickens induced by the infection of MD virus 
(MDV). Host resistance and susceptibility to MD are tightly determined by different 
molecular mechanisms. The distinct chicken miRNA transcriptional signatures were 
identified in MD-resistant and -susceptible chickens. In this study, the function of 
some cellular miRNAs on MDV infection was further revealed. The selected 
miRNAs, gga-mir-15b and gga-let-7i, were overexpressed in chicken fibroblast 
(CEF) cell line DF-1. MDV infection of the cells demonstrated that the miRNA 
expression levels were inversely correlated with MDV replication in the infected 
cells. This result highlighted the important function of the chicken miRNAs against 
MDV replication in cultured cells. 
Introduction 
Marek’s disease virus (MDV), an α-herpesvirus, is the causative agent for 
Marek’s disease (MD). MDV infection results in a lymphoproliferative disorder in 
susceptible chickens, which is one of major health threats for poultry industry. The 





vaccines to control MD since 1970s [1]. However, with the evolution of MDV 
towards higher virulence in chickens, virus appeared to be escaping the vaccine 
control, as new and acute symptoms were identified [19]. Therefore, understanding 
the molecular mechanism on MD resistance will help to improve the current disease 
control strategy.  
 MicroRNAs (miRNAs) are a class of small single-stranded non-coding RNA 
molecules, approximately 22 bp in length. MiRNAs mediate gene repression at post-
transcriptional level by imperfect complementarity to the 3’UTR or coding regions of 
transcripts [76]. MiRNAs were identified in multicellular eukaryotes and viruses, and 
are involved in diverse biological processes. It has been demonstrated that miRNAs  
play intricate roles in the cross-talk between host and pathogen [113, 184]. The 
cellular miRNAs have dual functions in virus-host interactions through the regulation 
of host and viral gene expression. Some miRNAs promoted the viral gene translation 
while some repressed virus propagation [113, 185, 186]. Therefore, regulation of 
cellular miRNAs through RNA inference (RNAi) could be a promising approach for 
MD control. 
In vivo and in vitro studies have revealed that MDV infection provokes the 
downregulation of miRNAs in MDV-transformed T cell lines and susceptible 
chickens, but does not affect miRNA expression in MD resistant chickens [5, 119, 
187]. All these findings suggest that miRNAs are essential to the functional immune 
response against MDV infection. Our previous work showed that the expression of 
chicken miRNAs was significantly decreased in MD susceptible inbred chicken line 





methyltransferase 3a (DNMT3a), were identified as the target of miRNAs gga-mir-
15b and gga-let-7i, which were both downregulated in the infected MD susceptible 
chickens. However, the impacts of gga-mir-15b and gga-let-7i on MDV infection 
were not known yet.  
 To explore the effects of miRNAs on MDV infection, in the current study two 
chicken miRNAs, gga-mir-15b and gga-let-7i, were overexpressed in the chicken 
embryonic fibroblast cell line DF-1 using the avian leukosis virus (ALV) construct-
based retroviral vectors (RCAS system) [125, 126]. The overexpression of the two 
cellular miRNAs repressed MDV replication in the MDV-infected DF-1 cells, and the 
expression of MDV oncoprotein Meq was reduced as well. Collectively, the results 
demonstrated the antiviral function of the cellular miRNAs against MDV infection. 
Materials and Methods 
Vector construction and cell transfection 
The miRNAs were cloned into a retroviral vector based on the replication-
competent avian leukosis virus construct (provided by  Dr. H.C. Liu  at North 
Carolina State University) [188]. The sequences of two pre-mature miRNAs (gga-
miR-15b and gga-let-7i) and scrambled control were synthesized (Eurofins) and the 
SphI and NgoMIV restriction enzyme sites were added to the 5’ end of the sense and 
anti-sense oligonucleotides, respectively (Table 3.1). The sense and antisense oligo 
stocks of 50 µM were mixed and incubated at 95˚C for 5 min, and then transferred to 





left in the water bath overnight to allow complete annealing. The pENTR3C entry 
vector was digested with SphI and NgoMIV restriction enzymes at 37˚C for 4-6 hrs 
with 1× NEB buffer 4 (NEB). The annealed pre-miRNA duplex was ligated to the 
entry vector with T4 DNA ligase by incubation at 4˚C overnight (Progema). The 
ligation products were transformed to the DH5α competent cells (ZYMO research) 
and the positive insertion was selected by Kanamycin after incubation at 37˚C 
overnight. The selected colonies were cultured at 37˚C with shaking. The plasmid 
DNA was isolated using QIAprep® Miniprep Kit (QIAGEN), and the correct 
insertions were confirmed by restriction enzyme digestion and DNA sequencing. 
To transfer the inserts to the destination vector, 150 ng of each of miRNA 
pENTR3C entry vectors with correct insertion were mixed with 150 ng of pRCASBP 
(A)-YDV ( provided by Dr. H.C. Liu at North Carolina State University), and 
incubated with Gateway® LR clonase mixture (Invitrogen) according to the 
manufacture’s recommendations. The products were transformed to the competent 
DH5α competent cells (ZYMO research) and selected by ampicillin after incubation 
at 37˚C overnight. The selected colonies were cultured at 37˚C with shaking. The 
plasmid DNA was isolated using QIAprep® Miniprep Kit (QIAGEN), and the correct 
insertions were confirmed by restriction enzyme digestion and DNA sequencing. 
The miRNA overexpression vector was delivered into DF-1 cells by 
transfection using Fugene® transfection reagent (Promega) based on the 
manufacturer’s instructions. The overexpression was confirmed 3 days post-infection 
by miScript system (QIAGEN) and immunofluorescence staining of viral gag protein 















Cell culture and MDV infection 
Chicken embryo fibroblast DF-1 cells were grown in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, streptomycin (100 
mg/ml) and penicillin (100 U/ml) (Invitrogen). Cells were maintained at 37°C in 
humidified 5% CO2 conditions. The very virulent + (vv+) strain of MDV (648A 
passage 40) was obtained from USDA-ARS Avian Disease and Oncology 
Laboratory. The DF-1 cells were inoculated with the MDV at multiplicity of infection 
(M.O.I) of 0.1 and incubated for 3 days.  
Quantification of MDV genomic DNA loads  
Genomic DNA from DF-1 cells was extracted by using Wizard Genomic 
DNA purification kit (Promega). RNase treatment was performed to remove RNA 
from DNA samples. DNA concentration was measured using Nanodrop. As 
previously described [168], the MDV genes Meq and ICP4 were amplified to 
quantify viral genomic DNA. Quantitative PCR was performed on genomic DNA (10 
ng/µl) with the iCycler iQ PCR system (Bio-Rad, USA) and QuantiTect SYBR Green 
PCR Kit (Qiagen, USA). Relative MDV loads were determined after normalization to 
a single-copy gene VIM (vimentin) [169]. Primers used in the PCR were listed in 
Table 2.1. 
Quantification of miRNA and mRNA levels using real-time PCR 
MiRNAs and mRNAs were extracted from the DF-1 cells using the miRNeasy 





manufacturer’s instructions. The on-column DNase digestion was done for miRNA 
and mRNA purification to remove DNA. MiRNA were reverse transcribed and 
quantified with a miScript Reverse Transcription Kit (QIAGEN), a miScript SYBR 
Green PCR Kit (QIAGEN), and 5 miScript Primer assays (QIAGEN). Reverse 
transcription and quantification of mRNA were performed with SuperScript™ III 
Reverse Transcriptase (Invitrogen) with oligo (dT)12-18 primers (Invitrogen), and the 
QuantiTect SYBR Green PCR Kit. In the reverse transcription control, PCR water 
(Invitrogen) was used to replace miRNA or RNA samples.  
Western blot 
Total protein was extracted from DF-1 cells with RIPA buffer (150 mM 
sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM 
Tris, pH 8.0) containing a protease inhibitor cocktail (Sigma). Briefly, the cell lysates 
were incubated at 4 °C for 2 hours with constant agitation and subsequently 
centrifuged at 4°C for 30 min. Protein concentration for each sample was determined 
by the BCA assay (Thermo Scientific). For Western blotting, 30 µg of proteins were 
heated at 95-100°C for 5 min and separated by 10% SDS-PAGE. After separation, 
proteins were transferred onto polyvinylidene fluoride (PVDF) membrane. The 
membrane was blocked with 5% nonfat milk in TBST containing 0.1% Tween 20. 
Primary antibodies against Meq, ATF2 (Santa Cruz), DNMT3a and β-actin (Abcam) 
were prepared at 1:500 to 1:1000 dilutions in TBST, respectively. Membranes were 
incubated with primary antibodies overnight at 4°C followed by washing quickly for 





incubated with anti-rabbit IgG or anti-mouse IgG secondary antibodies (Santa Cruz) 
diluted in TBST (1:5000) for 1 hr at room temperature. The membranes were quickly 
washed 3 times and then washed 3 more times for 5 min each.  Specific reactions 
were revealed with ECL (Amersham) and luminescence signals were recorded using 
ChemiDoc XRS (Bio-Rad). To quantitate the amount of protein, the signal volume 
was measured with Quantity One software using volume analysis. The band signals 
were measured, and background correction was applied. The background-adjusted 
volume singals of each band were export to excel. The relative protein expression was 
calculated as the ratio of the adjusted volume signals between protein of interest and 
β-actin.  Three independent experiments were performed.  
Results 
Validation of miRNA overexpression 
To confirm the transfection of ALV-based retroviral vector in DF-1 cells, 
immunostaining of the ALV gag protein was conducted (Figure 3.1). Green 
fluorescence was observed in the cytoplasm of the transfected cells, indicating gag 
protein expression. The qRT-PCR was done to confirm the overexpression of the 
specific miRNA. The result showed that gga-mir-15b was only highly expressed in 
cells transfected with the vector containing pre-gga-mir-15b sequence (RCAS-gga-
mir-15b) (p<0.05), while its expression level was lower in the cells transfected with 
scramble control vector (RCAS-sc) or gga-let-7i overexpression vector (RCAS-gga-





cells transfected with RCAS-gga-let-7i than the cells transfected with RCAS-sc or 
RCAS-gga-mir-15b (Figure 3.2). These results confirmed the overexpression of 
miRNAs using the retroviral constructs.  
 
Figure 3.1 The expression ALV gag protein. The left panel showed the location of 
nuclei using DAPI to stain DNA (blue). The middle panel was the location and 
expression ALV gag protein (green). The right panel indicated gag was expressed in 
the cytoplasm of the transfected DF-1 cells. 
 
 
Figure 3.2 The validation of miRNA expression by qRT-PCR. The x-axis included 
two miRNAs detected by qRT-PCR. The y-axis was the miRNA relative expression 
normalized using U6. Scramble control, gga-mir-15b and gga-let-7i represented DF-1 
cells transfected with RCAS-sc, RCAS- gga-mir-15b and RCAS- gga-let-7i. The 





The expression of target genes in miRNA overexpressed cells 
 Two chicken genes, activation transcription factor (ATF2) and DNA 
methyltransferase 3a (DNMT3a), are the known targets of gga-mir-15b and gga-let-7i 
[5]. The expression of DNMT3a was downregulated by about 72% in gga-let-7i 
overexpressed cells (p<0.05).  The overexpression of gga-mir-15b repressed 
DNMT3a by about 37%, but not statistically significant (Figure 3.3). ATF2 
expression was suppressed by approximately 73% by overexpression of gga-mir-15b 






Figure 3.3 Detection of DNMT3a and ATF2 by Western blotting. The DNMT3a 
and ATF2 were detected in the DF-1 cells transfected with RCAS-sc, RCAS-gga-mir-
15b and RCAS-gga-let-7i by the western blot (A). The result was quantitatied using 
the densitometry analysis (B). The results are represented as mean ± STD. A single 
asterisk (P <0.05) indicates the expression level in the test group was significantly 
different from the control.  
The virus loads in MDV-infected DF-1 cells with miRNA overexpression 





viral genes (Meq and ICP4) were used to estimate the virus copy numbers in the 
MDV-infected DF-1 cells with miRNA overexpression. Real time PCR of Meq 
showed that the virus genome copies were  about  61% in cells with gga-mir-15b 
overexexpression and 39% in cells with gga-let-7i (p<0.01) compared to the RCAS-
sc control cells (Figure 3.4). Similarly, relative to the RCAS-sc transfection control 
cells, ICP4 was declined about 40% in RCAS-gga-mir-15b transfected cells and 64% 
in RCAS-gga-let-7i transfected cells. The expression of MDV oncoprotein Meq was 
decreased about 34% in the DF-1 cells with gga-mir-15b overexpression cells 
(p<0.05) and 65% in cells with gga-let-7i compared to the transfection control cells 
(p<0.05) (Figure 3.5).  
 
Figure 3.4 Quantification of viral genome copy numbers. The virus genomic copy 
numbers were estimated by real time PCR amplification of viral gene Meq and ICP4 
in DF-1 cells with miRNA overexpression, and normalized to a single copy gene, 







Figure 3.5 Detection of oncoprotein Meq in MDV-infected DF-1 cells by Western 
blotting. The band intensity was analyzed by densitometry and shown as relative 
folds in comparison with control after normalization with actin. Scramble control, 
gga-mir-15b overexpression and gga-let-7i overexpression indicate DF-1 cells 
transfected with RCAS-sc, RCAS-gga-15b and RCAS-gga-let-7i vectors. The error 
bars indicate standard deviation (n=3).  
Discussion 
 Among the antiviral strategies, RNAi has drawn much attention due to its high 
efficiency and specificity [189]. Delivery of small interfering RNAs (siRNAs) by the 
transient transfection generated obvious effects against a variety of viruses [190, 
191], however, the constant expression of siRNAs is essential to inhibit the chronic 





vector system, was widely used in RNAi-based gene therapy [191]. The replication-
competent retroviral vector, ALV construct, was used to express short hairpin RNAs 
(shRNAs) and miRNAs in both chicken and mammalian systems [125, 188]. In the 
current study, chicken miRNAs, gga-mir-15b and gga-let-7i, were successfully 
delivered into DF-1 cells using ALV vector construct, which was confirmed by the 
expression of ALV gag protein in the transfected cells. The expression of either gga-
mir-15b or gga-let-7i did not change the transcription of the other miRNA, suggesting 
that the regulation of these two miRNAs was independent. The downregulation of 
ATF2 and DNMT3a, the known targets for the two miRNAs, is consistent with 
previous findings [5].   
Cellular miRNAs mediated antiviral effect through targeting the virus 
genomes in infected mammalian cells [113]. Several miRNAs were induced by the 
interferon-β to repress hepatitis C virus (HCV) replication through targeting HCV 
genomes [113]. Human miRNA has-mir-32 limited the proliferation of primate 
foamy virus type 1 (PFV-1) in human cells [114]. The current study demonstrated 
that chicken cellular miRNAs, gga-mir-15b or gga-let-7i, effectively inhibited MDV 
propagation in vitro. The quantitation of MDV genomic copy numbers using two 
viral genes, Meq and ICP4, showed similar reduction in the DF-1 cells with miRNA 
overexpression, ~40% in RCAS-gga-mir-15b cells and ~60% in RCAS-gga-let-7i 
cells. The result indicated that both the miRNAs had antiviral function. The miRNA 
gga-let-7i offered better protection to the cells than gga-mir-15b, however, neither of 
them could completely remove the virus. The downregulation of MDV oncoprotein 





of Meq or the reduction of total virus replication. Searching of miRNA binding sites 
on Meq mRNA did not find any possible gga-mir-15b and gga-let-7i interacting sites. 
Thus, presumably, the Meq was indirectly modulated by these two cellular miRNAs.  
Taken together, the current study suggested that the cellular miRNAs might 
participate in the host defense against the viral infection by regulating the viral 
replication or viral gene expression. Further work is required to uncover the 
involvement of miRNA targets in the antiviral responses. Moreover, different host 
miRNAs could be combined to improve the inhibitory effect against the viral 





Chapter 4: MDV Infection Induced Expression Changes of 
DNMT Genes Resulting in DNA Methylation Alternations in 
Marek’s Disease Resistant and Susceptible Chickens 
Abstract 
Cytosine methylation, an epigenetic modification to DNA, has been reported 
to be involved in host-virus interaction. Marek’s disease (MD) is characterized as a T 
cell lymphoma induced by a cell-associated alpha-herpesvirus, Marek’s disease virus 
type 1 (MDV1). As with many viral infectious diseases, DNA methylation variations 
were observed in the progression of MD. Three major DNA methyltransferases were 
differentially expressed in MD resistant line 63 and MD susceptible line 72 at 21 days 
after MDV infection. Therefore, the genome-wide DNA methylation was conducted 
to explore the methylation variations induced by MDV infection in both chicken lines 
using Methyl-MAPS (methylation mapping analysis by paired-end sequencing). 
Overall, the methylation levels were reduced in resistant line 63 chickens after MDV 
infection, and infection induced differential methylation regions (iDMRs) were 
identified. The number of iDMRs was larger line 72 chickens than in line 63 chickens, 
and most of iDMRs found in line 63 were overlapped with the iDMRs found in line 
72. The methylation variations in genes may control gene transcription, which may 
sequentially turn on or off specific pathways in the two lines.  Collectively, the 





methylome. The results suggested that the host DNA methylation may be associated 
with disease resistance or susceptibility. The methylation variations induced by the 
viral infection may consequentially change the host transcriptome and result in the 
diverse disease outcomes.       
Introduction 
  In mammalian cells, DNA methylation usually occurs at CG dinucleotides 
(CpG sites), and is catalyzed by the three DNA methyltransferases, including 
DNMT1 for maintaining methylation and the de novo methyltransferases DNMT3a 
and DNMT3b. The inhibition of DNMTs contributed to DNA demethylation through 
the passive mechanism [135]. Methylation is associated with the repression of 
transcription and essential for key biological processes, including development, X-
chromosome inactivation, imprinting and tissue specific gene expression [15]. Tissue-
specific variation in DNA methylation patterns have been observed; and abnormal 
DNA methylation contributes to disease, including cancer and some infectious 
diseases [8, 135, 192]. Methylome analysis has been conducted in different types of 
cancers. In a normal mammalian genome, the genome is primarily heavily methylated 
except for CpG dense promoters. In cancer cells, DNA methylation levels decrease at 
genome-wide, including hypomethylation in repetitive regions, while some tumor 
suppressor genes are observed to become hypermethylated [193]. DNA methylation 
alterations have also been identified in Epstein-Barr virus (EBV) transformed  
lymphoblastoid cell lines [2]. Likely, proper maintenance of DNA methylation 





Marek’s disease virus (MDV) is the causative agent for Marek’s disease 
(MD), the T cell lymphoma in chickens and other birds. Although vaccines against 
MD have been developed, vaccination efforts have driven the virus to greater 
virulence. MDV infection is divided into four different phases. The entry of virus to 
target cells initiates early cytolytic infection from 3-7 days post infection (DPI). 
Latent infection starts at 7-8 DPI and primarily occurs at activated CD4+ T cells. Late 
lytic infection is reactivated from latency around 2-3 weeks post infection in 
susceptible chickens, and then switches to transformation stage and lymphoid tumors 
are observed in chickens [1].  Thus, late cytolytic stage is a critical step for MD 
progression and disease outcome. As many viruses, MDV infection induces changes 
in DNA methylation patterns in the hosts and virus itself which contribute to MD 
progression by activating or silencing genes crucial for MD immunity [3, 8, 194].  
To explore the role of DNA methylation in MD immunology, two inbred 
chicken lines, were used. Most birds in line 72 develop tumors after MDV infection, 
and line 63 is resistant to the disease. These two chicken lines have the same major 
histocompatibility complex (MHC) haplotype but show significantly different MD 
incidences after MDV infection, which allows us to determine which genes affect 
MD resistance. DNMTs were found to be differentially regulated in line 63 and 72 
after MDV infection, which may explain the promoter methylation alterations 
triggered by the infection [3]. DNA methylation was lost at active promoters in MDV 
carrying T cell lines and MD tumors, and was present in some CpG regions in MDV 
genome [3]. However, conclusions from these studies are limited since they focused 





probed.   
The emergence of next generation sequencing (NGS) provides a unique 
opportunity to explore global methylation variation following MDV infection in MD 
resistant and susceptible chickens. Since DNA methylation cannot be reliably directly 
detected, several approaches are available for genome-wide methylation analysis, 
including antibody affinity enrichment of methylated DNA, sodium bisulfite 
conversion and enzymatic digestion [195]. A newly developed method, called 
Methyl-MAPS (methylation mapping analysis by paired-end sequencing) [196], was 
adopted to study MDV induced methylation fluctuation in MD resistant and 
susceptible chickens. This method yields high resolution information with no bias 
towards the CpG rich regions; both single-copy and repetitive regions are directly 
probed. The current study revealed that DNMTs were differentially expressed in 
thymus of line 63 and line 72 chickens 21 days post infection (DPI) when the virus 
was reactivated from the latent stage. Global methylation levels were found to differ 
between non-infected 63 and 72 lines, and were reduced after MDV infection in line 
63. The identified infection induced differential methylation regions (iDMRs) 
suggested that DNA methylation likely regulates distinct pathways in resistant and 
susceptible chickens. In vitro experiment demonstrated that methylation inhibition 
repressed spread of MDV. Collectively, DNA methylation is an important regulator 
of MD resistance and susceptibility, and the findings may improve our understanding 
of the role of DNA methylation in other infectious diseases and viral-infection 





Materials and Methods 
Experimental Animals and Sample Preparation 
Line 63 and line 72 (USDA-ARS Avian Disease and Oncology Laboratory, 
East Lansing, Michigan, USA) are two highly inbred lines of specific-pathogen-free 
white leghorn chickens that are resistant and susceptible, respectively, to MD tumors. 
Chickens from each line were separated into two groups. One group was infected 
with a very virulent (vv+) strain of MDV (648A passage 40) at day 5 after hatching, 
while the other group did not receive MDV. Four chickens were selected from each 
group at 21 DPI, and none of them developed tumors during the experiment period. 
Fresh thymus samples were harvested individually and stored in RNAlater solution 
(QIAGEN) at -80°C for DNA or RNA extraction. The entire animal experiment was 
conducted following the procedures and guidelines described in the “Guidelines for 
Animal Care and Use” manual approved by the Animal Care and Use Committee, the 
USDA-ARS, and the Avian Disease and Oncology Laboratory (Approval ID 111-26). 
DNA preparation and endonuclease digestion 
Genomic DNA from four samples of each group was extracted using the 
Wizard Genomic DNA purification kit (Promega). The RNase treatment was 
performed to remove RNA from DNA samples. DNA concentration was measured by 
the Qubit dsDNA Broad-Range Assay (Invitrogen).   
Four DNA samples from each group were pooled together with equal 





methyl-dependent (McrBC) or 5 methyl-sensitive restriction enzymes (HpaII, 
HpyCH4VI, AciI, HhaI and BstUI), respectively (New England Biolabs, referred to 
as RE). The amount of starting DNA was 15 ug for both RE and McrBC digestions. 
Three rounds of McrBC digestion were performed to assure complete digestion of 
methylated DNA. The digestion reaction included 1×NEB buffer 2, 2×GTP, 1×BSA, 
and 10 Units of McrBC per microgram of DNA and performed at 37˚C for 4-6 hrs. 
For the first two rounds, DNA was extracted using phenol-chloroform extraction and 
ethanol precipitation. Briefly, 2 volumes of phenol and chloroform were added, 
shaked for 5 min and then centrifuged at 14,000 rpm for 10min. The upper layer was 
transferred to a new tube, and 6 volumes of 100% ice-cold ethanol were added with 
0.1 volume of 3M Sodium Acetate pH 5.5 and 5 µl of 20 mg/ml glycogen. Tubes 
were mixed well, incubated at -20 ˚C for 30 min, and then spun at 4 ˚C at 14,000 rpm 
for 15min. The supernatant was decanted, and the pellet washed with 6 volumes of 
70% cold ethanol. This was followed by a spin at 4˚C at 14,000 rpm for 5 min. The 
supernatant was discarded, and pellet was dried and resuspended in 50 µl TE. After 
the last round of digestion, DNA was purified using QIAquick spin columns 
(QIAGEN) to remove the GTPs. Four rounds of RE digestion were conducted and 
followed by phenol-chloroform extraction and ethanol precipitation. The first round 
of RE was set up with 1×NEB buffer 2, 10 Units of HpaII and 10 Units of 
HpyCH4IV per microgram of DNA, and digested at 37˚C for 4-6 hrs. The second 
round included 1×NEB buffer 3, 1×BSA, and 10 Units of AciI and 5 Units of HhaI 
per microgram of DNA and conducted at 37˚C for 4-6 hrs. The third round was 





2-3 hrs. The last round repeated the HpaII and HpyCH4IV digestion for 2-4 hrs at 37 
˚C. 
SOLiD mate-pair library construction 
 Mate-pair libraries were prepared with slight variation to the SOLiD library 
preparation guide. Fractionated DNA was repaired using End-It DNA End-repair kit 
(Epicentre), and incubated at room temperature for 45 min. DNA was purified using 
QIAquick spin columns (QIAGEN) to remove the ATPs and dNTPs, and quantified 
by Qubit dsDNA Broad-Range Assay (Invitrogen). Endogenous EcoP15I sites were 
then methylated using EcoP15I enzyme with 1×NEB buffer 3, 1×BSA, 360 µM 
SAM. The methylation reaction was performed at 37˚C for 2-3 hrs, and then boosted 
with additional EcoP15I, NEB buffer 3, BSA, and SAM for another 2-3 hrs at 37˚C. 
The DNA was purified using QIAquick spin columns (QIAGEN) and quantified by 
Qubit dsDNA Broad-Range Assay (Invitrogen). The EcoP15I cap adapter (50 
pmol/µl) was ligated to the end-repaired and EcoP15I methylated DNA using Quick 
Ligation Kit (NEB). The reaction was incubated at room temperature for 10 min, and 
purified using MinElute (QIAGEN) to remove excess adapters.  
 DNA samples were run on 1% agarose gel at 50 V for 1.5-2 hrs. DNA was 
selected based on 7 fragment sizes: 0.8-1.1 kb, 1.1-1.5kb, 1.5-2 kb, 2-3kb, 3-5 kb, 5-
8kb and >8kb. Each fraction was purified using QIAquick Gel Extraction kit 
(QIAGEN), and the concentration was measured using Qubit dsDNA High-
Sensitivity assay kit (invitrogen). DNA from each fraction was circularized with the 





DNA was purified using QIAquick spin columns (QIAGEN). Fractions were then 
combined into two tubes, one for <2 Kb and the other for >2 kb. Circularized DNA 
was isolated using ATP-dependent Plasmid-safe DNase (Epicentre) to degrade the 
linear DNA. The purified DNA samples were digested with EcoP15I, 1×NEB buffer 
3, 1×BSA, 2mM ATP and 0.1 M Sinefungin overnight at 37˚C on PCR machine. The 
reaction was boosted the next morning with fresh EcoP15I, ATP, BSA and 
Sinefungin for 1 hr, and terminated by denaturing at 65˚C for 20 min. The digested 
DNA was repaired by 5 Units of Klenow (NEB) in the presence of 10 mM dNTPs for 
30 min at 25˚C, and then heat inactivated at 65˚C for 20 min. P1 and P2 adapters 
were added to the end repaired DNA using Quick Ligation Kit (NEB). The ligation 
reaction was terminated by heat inactivation. P2 adapters contained distinct barcodes 
for each library so libraries can be later pooled for sequencing. The <2 kb and > 2kb 
fractions were combined together for library purification. 
 M280 streptavidin beads (Invitrogen) were washed with 1× bead wash buffer 
(2% Triton X-100, 2% Tween 20, and 10mM EDTA) and 1×BSA, and resuspended 
in 1× binding buffer (40mM Tris-HCl, 4M NaCl, and 4mM EDTA). DNA samples 
were added to the beads, and incubated by rotation at room temperature for 15 min. 
The library DNA was bound to the beads through the biotin on the T30 internal 
adapter. The DNA-bead complex was washed with bead washing buffer and 1×NEB 
buffer 2. Finally, the complex was collected by quick spin and placing on a magnet. 
Washed library-bound beads were resuspended in 1×NEB buffer 2. Nick translation 
was performed on DNA-beads using DNA Polymerase I (NEB) in the presence of 





buffer. Trial PCR was performed by serial dilution of beads to ensure the existence of 
156-bp products and to determine the sufficient cycles to obtain enough products. 
Final libraries were amplified using all the beads and Pushion High Fidelity DNA 
Polymerase (NEB) with 19-23 cycles. Each 50 µl reaction included 1 µl bead 
template, 1 µl of 50 µM L-PCR-P1 primer, 1 µl of 50 µM L-PCR-P2 primer, 1× 
Phusion HF buffer, dNTPs, and 0.02 Units of Pushion Hot Start DNA Polymerase. 
The PCR products were combined together for ethanol precipitation. 
 A 6% DNA PAGE gel (Lonza) was used to purify the 156-bp library DNA. 
The gel was pre-run for 5 min, and PCR products as well as a 25 bp DNA ladder 
(Invitrogen) were loaded on the gel and run at 115 V for 55 min. The gel was stained 
in 1:6,000 ethidium bromide (10 mg/ml) in TBE for 10 min, destained in water for 10 
min twice, and the 156-bp library band excised. The gel fragment was shredded, the 
library eluted in PAGE elustion buffer, and gel fragments removed using a Nanosep 
MF Centrifugal Devices 0.45 micron filter column (Pall). The eluted DNA was 
purified with MinElute kit (QIAGEN). The final library DNA concentration was 
measured using the Qubit HS assay kit (Invitrogen), and the quality and quantity was 
assessed by Bioanalyzer DNA 1000 LabChip (Agilent). 
DNA sequencing  
 The DNA libraries were sequenced by EdgeBio (EdgeBio). Biscally, each 
sequencing library was amplified on 1 µm beads using emulsion PCR according to 
the SOLiD emulsion PCR protocol (Applied Biosystem). The DNA libraries were 





obtained by sequencing from forward and reverse on each bead. Eight libraries from 4 
samples were pooled and sequenced on a single chip using the standard SOLiD 
protocol.  
Tag mapping and data analysis 
 Sequence tags were mapped using SOLiD system software analysis package 
Corona-lite (Applied Biosystem). Two mismatches in each 25 bp read to the chicken 
genome (http://genome.ucsc.edu) were allowed. Reads were filtered to remove 
fragments without at least one enzyme cut site on the fragment end. Read counts were 
normalized as in Edwards et al [196]. The methylation level for each CpG site was 
calculated as the number of reads from methylation (RE) library divided by the 
number of reads from both RE and McrBC libraries. Each CpG site was annotated 
according to its genomic location (promoter, gene body, intergenic, repetitive regions 
and CpG islands).The differential methylation regions (DMRs) were discovered by 
merging adjacent sliding windows with at least 3 differentially methylated CpGs in a 
2 kb window.  DMRs were reported only if their length was greater than 3 kb. 
Fisher’s Exact test was used to identify the differential methylation CpG site 
controlling for an FDR greater than 0.01. The annotation information, including 
Refseq, repeatMask, CpG islands were obtained from the UCSC genome browser 
(galGal3).  
Bisulfite conversion, pyrosequencing and bisulfite sequencing  





DNA Methylation Golden Kit) using the standard protocol provided by the 
manufacturer. PCR primers for methylation validation were listed in Table 4.1. For 
pyrosequencing, we used biotin labeled universal primer in the PCR reaction. The 
bisulfite PCR included 1 µl of 1:5 diluted bisulfite converted DNA, primers and PCR 
reagents from Hotstar Taq polymerase kit (QIAGEN) with four biological replicates. 
The methylation level was detected individually by Pyro Q-CpG system (PyroMark 
ID, Biotage, Sweden) using 20 µl of PCR products. For bisulfite sequencing, an equal 
amount of DNA from four samples of treated or control groups from each chicken 
line were pooled together, serving as a template for the bisulfite conversion and the 
bisulfite PCR, and then PCR products were purified (QIAquick Gel Extraction Kit, 
QIAGEN). The purified PCR products were ligated to pCR® 2.1 Vector (The 
Original TA cloning® Kit, Invitrogen), transformed to DH5α competent cells 
(ZYMO Research), and screened for successful insertions (blue-white selection) after 
incubation at 37˚C overnight. Ten white colonies from each group were cultured in a 
37˚C shaker overnight. Plasmid DNA was isolated using the QIAprep® Miniprep Kit 
(QIAGEN), and M13 reverse primer was used for sequencing. 
Purification and quantification of mRNA levels 
RNA was extracted from four samples per group using the RNeasy Mini Kit 
(QIAGEN) and the standard method described by the manufacturer. An on-column 
DNase digestion was performed to remove any contaminant DNA. RNA 
concentration was measured by Nanodrop. Reverse transcription was performed on 1 





with oligo (dT) 12-18 primers (Invitrogen); mRNA levels were quantified using 
SYRB Green PCR Kit (QIAGEN) with four biological replicates from each group. 
PCR primers for mRNA quantification are listed in Table 4.1.  























Reverse 5’-GGGACACCGCTGATCGTTT AAACACACACACACGATCC-3’ 
Sequencing 5’-GGGGGAAATTGAGGTA-3’ 
GAPDHB Forward 5’-GAGGGTAGTGAAGGCTGCTG-3’ Reverse 5’-ACCAGGAAACAAGCTTGACG-3’ 
DNMT1B Forward 5’-CCACCAAAAGGAAATCAGAG-3’ Reverse 5’-TAATCCTCTTCTCATCTTGCT-3’ 
DNMT3aB Forward 5’-ATGAACGAGAAGGAAGACATC-3’ Reverse 5’-GCAAAGAGGTGGCGGATCAC-3’ 





A: PCR primers for bisulfite sequencing and pyrosequencing. B: Primers for real time-
PCR.  
DNA dot blot 





for 5 min, and snap cooled on ice. The denatured DNA was neutralized with 0.1 
volume of 6.6 M Ammonium acetate. DNA samples were then loaded on a 
nitrocellulose membrane (Bio-rad), and UV cross-linked. Blocking was performed 
using 10% non-fat milk. The membrane was incubated with primary antibodies 
against 5’-methylcytonsine (5mC, Active Motif) and 5’-hydroxymethylcytosine 
(5hmC, Diagenode), and diluted in blocking solution (1:5,000) at 4 ˚C overnight. 
After 3 washes, the membrane was incubated with anti-rabbit IgG and anti-mouse 
IgG secondary antibodies (Santa Cruz) and diluted in TBST (1:5000) for 1 hr at room 
temperature. Membranes were developed with ECL (Amersham) and measured using 
ChemiDoc XRS (Bio-Rad). Each dot was circled, and the average volume in the 
circle was exported to Excel to estimate 5mC and 5hmC contents using Quantity One 
software (Bio-rad). 5mC and 5hmC positive controls were synthesized by PCR using 
5mCTPs and 5hmCTPs (ZMYO research).  
Cell culture and MDV infection 
The chicken embryo fibroblast cell line DF-1 was grown in Dulbecco’s 
modified Eagle’s medium supplemented with 10%, fetal bovine serum, streptomycin 
(100 mg/ml) and penicillin (100 U/ml) (Invitrogen). Cells were maintained at 37°C in 
humidified 5% CO2 conditions. The very virulent + (vv+) strain of MDV (648A 
passage 40) was obtained from USDA-ARS Avian Disease and Oncology 
Laboratory. The DF-1 cells were inoculated with the virus at multiplicity of infection 
(M.O.I) of 0.1 for 3 days. The DNA methylation inhibitor 5-azacytidine (Fisher) was 






 The DF-1 cells were fixed with 4% of paraformaldehyde for 15 min, and 
permeabilized using 0.5% Triton-X 100 in PBS for 15 min. Primary antibodies were 
prepared at 1:500 and 1:1000 dilutions in PBS, and incubated with cells for 1 hr. 
After washing the cells 3 times, FITC-labeled donkey anti-mouse or donkey anti-
rabbit IgG secondary antibodies were diluted 1:1,000 in PBS, and incubated with 
cells for 30 min. The nuclei were labeled with 4', 6-diamidino-2-phenylindole (DAPI) 
(Invitrogen). The immunoreactive complexes were visualized with a Zeiss LSM 510 
confocal fluorescence microscope, and the images were processed using LSM Image 
Examiner software (Zeiss). 
Results 
The expressions of DNMTs in MDV infected chickens 
 To test the influence of MDV infection on DNMT expression, the mRNA 
levels of each of three DNA methyltransferases were examined by qPCR in the 
thymus of lines 63 and 72 at 21 DPI (Figure 4.1).  Transcriptional levels of DNMT1 
were ~ 20% higher in line 72 compared to line 63 (p>0.05), and did not significantly 
altered in in either line after MDV exposure. DNMT3a mRNA was similar in non-
infected line 63 and line 72. However, its expression was repressed 30% in infected 
line 63 chickens (p<0.05). The expression of DNMT3b was 2 fold higher in line 72 
than in line 63 before MDV infection (p>0.05), and its transcription was further 





(p<0.01).   
 
Figure 4.1 The mRNA Quantification of chicken DNMTs. Expression of DNMT1, 
DNMT3a and DNMT3b was measured by qRT-PCR in thymus samples from 
noninfected and infected line 63 and line 72 chickens, and normalized to GAPDH. The 
quantitative results are represented as mean ± SEM (n=4). A single asterisk (p-values 
<0.05) and double asterisks (p-values < 0.01) indicate the transcription level in the 
specific group was significantly different when compared to the adjoined group.  
L72.inf: infected line 72; L72.non.inf: noninfected line 72; L63.non.inf: noninfected 
line 63; L63.inf: infected line 63. 
Global mapping of DNA methylation in chickens 
To explore the consequences of differential expression of DNMT3a and 
DNMT3b in the two chicken lines, genome-wide DNA methylation analysis was 
carried out using Methyl-MAPS. The methylated compartment in the chicken was 
detected by the digestion with five methyl-sensitive restriction enzymes, and the 
unmethylated part was investigated by the methyl-dependent enzyme McrBC. From 





mapping to chicken genome. For each sample, 2.7 to 3.1 million CpG sites were 
detected, and 66-76% of them had coverage greater than 10 reads/site, which were 
used for the further analysis (Table 4.2).  
Table 4.2 The Global mapping statistics. 
Sample Library Raw Reads F % R % No. CpGs No. of CpGs(>=10) 
L6
3.non 
McrBC 38,941,424 51.27 57.99 3,002,069 1,991,421 RE 47,622,587 54.48 58.32
L7
2. non 
McrBC 26,072,658 45.03 50.13 2,751,367 1,918,821 RE 51,831,801 50.77 55.74
L6
3. inf 
McrBC 50,833,633 50.43 54.99 3,103,734 2,322,557 RE 42,467,075 53.35 59.03
L7
2. inf 
McrBC 71,914,437 58.70 63.53 3,096,603 2,392,480 RE 89,731,607 57.28 61.17
Eight DNA libraries from 4 samples were sequenced. McrBC and RE represented the 
libraries from methyl-dependent and five methyl-sensitive enzyme digested DNA. 
Raw reads indicated the number of reads obtained from sequencing before data filter. 
F% and R% indicated the percentage of mapped reads from the forward and reverse 
primer sequencing. Number of CpG sites and number of CpG sites with coverage 
greater than 10 reads/site were listed. L72.inf: infected line 72; L72.non: noninfected 
line 72; L63.non: noninfected line 63; L63.inf: infected line 63.   
 
In slico analysis of chicken genome showed that this method theoretically, 
covered 3,317,773 CpGs, which can be recognized by both methyl-dependent and 
methyl-sensitive restriction endonucleases (MR sites), counting for ~32% of CpGs in 
the chicken genome. Most of the CpGs were covered by 20-200 reads, and some had 
the coverage greater than 200 (Figure 4.2).  The MR site coverage and CpG sites 
coverage were similar among 4 samples. With the cutoff of minimum 10 reads/site, 
61.97-78.16% of MR sites were detected which included 19.97-25.18% of chicken 






Figure 4.2 The CpG coverage distributions. The y-axis was the fraction of CpG 
sites, and the x-axis was the number of reads/CpG sites. 200 indicates the number of 
sites with 200 or greater reads. Sequencing libraries: 72.inf: infected line 72; 72.non: 
noninfected line 72; 63.non: noninfected line 63; 63.inf: infected line 63.   
  
Table 4.3 The CpG coverage.  
 L63.non L72.non L63.inf L72.inf 
MR site Coverage 72.99% 78.16% 61.97% 64.19% 
CpG Coverage 23.52% 25.18% 19.97% 20.68% 
MR sites indicated the CpGs which were able to be recognized by methyl-dependent 
(McrBC) and methyl-sensitive enzymes.  
 
Totally, 2,575,854 CpGs were detected by Methyl-MAPS. Among these 
CpGs, 1,073,930 were annotated (CpGs in total) and distributed into 5 categories: 
exon, repetitive DNA, promoter absent of CGI, CGI overlapped promoter 
(CGI_promoter) and CGI_others (CGIs not in the other 4 categories) (Figure 4.3). An 
additional 1,501,924 CpGs (~58.31% of all detected CpGs) were unannotated. Nearly 
one third of annotated CpGs were found in CpG islands. About 42% of CpGs were in 
the annotated promoter regions, including 27.9% of them in the promoters within 
CGIs and 14.44% in the promoters lack of CGIs. There were 10.56% of CpG sites 





including the simple repeats (~2.16%) and satellite (0.16%), retrotransposons 
(11.51%) and DNA transposons (1.17%).  The variations among four samples were 
demonstrated in Table 4.4. More CpGs on repetitive DNA, exons and promoter were 
detected in non-infected line 72, whereas the distribution of CpG in infected lines 63 
and 72 was similar after MDV infection.   
 
Figure 4.3 The distributions of annotated CpGs. The annotation of CpGs includes 
5 categories: exon, repetitive DNA, promoter absent of CGI, CGI overlapped 
promoter (CGI_promoter) and CGI_others (CGIs not in the other 4 categories).   
 
Table 4.4 The distributions of annotated CpGs among 4 samples.  
 L63.non L72.non L63.inf L72.inf 
Repetitive DNA 15.34% 19.48% 13.21% 13.88% 
CGI_other 31.84% 28.78% 33.57% 32.86% 
CGI_promoter 27.12% 19.93% 30.48% 30.66% 
Exon 10.84% 14.62% 9.23% 9.24% 
Promoter 14.87% 17.20% 13.52% 13.37% 
L72.inf: infected line 72; L72.non: noninfected line 72; L63.non: noninfected line 63; 
L63.inf: infected line 63. 
DNA methylation variations induced by MDV infection 





in line 72 (0.44) than in line 63 (0.39) regardless of infection (Figure 4.4 and Figure 
4.5).  While methylation levels in line 72 stayed relatively constant after MDV 
infection, the global methylation level decreased to 0.17 in line 63 (Figure 4.4).  The 
5mC content in each individual was measured using anti-5mC dot blot (Figure 4.5). 
The quantitative result was in a good agreement with the sequencing results, which 
the methylation levels were decreased about 38% in infected line 63 (p<0.05), and 
were increased about 6% in the infected line 72 chickens (p>0.05). Between 
noninfected chickens, the methylation was about ~17% less in line 63 than line 72.  To 
figure out how the methylation altered among 4 samples, we categorized the CpG 
sites as methylation (methylation level greater than 75%), intermediate methylation 
(25-75%), and unmethylation (<25%) groups. The methylated sites were dramatically 
decreased in line 63, while the methylated sites were increased slightly in line 72. In 
line 63, about two thirds of methylated CpGs became unmethylated, and the 
proportion of unmethylated CpGs was increased 1.5 times after MDV infection 
(Figure 4.6). In line 72, the proportion of CpGs in each class was similar after MDV 
infection, despite of 6% of increase in methylation category and the 2% of decrease in 
the unmethylation class.  Before MDV infection, the number of methylated CpGs was 
less in line 63 than in line 72, and the number of CpG with the intermediate 







Figure 4.4 The boxplot of methylation levels for the detected CpGs. The y-axis 
was the methylation levels for all CpG sites calculated as the number of reads from 
methylated (RE) library divided by the number of reads from both methylated and 
unmethylated (McrBC) libraries. L72.inf: infected line 72; L72.non: noninfected line 








Figure 4.5 Quantification of 5mC content by anti-5mC dot blot. The 5mC content 
was measured in DNA from thymus using dot blot, showing as (mean ±STD, n=4). A 
single asterisk (p-values <0.05) indicated the 5mC contents in the specific group was 
significantly different when compared to other groups.  L72.inf: infected line 72; 








Figure 4.6 The classification of CpG based on the methylation levels. The CpGs 
were divided into 3 categories based on the methylation levels greater than 75% 
(Methy), 25-75% (inter) and unmethy (<25%). The number on the top of each bar 
represented the number of analyzed CpGs, and the percentage of CpGs in each 
category was labeled in the bar. L72.inf: infected line 72; L72.non: noninfected line 72; 
L63.non: noninfected line 63; L63.inf: infected line 63. 
 
Many detected CpGs with different methylation levels were located in gene 
regions. MHCII (major histocompatibility complex II) region was taken as an 
example since it is one of the determinants for MD resistance, and its haplotype is the 
same between line 63 and line 72. The methylation status of MHCII region in non-
infected and infected chickens is shown in Figure 4.7A. Methylation patterns are 
similar between non-infected line 63 and line 72. After infection, the methylation 
levels were increased in line 72 in region 1, and reduced in region 2. These two 
regions did not show methylation variations in line 63 after infection. Besides CpG 
methylation in genes, the methylation of CpGs on the repetitive DNA sequences was 





interspersed nuclear elements (LINE) in chicken, counting for ~8.7%, and long-
terminal repeats (LTRs) and DNA transposons both counting for 1.1%. An example 
of differential methylation at repeat elements after infection is shown in Figure 4.7B. 
The CGIs embeded in the repetitive regions (region 3) were highly methylated in 
uninfected line 72, and showed moderate methylation level in uninfected line 63. The 
methylation levels at this CGI were decreased after MDV infection in two lines, and 
line 72 chickens showed higher methylation than line 63. It was clear that the LTR 
repeat (region 4) upstream of chicken transcript was less methylated in line 72 than 
line 63 before MDV infection, whereas its methylation was raised in line 72 after the 







Figure 4.7 The genome-wide DNA methylation profiling.  The top includes the 
genomic location and annotation information. MR site track indicated potential 
McrBC and RE cut sites. The bars mean the absolute read counts mapped to the CpG 
site.The red bars represent CpGs cleaved by McrBC and thus methylated, while the 
blue indicates CpGs cleaved by RE and thus unmethylated. The black denotes CpGs 
cleaved by both methyl-dependent and methyl-sensitive enzymes that have moderate 
methylation levels. (A) The genome browser view of the methylation status of the 
MHCII locus in lines 63 and 72 before and after MDV treatment. Region 1 and 2 
showed methylation variations in two lines after infection. (B) The methylation status 
of a region of repetitive DNA sequences on chromosome 1. Region 3 and 4 are two 
examples showing methylation variations induced by MDV infection. 
Methylation variation in CGIs and repetitive regions 
 A total number of 1,622,778 CpGs were located among the 22,806 CGIs in 
the chicken genome, and one thirds of these CpGs (540,390) were directly probed, 
including 16,927, about 74% of CGIs. CGIs had low average levels of methylation 





63 and line 72. The average methylation was reduced in line 63 from 0.16 to 0.09 after 
MDV infection, and was slightly increased in the infected line 72 from 0.16 to 0.20 
(Figure 4.8). The methylation levels of the promoter CGIs were reduced in both lines 
after MDV infection, from 0.29 to 0.27 in line 63 and from 0.30 to 0.28 in line 72. To 
validate the genome-wide methylation results, 5 CpG sites in a CGI on chromosome 2 
(29,264-29,264,968), upstream of HDAC9 (histone deacetylase 9), were analyzed by 
pyrosequencing (Figure 4.9A and Appendix V). The average methylation difference 
was about 0.08 between line 63 and line 72 before virus infection, and the differences 
were greater than 0.1 in CpG site 1,2 and 5 (p<0.05 and p<0.01). The methylation 
was reduced about 5% and 10% after MDV infection, making the methylation levels 
similar between infected line 63 and line 72 (p>0.05). The methylation of the other 
CGI on chromosome 5 (8,429,672-8,430,025), at the promoter of FAR1, containing 
33 CpGs was measured using bisulfite sequencing, showing the methylation levels 
were reduced after infection by 8% and 18% in lines 63 and line 72 respectively 






Figure 4.8 The CGI methylation status. The y-axis was the methylation levels of 
CpGs within repetitive regions. The x-axis indicated 4 groups. L72.inf: infected line 







Figure 4.9 Pryosequencing and bisulfite sequencing confirmation of promoter 
CGI methylation. (A) The pyrosequencing from CGI upstream of HDAC9. The y-
axis is the absolute DNA methylation level of each CpG site. A single asterisk means 
p-values <0.05 and double asterisks p-values < 0.01. Each group includes 4 biological 
replicates. (B) The validation of CGI methylation on FAR1 promoter by bisulfite 
sequencing. Each line represents a sequence of a plasmid, and each dot indicates a 
CpG site. The open dot indicated the unmethylated CpGs, and black dot was the 
methylated CpGs. The grey one denoted the CpG was undetected, and yellow one 
was the mutation. The methylation level was calculated as the number of methylated 
CpG sites divided by the total detected CpGs (yellow and grey were excluded). 
L72.inf: infected line 72; L72.non: noninfected line 72; L63.non: noninfected line 63; 






Repetitive DNA regions contain 950,055 CpGs, about 27.05% of annotated 
chicken CpGs. The overall methylation levels of the repeat associated CpGs are 
plotted in Figure 4.10. The average methylation levels were similar between line 63 
(0.31) and line 72 (0.35). These CpGs on the repetitive regions were hypomethylated 
in line 63 (0.16) but not in line 72 (0.37) after MDV infection.  
 
Figure 4.10 The CpG methylation in repetitive DNA regions. The y-axis was the 
methylation levels of CpGs within CGIs. L72.inf: infected line 72; L72.non: 
noninfected line 72; L63.non: noninfected line 63; L63.inf: infected line 63. 
Methylation variations across genes 
To ascertain the viral-induced methylation changes associated with genes, the 
CpG distribution and DNA methylation levels across gene body were plotted in 
Figure 4.11. The CpG density gradually increased towards the transcriptional start 





the increased CpG density towards the TSS, the methylation was declined. The CpG 
density reached the highest level at the 5’ and 3’ of splice site of the first exons, and 
these promoter-associated CGIs were unmethylated. For example, a CGI located 
upstream of FABP3 (Fatty acid binding protein 3) were hypomethylated, with the 
methylation levels less than 0.1 among 4 groups (Figure 4.12 and Appendix VI). 
Within the coding region, compared to the low CpG density and methylation in 
introns, the internal exons and the last exon were enriched of the methylated CpGs, 
and both of the CpG density and methylation reached the maximum at the 5’ and 3’ 
ends. The CpGs were poor in the regions coding for 3’UTR and Poly (A) tail, and 
methylation in these regions was similar to the gene body. 
 The methylation across genes was similar among noninfected chickens of line 
63 and line 72 as well as infected line 72, and was reduced in the line 63 infected 
chickens (Figure 4.12). The CpGs in the gene body showed higher methylation levels 
in infected line 72 than other groups. At the promoter region upstream of TSS, the 
difference between infected and noninfected line 63 was about 0.2. For example, the 
methylation of 19 CpGs ~200 bp upstream of GATA2 (GATA binding protein 2) were 
decreased from 53.1% to 34.6% in line 63 after MDV infection, and only reduced 2% 






Figure 4.11 CpG distribution and DNA methylation pattern in chicken genes. 
CpG density and methylated CpG were plotted across gene from the prompter to the 
transcription terminal site.     
 
Figure 4.12 The methylation of CGI upstream of FABP3. The methylation was 






Figure 4.13 The bisulfite sequencing of CpGs upstream of GATA2. Each line 
represents a sequence of a plasmid, and each dot indicates a CpG site. The open dot 
indicated the unmethylated CpGs, and black dot was the methylated CpGs. The grey 
one denoted the CpG was undetected, and yellow one was the mutation. The 
methylation level was calculated as the number of methylated CpG sites divided by 
the total detected CpGs (yellow and grey were excluded). L72.inf: infected line 72; 
L72.non: noninfected line 72; L63.non: noninfected line 63; L63.inf: infected line 63. 
Identification of infection induced differential methylation regions 
(iDMRs)  
The differential methylation site was defined as the absolute methylation level 
difference for each CpG between infected and noninfected sample greater than 30%. 
Based on the cutoff, 307,354 and 755,196 CpGs were identified as differential 
methylation sites between infected and noninfected chickens in line 63 and line 72, 
respectively. The adjacent differential methylation CpG sites were merged to get the 





7,952 iDMRs, which overlapped with 1,247 refseq genes and 1,603 repetitive regions. 
In line 72, 19,976 iDMRs were identified, which covered 3,079 genes and 4,683 
repeats. For example, the CpG sites of CR1-B on chromosome 3: 110,191,142-
110,191,684, were identified as the iDMRs in line 72, but not in line 63 due to the 
smaller methylation alterations induced by MDV infection (Figure 4.14 and appendix 
VIII). Before MDV infection, the DNA methylation was about 15% higher in line 72 
than in line 63, and decreased about 5% in line 63 and 25% in line 72, respectively, 
after MDV infection. Among iDMRs, 94.6% of iDMRs in lines 63 were overlapped 
with iDMRs in line 72, which contains 884 genes and 1,496 repeated sequences. The 
iDMR was identified in the promoter of GH (growth hormone), the previously 
identified candidate gene of MD resistance, with the large reduction of methylation in 
line 72 and small decreases in line 63 after MDV infection (Appendix IX).  
 
Figure 4.14 The validation of CR1-B methylation. Each line represents a sequence 
of a plasmid, and each dot indicates a CpG site.  The open dot indicated the 
unmethylated CpGs, and black dot was the methylated CpGs. The grey one denoted 
the undetected CpG, and yellow one was the mutation. The methylation level was 
calculated as the number of methylated CpG sites divided by the total detected CpGs 
(yellow and grey were excluded). L72.inf: infected line 72; L72.non: noninfected line 
72; L63.non: noninfected line 63; L63.inf: infected line 63. 
 





identified ~600 bp upstream of CDC42 (cell division cycle 42) in line 72, with the 
reduced methylation level of 0.04 in line 63 and 0.33 in line 72 after MDV infection, 
respectively (Figure 4.15 and Appendix X). Correspondingly, the mRNA level of 
CDC42 was upregulated about 24% in line 72 after MDV infection (p<0.05), and 
were similar in line 63 (Figure 4.16). 
These iDMR-related genes were enriched in the different pathways in line 63 
and 72, such as the VEGF signaling and IL-6 signaling in line 63 and NF-κB related 
pathways in line 72 (Table 4.5). The iDMRs were separated into increased_iDMRs 
and decreased_iDMRs based on the directional methylation variation after MDV 
infection in two lines. The IPA annotation provided the link between biological 
functions and decrease_ or increased_iDMRs in two lines (Table 4.6). In line 63, 
genes associated with decreased iDMRs were enriched in the functions of infection 
diseases and inflammatory response. And in line 72, the MDV suppressed iDMRs 
were overlapped with genes involving in cancer and genetic disorder. The 
methylation of cancer related genes was increased in line 63 and decreased in line 72 







Figure 4.15 The bisulfite sequencing of iDMR upstream of CDC42. Each line 
represents a sequence of a plasmid, and each dot indicates a CpG site. The open dot 
indicated the unmethylated CpGs, and black dot was the methylated CpGs. The grey 
one denoted the CpG was undetected, and yellow one was the mutation. The 
methylation level was calculated as the number of methylated CpG sites divided by 
the total detected CpGs (yellow and grey were excluded). L72.inf: infected line 72; 







Figure 4.16 The quantification of CDC42 mRNA level. The transcription of 
CDC42 was measured and normalized using GAPDH in the thymus samples from the 
two lines before and after MDV infection at 21 dpi. The quantitative results are 
represented as mean ± STD. A single asterisk indicated p-values <0.05. For each 
group, n=4.  
 
Table 4.5 Top Canonical Pathways   
T63_IT63 T72-IT72 
Glucocorticoid Receptor Signaling Hepatic Fibrosis / Hepatic Stellate Cell Activation 
Glioblastoma Multiforme Signaling Glucocorticoid Receptor Signaling 
VEGF Signaling NF-κB Activation by Viruses 
Clathrin-mediated Endocytosis 
Signaling NF-κB Signaling 
IL-6 Signaling PTEN Signaling 
 
Table 4.6 Top Networks 
T63_IT63 T72-IT72 
Increase Decrease Increase Decrease 
Connective tissue  
disorder 






Cell morphology Infectious disease Cell death Cell death 














Increase and decrease indicated that the methylation level was up- or down-regulated 
after MDV infection. 
DNA demethylation 





MDV infection, the contents of 5hmC, the intermediate in the active demethylation 
pathway, were detected among 4 samples using anti-5hmC dot blot (Figure 4.17). The 
quantitative results showed that 5hmC content in 10 µg DNA sample was less than 
the 10 ng of 5hmC positive control. 
 
Figure 4.17 Quantitification of 5hmC content by anti-5hmC box blot. The up 
panel was the dot blot of 10 ug of DNA from thymus with 5hmC positive controls of 






Methylation inhibition and MDV infection in vitro 
 Because of the decreased DNA methylation on MD resistant line 63, it is 
reasonable to speculate that methylation was involved in the MD resistance. To study 
the role of DNA methylation on MDV infection, the methylation inhibitor 5’-
azacytidine (5’AZA) was used to treat the MDV infected DF-1 cells. The virus 
genome contents were declined 40-57% in infected cells in the presence of 5’AZA 
relative to the untreated control cells (p<0.05) (Figure 4.18). The MDV oncoprotein 
Meq expressed in most cells in the control group, and was absent in some drug treated 
cells (Figure 4.19).  
 
Figure 4.18 Quantification of viral genome copy numbers. The virus copy 
numbers were evaluated based on viral gene Meq and ICP4 in MDV infected DF-1 
cells with or without 5’AZA treatment, and normalized to a single copy gene, Vim. 







Figure 4.19 The expression of MDV oncogene Meq. The left panel showed the 
location of nuclei using DAPI to stain DNA (blue). The middle panel was the location 
and expression MDV oncoprotein Meq (green). The right panel indicated Meq 
expression in the MDV infected DF-1 cells with or without 5’AZA. 
Discussion 
 Virus infection and tumorigenesis change DNMTs transcriptional patterns. 
Compared to the adjacent normal tissues, tumor tissues showed abnormal DNMTs 
mRNA levels [197-199]. EBV infection upregulated DNMT3a expression, and 
decreased DNMT1 and DNMT3b [200]. Additionally, our lab found that DNMT1 was 
activated in the spleen of susceptible chickens and DNMT3b was silenced in the 
resistant chicken after MDV infection during MD development [3]. These results 
suggest that the expression variations of DNMTs depended on the disease 
progression, tissues and cell types as well as the genetics of the host. DNMT3a and 
DNMT3b were two methyltransferases for de novo methylation, they interacted with 
DNMT1, the methyltransferase for maintaining methylation, to establish and spread 
methylation [201]. Changes in DNMTs can influence DNA methylation levels [202],  





may result in the reduction of DNA methylation. The results demonstrate that DNA 
methylation variations at a genome-wide scale are coordinated with the 
transcriptional differences in DNMTs induced by MDV infection in MD resistant line 
63 and susceptible line 72. The higher methylation in uninfected line 72 indicated that 
the inherited, pre-established DNA methylome may contribute to the MD 
resistance/susceptibility. 
 Previously the chicken methylome was characterized using MeDIP-seq, an 
antibody binding affinity based method [203]. However, this method is biased to the 
highly methylated CpG-rich regions with lower resolution and coverage [195, 203, 
204]. In the current study we applied Methyl-MAPS, which allowed quantification of 
methylation at single copy and repetitive regions and avoided the bias due to the 
differences in methylation level or CpG density [196]. The MeDIP method only 
identified about 9-13% methylated CGIs in chicken genome, and was unable to detect 
CGIs with low methylation level [203]. The coverage of CGIs was improved to 74% 
by the current study, including CGIs at the promoters, intragenic and intergenic 
regions with high, low and intermediate methylation. Through intensive analysis, we 
found that there was a negative correlation between CpG density and DNA 
methylation at the TSS region and a positive association at other regions in chicken. 
The methylation pattern across genes was also detected in human and chicken [196, 
203]. DNA methylation was depleted at the CGI associated promoter regions, which 
has been shown in other vertebrates to allow transcription factors and polymerase II 
to initiate transcription [205]. 





susceptible chickens. In this study, we found that the global methylation level was 
higher in line 72 than in line 63 before infection, and average methylation level was 
dramatically reduced in line 63 but increased a little in line 72 after infection. The 
results were also confirmed by the 5mC dot blot. The slight upregulation of 
methylation in infected line 72 was because the number of unmethylated and 
moderately methylated CpGs declined and the number of CpGs with methylation 
status increased. More CpGs fell into the unmethylated group and fewer were in the 
methylation and intermediate methylation classes in uninfected line 63 than in line 72, 
leading to the lower methylation in line 63 before MDV infection. The decreases in 
methylation across entire gene in infected line 63 suggested that gene transcription 
may be triggered by the infection. The overall hypomethylation in MDV infected line 
63 was caused by the methylation decreases in CGIs, repetitive regions and genes.  
Considering methylation as a key factor of transcriptional regulation, less methylation 
in line 63 may cause more active transcription in the resistant chickens than in 
susceptible chickens before MDV infection. The infection may further activate 
transcription in line 63 and silence expression in line 72. We found differential 
methylation at the MHCII locus between line 63 and line 72 before viral infection. 
Since the MHC locus contains several immune-related genes, we believe that the pre-
established methylation pattern in lines 63 and 72 may influence their immunity to 
MDV infection, and also contribute to the infection induced methylation alterations in 
two chicken lines.   
MDV infection changed methylation status of repetitive DNA sequences. A 





the methylation of these elements may be sensitive to the viral infection. Repeat DNA 
can exert regulatory functions on gene activities, and some cis-elements are 
originated from transposable elements (TEs) in humans, including LINEs and LTRs 
[206, 207]. DNA methylation of TEs was a determinant for their mobility, and can 
affect nucleosome binding and a variety of regulatory influences on nearby gene 
expression [208, 209]. Moreover, repetitive regions are often hypomethylated in 
cancer cells, resulting in the genomic instability [210]. In the chicken genome, less 
than 9% of the genome is comprised of interspersed elements. This is markedly lower 
than in the mammalian genome, which contains 40-50% [211]. The lower number of 
TEs is probably due to the lack of active elements in the chicken genome [212]. 
Therefore, it is reasonable to speculate that methylation variation at chicken TEs had 
potential influences on gene transcription, but not their retrotransposition [212]. It has 
been shown that CR1 elements upstream of STAT1 (signal transducer and activator of 
transcription 1) and IL12A (interleukin 12A), contain potential binding sites for 
GATA1 (GATA binding protein 1). The methylation levels on these two elements 
were downregulated after MDV infection, which were coordinated with the 
upregulation of mRNA levels. Since methylation inhibits transcription factor binding, 
the decreased methylation at repetitive regions may up- or down-regulate gene 
expression through the interaction between transcriptional activators or repressors 
after MDV exposure in both chicken lines. Our results also suggest that MDV 
infection changed the methylation levels at repetitive DNA, such as CR1 and LTR, 
which might have regulatory functions in response to infection.  





DNA methylation in the responses to MDV infection.  For example, we discovered an 
iDMR at the promoter of the MD resistance candidate GH [36, 213]. In addition, the 
enhanced transcription level of CDC42 was coordinated with an observed decline in 
DNA methylation in nearby iDMR, consistent with the fact that methylation silenced 
the gene transcription [210]. CDC42, a small GTPase protein, works with other 
proteins to modulate cell cycle and adhesion [214]. The less methylation and higher 
transcription level of CDC42 in infected line 72 implicated that it may contribute to 
MD susceptibility by the deregulation of cell cycle and proliferation. The 
biofunctional analysis demonstrated that different pathways may be provoked after 
the infection in each line via changes in methylation status. NF-κB is known to 
regulate the immune response to infection, and is associated with human cancer and 
tumor development. [215].  NF-κB related pathways were only found in line 72, 
suggesting line-specific DNA methylation variation might affect the disease 
susceptibility via target immune related pathways. Given the fact that methylation 
inhibits gene expression, the decreased methylation in iDMRs may activate genes 
controlling infectious disease and inflammatory responses in line 63, which will clean 
the virus from the host. Genes and pathways with functions related to the lipid 
metabolism and energy production may be suppressed by hypermethylation on 
iDMRs of infected line 72. The repression of lipid metabolism and abnormal cellular 
energy production have been characterized as the consequence of infection and nearly 
all of cancer [216, 217], suggesting that MDV infection may impair host metabolism 
via DNA methylation. It is worth noting that the relationship between atherosclerotic 





the involvement of DNA methylation in this process needs to be further elucidated. 
From our results, it seems the disturbance of DNA methylation after MDV 
infection did not involve active DNA demethylation through the conversion to 5hmC. 
Together with the downregulated DNMT3a expression, the decreased methylation in 
line 63 is likely controlled by passive demethylation. Since the methylation levels 
were lower in line 63 than line 72, the DNA methylation inhibition presumably 
improves MD resistance. Methylation inhibitor treatment limited MDV replication in 
vitro, which was confirmed by the independent estimation of virus copy numbers 
using ICP4 and Meq. Lower expression of Meq in the drug treated infected cell 
suggested that 5’AZA either limited viral replication and spread or inactivated Meq 
transcription. However, there is a debate about the function of 5’AZA on MDV 
infection. Meq expression was elevated in the MDV infected B lymphocytes 
transformed by the avian leukosis virus (ALV) [220]. This disagreement may be 
explained by the differences between ALV transformed B cells and the chicken 
model used. The line 63 chickens are resistant to MD but susceptible to ALV, whereas 
line 72 chickens are resistant to ALV and susceptible to MD [56]. Resistance to ALV 
and MDV may be mediated by different mechanisms. Methylation inhibition may 
enhance ALV propagation, which may further assist MDV infection. In addition, the 
promoter of Meq was absent of DNA methylation in the MDV infected cells [3], and 
the methylation inhibitor was unable to directly regulate Meq expression, increasing 
the possibility that ALV infection favors secondary infection with MDV. 
In summary, genome-wide and quantitative DNA methylation analysis in the 





methylation changes related to MDV infection. The comparison of methylation 
between MD resistant chicken line 63 and MD susceptible chicken line 72 suggested 
that less methylation in the host may be related to MD resistance by activating genes 
with anti-viral and anti-tumor functions. Higher methylation in the MD susceptible 
chickens might favor viral replication and spread by the disruption of the normal 
growth and immune responses. These results suggest a mechanism of disease 
resistance determined by DNA methylation patterns, and support the notion that 
methylation variations could be both the cause and the consequence of viral infection. 
Further work is required to functionally link observed gene expression and DNA 
methylation changes, together with histone modification analysis. Such analysis will 
provide a foundation to understand the role of the epigenetics in the crosstalk between 
virus and host through regulating gene expression. Additionally, the comprehensive 
integration of both genetic and epigenetic information will help to identify candidate 
genes implicated in disease resistance or susceptibility, and improve our 
understanding the epigenetic predisposition to viral infection and give clues for 







Chapter 5: Conclusions and Future Directions 
Summary 
The long term goal of our lab is to understand mechanisms involved in host-
virus interaction with a particular focus on MDV-induced changes in host epigenome 
and disease predisposition. We use MHC-independent MD resistant line 63 and 
susceptible chicken line 72 as the experimental models. The overall goal of this 
dissertation project was to identify MDV-induced miRNAs and understand how 
MDV infection changes global methylation level in host genome.  Two specific aims 
were pursued to achieve the overall goal. Specific aim 1: To identify MDV-induced 
miRNA expression signatures in line 63 and line 72 and investigate the roles of 
differentially expressed miRNAs in MDV disease development; Specific aim 2: To 
compare MDV infection induced changes in global methylation levels in line 63 and 
line 72. The results from this dissertation work provide important information about 
the roles of miRNAs and DNA methylation in mediating MD resistance or 
susceptibility.   
MicroRNAs 
Chicken MD resistant lines 63 and susceptible 72 have been extensively used to 
study the genetic mechanisms by which animals show striking differences in response 
to MDV infection. So far, the difference in miRNA expression profiles before and 





that MDV infection induces a significantly different changes in miRNA expression in 
lines 63 and 72 and these infection responsive miRNAs have functional roles in 
mediating MD resistance or susceptibility. MiRNA microarray experiment showed 
that prior to MDV infection, line 63 and line 72 had similar miRNA expression 
signatures, however, after MDV infection, these two lines were found to have 
dramatic difference in miRNA expression levels. As expected, MDV did not induce a 
significant change in miRNAs expression in line 63 but repressed 58 and increased 6 
of host miRNAs in line 72. While the virus originated miRNAs were not expressed in 
line 63, 10 MDV miRNAs were highly expression in line 72 after MDV infection. 
Both host and viral miRNAs potentially regulated immune response by targeting 
important genes in host tissues such as oncogenes and tumor suppressors. 
Bioinformatics analysis revealed that differentially expressed miRNAs gga-mib-15b 
and gga-let-7i may target ATF2 and DNMT3a, respectively. ATF2 is the 
transcriptional activator that interacts with MDV oncoprotein Meq. DNMT3a is the 
de novo DNA methyltransferase that establish methylation patterns. Further analysis 
found that ATF2 and DNMT3a transcription levels did not differ from two lines after 
MDV infection; however, their protein levels were increased in infected line 72 but 
not in infected line 63. Luciferase reporter assays proved that chicken miRNA gga-
mir-15 and gga-let-7i controlled ATF2 and DNMT3a expression through the 
interaction within the coding regions. Interestingly, when DF-1 cells were transfected 
with gga-mib-15b or gga-let-7i overexpression vector, relative to control cells, cells 
containing overexpression vectors were found to have reduced level of MDV 





indicating miRNAs have functional roles in preventing MDV infection at the cellular 
level. In summary, these projects provide functional data for the first time that 
miRNA play pivotal roles in mediating MDV-host interaction.  
DNA methylation 
DNMTs are important enzymes required for DNA methylation. Three 
different DNMTs (DNMT1, DNMT3a, and DNMT3b) have been identified in chicken. 
DNMT1 transcript level was higher in line 72 than that in line 63. In both lines, MDV 
infection did not change DNMT1 expression; however, DNMT3a and DNMt3b are 
different stories. DNMT3a and DNMT3b mRNA abundances were similar in line 63 
and line 72 before MDV challenge. Following MDV infection, DNMT3a was down-
regulated in line 63, no change was observed in line 72. Strikingly, DNMT3b was 
consistent in line 63 but showed a significant increase in line 72.  Changes in DNMT3a 
and DNMT3b transcript abundances may contribute to different global methylation 
patterns in line 63 and line 72. Therefore we hypothesized that MDV induced changes 
in DNMTs transcription result in methylation changes in line 63 and line 72 and 
different methylation patterns might be related to MD resistance and susceptibility. A 
comprehensive chicken methylome was delineated by using a high throughput 
method termed Methyl-MAPS, which covered over 20% of CpGs with low, high or 
intermediate methylation in chicken genomes. The sequencing results and 5mC dot 
blot demonstrated that the methylation levels were higher in line 72 than in line 63 
before MDV infection, which was coordinated well with higher DNMT1 mRNA in 





presumably caused by the repressed DNMT3a, and the methylation were slightly 
increased ~6% in infected line 72, corresponding well with the enhanced DNMT3b 
expression. The passive demethylation through DNMTs was likely to be the only 
reason reducing the methylation in line 63 since the active methylation via 5hmC was 
silenced in both lines. The decreased methylation in infected line 63 was largely due 
to the hypomethylation of CpG islands, repetitive DNA and gene regions. Based on 
the methylation variations, we identified the infection induced differential 
methylation regions (iDMRs) in line 63 and in line 72, and these iDMRs might 
regulate genes and pathways with different functions in the two lines. More 
importantly, we found the methylation inhibitor 5’AZA restricted MDV replication or 
spread in the infected DF-1 cells, suggesting the function of DNA methylation in 
MDV infection. Collectively, these studies provided the most detailed chicken 
methylome and discovered the involvement of DNA methylation in MD resistance 
and susceptibility. Taken together, all the results supported the notion that the pre-
established methylation patterns and MDV infection driven methylation alterations 
are indispensable for MD resistance and susceptibility in line 63 and line 72.  
Conclusions 
  This dissertation project has advanced our understanding on MD resistance 
and susceptibility through two aspects: miRNA and DNA methylation. The 
maintenance of chicken miRNA expression at the proper levels might contribute to 
MD resistance. The host miRNAs play antiviral functions through limiting viral 





causative factors for the MD resistance and susceptibility. The methylation profiles 
determined transcriptional activation and silencing after infection, which sequentially 
drove the methylation variations and influenced the disease outcomes. Moreover, 
DNA methylation and miRNAs were regulated mutually. Cellular miRNAs were 
identified to target DNA methyltransferase, which was indispensable for maintaining 
and spreading methylation. And DNA methylation might regulate miRNA expression 
as controlling gene transcription. Both miRNAs and DNA methylation, together with 
other genetic and epigenetic elements, such as SNPs, DNA copy number variations 
and histone modifications, provide the foundation for disease predisposition.   
Future Directions 
 The present study proved the antiviral function of miRNAs through 
overexpression of a single miRNA using the retroviral vector. Further work is 
required to clarify the contribution of the miRNA target genes in this process. 
Although the functions of many genes have been clearly identified in model systems 
using transgenic and knockout approaches, in chickens, it is very challengeable. One 
way to investigate the gene function is to knockdown the gene of interest using RNA 
interference (RNAi). The knockdown of miRNA target genes can be accomplished by 
RNAi using the same retroviral vector in the DF-1 cells [221]. Short hairpin RNAs 
(shRNAs) can be synthesized to match the transcripts and introduced into the 
retroviral vector [222]. The infection of the target gene deficient cells could 
characterize the function of the miRNA target genes in responses to MDV. 





interfering RNAs (siRNAs) avoided the viral escape [188, 191]. Therefore, the 
construction of a retroviral vector that expresses the multiple miRNA simultaneously 
might further repress the viral replication by targeting more host and viral genes.  
Meanwhile, elucidating the regulation of viral genome by the cellular miRNAs is an 
important part to understand the crosstalk between host and virus. It has been shown 
that human miRNAs promoted hepatitis C virus translation by binding at the 5’UTR 
of the viral RNA [185]. Thus, compared to the host genes, cellular miRNAs use 
different mechanisms to regulate foreign RNA expression. The interaction between 
MDV and chicken miRNAs will be illustrated by the identification of cellular miRNA 
binding sites on viral transcripts, which may further uncover the mechanism of 
antiviral function of cellular miRNAs. 
    A functional test in the present study was done in vitro. Similar in vivo studies 
are necessary to understand the role of miRNAs in pathological conditions after MDV 
infection.  The attempt to overexpress miRNAs in chicken was not successfully 
achieved by using ALV based vector, due to the extremely lower transfer efficiency 
in the germ line cells, which requires other delivery methods [223, 224]. The tissue-
specific knockdown of gene expression by lentiviral vector has been successfully 
demonstrated in a mammalian system [225]. Using the lentivrial vector is a promising 
approach to stably express miRNAs in specific tissues in chickens. Together with 
vaccination, this would allow the development of new methods to improve the current 
protective strategy. 
  The other accomplishment of this study is the identification of MDV induced 





gene expression regulation by influencing the transcription factor binding [226]. 
Therefore, a motif search in the constitutive or infection specific iDMRs would allow 
identification of the transcriptional factors involved in MD resistance and 
susceptibility. Transcription factor binding motifs were enriched in the lineage-
specific and normal or cancer cell specific hypomethylated regions, indicating the 
possibility of identifying trans acting factors in regions with DNA methylation 
changes [227, 228]. Additionally, histone modifications regulate gene activation. Our 
lab has profiled the active gene marker histone 3 lysine 4 trimethylation (H3K4me3) 
and the silencing gene marker histone 3 lysine 27 trimethylation (H3K27me3) in MD 
resistant line 63 and MD susceptible line 72 before and after infection. The 
combination of the histone modification profiles and DNA methylation profiles with 
gene expression would provide more information about the epigenetic variations 
induced by MDV infection, and also about the feedback of epigenetic alterations to 
disease resistance through switching on/off the gene expression.       
Finally, the present study uncovered a role of inherited DNA methylation 
patterns in MD resistance and susceptibility in chickens. Thus, we attempted to test 
the feasibility of finding DNA methylation patterns as biomarkers to select MD 
resistant chickens. DNA methylation has gained more attentions from the biomarker 
discovery field since it is able to be measured quantitatively compared to other 
epigenetic markers. Biomarker discovery in cancer includes five phases, 
identification of markers, clinical detection, longitude study, screening study, and 
lastly case control study [229]. In humans, several studies have revealed that DNA 





early diagnosis [230, 231]. The current study was the first step in characterizing the 
involvement of DNA methylation in MD resistance and susceptibility. More 
sophisticated analyses are required to delineate the regulatory functions of DNA 
methylation in MD predisposition in chickens, and to apply the discoveries in genetic 





















Appendix I. Differentially expressed chicken microRNAs between infected and 
noninfected Line72 groups 
Name logFC P.Value FDR 
gga-miR-99a 1.760595 3.29E-06 5.92E-05 
gga-miR-181a 1.949209 4.76E-06 6.91E-05 
gga-miR-181b 1.741941 5.12E-06 6.91E-05 
gga-miR-103 1.350569 1.18E-05 0.000148 
gga-miR-128 1.263305 1.93E-05 0.000223 
gga-miR-455 1.273726 5.08E-05 0.000549 
gga-let-7b 1.241415 5.84E-05 0.000591 
gga-miR-10b 1.214064 0.000101 0.000915 
gga-miR-456 1.166798 0.000113 0.000915 
gga-miR-1b 1.208345 0.000166 0.00128 
gga-miR-107 1.260672 0.000174 0.001283 
gga-miR-30a-3p 1.744581 0.000225 0.001587 
gga-miR-100 1.145376 0.000312 0.002104 
gga-let-7a/gga-let-7j 1.325531 0.00036 0.002308 
gga-miR-146a -1.21913 0.00037 0.002308 
gga-miR-30d 1.087841 0.0004 0.0024 
gga-miR-147 -1.01843 0.000542 0.003135 
gga-miR-17-3p 1.220382 0.000676 0.003776 
gga-miR-218 1.116341 0.000703 0.003795 
gga-miR-9 1.110438 0.000789 0.004124 
gga-miR-138 0.809944 0.001534 0.00751 
gga-let-7f 0.795792 0.001566 0.00751 
gga-miR-199 0.762491 0.001576 0.00751 
gga-miR-124a 0.923271 0.001945 0.009004 
gga-miR-18b 0.836313 0.002905 0.01286 
gga-miR-125b 0.870999 0.002937 0.01286 
gga-miR-153 1.453438 0.003084 0.013146 
gga-miR-221 0.782907 0.003887 0.016148 
gga-miR-30c 0.703324 0.004367 0.017688 
gga-miR-92 0.864246 0.004583 0.018108 
gga-miR-133b 0.920419 0.00512 0.019748 
gga-miR-204/gga-miR-211 0.860571 0.006747 0.025417 
gga-miR-30a-5p 0.708035 0.007139 0.026286 
gga-let-7c 0.74543 0.007522 0.027077 
gga-miR-30b 0.576117 0.008145 0.027771 





gga-miR-302b* -0.78133 0.008365 0.027771 
gga-miR-181a* 0.908167 0.0092 0.029596 
gga-let-7k 1.067455 0.009317 0.029596 
gga-miR-140 0.616854 0.009505 0.029611 
gga-miR-193 0.772655 0.010378 0.031715 
gga-miR-27b 0.814612 0.011326 0.033361 
gga-miR-148a 0.927259 0.011542 0.03339 
gga-miR-126 0.979227 0.012862 0.036554 
gga-let-7i 0.54566 0.013985 0.039062 
gga-miR-33 0.785207 0.014266 0.039171 
gga-miR-466 -1.39321 0.014926 0.040066 
gga-miR-126* 0.818411 0.015086 0.040066 
gga-miR-34a 0.508048 0.015553 0.040638 
gga-miR-18a 0.766642 0.015945 0.041002 
gga-miR-15b 0.530495 0.016677 0.041865 
gga-miR-375 0.66711 0.016798 0.041865 
gga-miR-223 -0.69745 0.018769 0.04551 
gga-let-7g 0.576923 0.018822 0.04551 
gga-miR-190 0.667463 0.021096 0.050258 
gga-miR-7 -0.59965 0.0216 0.050714 
gga-miR-184 -0.79159 0.025407 0.058799 
gga-miR-499 0.604568 0.025957 0.059226 
gga-miR-17-5p 0.643931 0.032926 0.073068 
gga-miR-21 -0.70144 0.033677 0.073726 
gga-miR-122 0.701345 0.039442 0.084073 
gga-miR-205b -0.53455 0.040507 0.085223 
gga-miR-26a 0.658442 0.04147 0.086131 
gga-miR-489 0.750998 0.046173 0.094684 














Appendix II. Differentially expressed chicken microRNAs between infected Line 
63 and Line72 groups 
Name logFC P.Value FDR 
gga-miR-99a 2.22393 2.71E-07 8.79E-06 
gga-miR-455 1.594012 5.64E-06 9.14E-05 
gga-miR-100 1.69626 8.07E-06 0.000119 
gga-miR-10b 1.431896 2.15E-05 0.00029 
gga-let-7b 1.293156 3.98E-05 0.000461 
gga-miR-181a 1.49834 6.25E-05 0.000622 
gga-miR-125b 1.390395 6.70E-05 0.000622 
gga-miR-181b 1.334056 6.91E-05 0.000622 
gga-miR-147 -1.26644 8.28E-05 0.000697 
gga-miR-199 1.084724 8.60E-05 0.000697 
gga-miR-103 1.088025 9.30E-05 0.000717 
gga-miR-107 1.329872 0.000108 0.000799 
gga-let-7c 1.150765 0.000329 0.00232 
gga-miR-153 1.847916 0.000515 0.003361 
gga-miR-146a -1.17015 0.000519 0.003361 
gga-miR-128 0.868683 0.000553 0.003445 
gga-miR-126* 1.319732 0.000635 0.003808 
gga-miR-218 1.123449 0.000668 0.003867 
gga-let-7f 0.884625 0.0007 0.003908 
gga-miR-302b* -1.10584 0.000771 0.004163 
gga-miR-30a-3p 1.437773 0.001082 0.005538 
gga-miR-199* 1.306179 0.001181 0.0058 
gga-miR-1b 0.921415 0.001487 0.006902 
gga-miR-456 0.851689 0.001491 0.006902 
gga-miR-34a 0.734018 0.001538 0.006923 
gga-miR-383 1.117926 0.001627 0.007124 
gga-miR-30b 0.731435 0.001693 0.007216 
gga-miR-30d 0.868993 0.002237 0.009293 
gga-let-7k 1.303096 0.002632 0.010603 
gga-miR-30c 0.756482 0.002683 0.010603 
gga-let-7a/gga-let-7j 0.996138 0.003125 0.012054 
gga-miR-193 0.913973 0.003701 0.013626 
gga-miR-148a 1.092814 0.004294 0.015457 
gga-miR-205b -0.81643 0.004549 0.01568 
gga-miR-122 1.046192 0.004798 0.015976 
gga-miR-7 -0.78138 0.004874 0.015976 
gga-miR-365 0.653083 0.008264 0.025158 
gga-miR-200b 1.649155 0.008472 0.025158 





gga-miR-26a 0.901929 0.008696 0.025158 
gga-miR-27b 0.835299 0.009832 0.027944 
gga-miR-184 -0.92207 0.011634 0.032494 
gga-miR-126 0.988679 0.012204 0.033508 
gga-miR-190 0.71046 0.01536 0.041472 
gga-miR-124a 0.657104 0.015924 0.04229 
gga-miR-142-5p -0.8538 0.017161 0.044128 
gga-miR-466 -1.33813 0.018389 0.046548 
gga-miR-223 -0.69342 0.019322 0.048068 
gga-let-7i 0.511276 0.019583 0.048068 
gga-miR-138 0.528106 0.021019 0.050823 
gga-miR-24 0.57525 0.02276 0.054222 
gga-miR-429 1.645703 0.025175 0.059107 
gga-miR-29b -0.6612 0.025809 0.059715 
gga-miR-133b 0.683815 0.026171 0.059715 
gga-miR-499 0.579396 0.031524 0.07093 
gga-miR-21 -0.70396 0.033152 0.073569 
gga-miR-18b 0.538932 0.033743 0.07387 
gga-miR-221 0.524929 0.034307 0.074102 
gga-miR-215 -0.7945 0.038339 0.079845 
gga-let-7g 0.483645 0.042131 0.085316 
gga-miR-140 0.448124 0.045048 0.090096 
gga-miR-204/gga-miR-211 0.574843 0.049942 0.098665 
























Appendix III. Differentially expressed MDV microRNAs in chickens of the 
infected Line 63 and Line72 groups 
Name logFC P.Value FDR 
mdv1-miR-M6 -6.60394 1.65E-09 1.69E-07 
mdv1-miR-M8 -7.54209 2.08E-09 1.69E-07 
mdv1-miR-M5 -4.87375 2.78E-08 1.50E-06 
mdv1-miR-M3 -5.11485 5.01E-08 1.58E-06 
mdv1-miR-M2 -3.84215 5.60E-08 1.58E-06 
mdv1-miR-M4 -6.64692 5.84E-08 1.58E-06 
mdv1-miR-M2* -3.62937 5.76E-07 1.33E-05 
mdv1-miR-M7 -3.55253 2.22E-06 4.50E-05 
mdv1-miR-M1 -3.92847 4.08E-06 6.61E-05 
mdv1-miR-M4* -2.50929 0.000102 0.000915 

























Appendix IV. Pathways predicted by IPA 
Pathways  log(p-value) 
HGF Signaling -4.57 
EGF Signaling -4.17 
T Cell Receptor Signaling -4.09 
ILK Signaling -3.90 
Neurotrophin/TRK Signaling -3.88 
Inositol Phosphate Metabolism -3.80 
IGF-1 Signaling -3.44 
Nitric Oxide Signaling in the Cardiovascular System -3.32 
Renal Cell Carcinoma Signaling -3.21 
B Cell Receptor Signaling -3.11 
Molecular Mechanisms of Cancer -3.10 
ERK/MAPK Signaling -3.09 
Ovarian Cancer Signaling -3.09 
FGF Signaling -3.07 
ERK5 Signaling -3.06 
Glioblastoma Multiforme Signaling -3.04 
Melanocyte Development and Pigmentation Signaling -3.02 
Protein Ubiquitination Pathway -2.90 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid 
Arthritis -2.88 
Ceramide Signaling -2.81 
Hypoxia Signaling in the Cardiovascular System -2.79 
PKCθ Signaling in T Lymphocytes -2.79 
Regulation of IL-2 Expression in Activated and Anergic T 
Lymphocytes -2.77 
Colorectal Cancer Metastasis Signaling -2.74 
Glioma Invasiveness Signaling -2.74 
Wnt/β-catenin Signaling -2.71 
Prostate Cancer Signaling -2.68 
Integrin Signaling -2.68 
SAPK/JNK Signaling -2.64 
Myc Mediated Apoptosis Signaling -2.63 
TGF-β Signaling -2.59 
BMP signaling pathway -2.56 
Cardiac Hypertrophy Signaling -2.44 
FAK Signaling -2.43 
RANK Signaling in Osteoclasts -2.43 





NF-κB Signaling -2.39 
Cholecystokinin/Gastrin-mediated Signaling -2.38 
Rac Signaling -2.28 
PI3K Signaling in B Lymphocytes -2.27 
Huntington's Disease Signaling -2.23 
HMGB1 Signaling -2.18 
RAN Signaling -2.17 
Renin-Angiotensin Signaling -2.12 
PDGF Signaling -2.09 
GNRH Signaling -2.07 
Role of NFAT in Cardiac Hypertrophy -2.07 
Aldosterone Signaling in Epithelial Cells -2.05 





















Appendix V The genome browser view of two CGI methylation.  
The CGI up stream of HDAC9 (A) was on chromosome 2: 29,264-29,264,968 
and the CGI upstream of FAR1 (B) was on chromosome 5: 8,429,672-8,430,025. And 












Appendix VI The genome browser view of FABP3 CGI methylation. 
The CGI upstream of FABP3 on Chromosome 23 :569,948-570,011. The 
horizontal green bar indicated the position of CGI. And the vertical blue bars 




















Appendix VII. The genome browser view of GATA2 promoter methylation. 
The 19 CpGs on GATA2 promoter, located at chromosome 12: 9,444,841-
9,445,317, showed different methylation. The horizontal green bar indicated the 



















Appendix VIII The genome browser view of CR1-B methylation. 
The CR1-B, on chromosome 3: 110,191,142-110,191,684, showed different 
methylation level in line 63 and line 72 after MDV infection. The horizontal blue bar 
indicated the position of infection induced differential methylation region (iDMR). 



















Appendix IX The genome browser view of GH DMR. 
The horizontal blue bars indicated the position DMRs in 4 comparisons. And 


















Appendix X. The genome browser view of CDC42 DMR. 
The 19 CpGs upstream of CDC42, at chromosome 21: 6,564,439-6,565,113, 
were identified as iDMRs in line 72. The horizontal blue bars indicated the position 
iDMRs in 4 comparisons. And the vertical red and blue bars represented the 










1. Davison TF, Nair V: Marek's disease: an evolving problem. Amsterdam; 
Boston: Elsevier; 2004. 
2. Grafodatskaya D, Choufani S, Ferreira JC, Butcher DT, Lou Y, Zhao C, 
Scherer SW, Weksberg R: EBV transformation and cell culturing 
destabilizes DNA methylation in human lymphoblastoid cell lines. 
Genomics 2010, 95(2):73-83. 
3. Luo J, Yu Y, Chang S, Tian F, Zhang H, Song J: DNA Methylation 
Fluctuation Induced by Virus Infection Differs between MD-resistant and 
-susceptible Chickens. Front Genet 2012, 3:20. 
4. Brown AC, Nair V, Allday MJ: Epigenetic regulation of the latency-
associated region of Marek's disease virus in tumor-derived T-cell lines 
and primary lymphoma. J Virol 2012, 86(3):1683-1695. 
5. Tian F, Luo J, Zhang H, Chang S, Song J: MiRNA expression signatures 
induced by Marek's disease virus infection in chickens. Genomics 2012, 
99(3):152-159. 
6. Triboulet R, Mari B, Lin YL, Chable-Bessia C, Bennasser Y, Lebrigand K, 
Cardinaud B, Maurin T, Barbry P, Baillat V et al: Suppression of 
microRNA-silencing pathway by HIV-1 during virus replication. Science 
2007, 315(5818):1579-1582. 
7. Moore PS, Chang Y: Why do viruses cause cancer? Highlights of the first 
century of human tumour virology. Nat Rev Cancer 2010, 10(12):878-889. 
8. Ferrari R, Berk AJ, Kurdistani SK: Viral manipulation of the host 
epigenome for oncogenic transformation. Nat Rev Genet 2009, 10(5):290-
294. 
9. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in 
cancer. Nat Rev Cancer 2006, 6(4):259-269. 
10. Feng S, Jacobsen SE, Reik W: Epigenetic reprogramming in plant and 
animal development. Science 2010, 330(6004):622-627. 
11. Katada S, Imhof A, Sassone-Corsi P: Connecting threads: epigenetics and 
metabolism. Cell 2012, 148(1-2):24-28. 
12. Rodriguez-Paredes M, Esteller M: Cancer epigenetics reaches mainstream 
oncology. Nat Med 2011, 17(3):330-339. 
13. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, 
Wright KL, Atadja PW, Bhalla K et al: The histone deacetylase HDAC11 
regulates the expression of interleukin 10 and immune tolerance. Nat 
Immunol 2009, 10(1):92-100. 
14. Wilson CB, Rowell E, Sekimata M: Epigenetic control of T-helper-cell 
differentiation. Nat Rev Immunol 2009, 9(2):91-105. 
15. Suzuki MM, Bird A: DNA methylation landscapes: provocative insights 
from epigenomics. Nat Rev Genet 2008, 9(6):465-476. 
16. Shiota K, Kogo Y, Ohgane J, Imamura T, Urano A, Nishino K, Tanaka S, 





and somatic cells in mice. Genes Cells 2002, 7(9):961-969. 
17. Dudnikova E, Vlasov A, Norkina S, Kireev D, Witter RL: Factors 
influencing the attenuation of serotype 1 Marek's disease virus by serial 
cell culture passage and evaluation of attenuated strains for protection 
and replication. Avian Dis 2009, 53(1):63-72. 
18. Witter RL: Increased virulence of Marek's disease virus field isolates. 
Avian Dis 1997, 41(1):149-163. 
19. Osterrieder N, Kamil JP, Schumacher D, Tischer BK, Trapp S: Marek's 
disease virus: from miasma to model. Nat Rev Microbiol 2006, 4(4):283-
294. 
20. Tulman ER, Afonso CL, Lu Z, Zsak L, Rock DL, Kutish GF: The genome of 
a very virulent Marek's disease virus. J Virol 2000, 74(17):7980-7988. 
21. Brown AC, Baigent SJ, Smith LP, Chattoo JP, Petherbridge LJ, Hawes P, 
Allday MJ, Nair V: Interaction of MEQ protein and C-terminal-binding 
protein is critical for induction of lymphomas by Marek's disease virus. 
Proc Natl Acad Sci U S A 2006, 103(6):1687-1692. 
22. Barrow AD, Burgess SC, Baigent SJ, Howes K, Nair VK: Infection of 
macrophages by a lymphotropic herpesvirus: a new tropism for Marek's 
disease virus. J Gen Virol 2003, 84(Pt 10):2635-2645. 
23. Baigent SJ, Ross LJ, Davison TF: Differential susceptibility to Marek's 
disease is associated with differences in number, but not phenotype or 
location, of pp38+ lymphocytes. J Gen Virol 1998, 79 ( Pt 11):2795-2802. 
24. Hunt HD, Lupiani B, Miller MM, Gimeno I, Lee LF, Parcells MS: Marek's 
disease virus down-regulates surface expression of MHC (B Complex) 
Class I (BF) glycoproteins during active but not latent infection of 
chicken cells. Virology 2001, 282(1):198-205. 
25. Koppers-Lalic D, Reits EA, Ressing ME, Lipinska AD, Abele R, Koch J, 
Marcondes Rezende M, Admiraal P, van Leeuwen D, Bienkowska-Szewczyk 
K et al: Varicelloviruses avoid T cell recognition by UL49.5-mediated 
inactivation of the transporter associated with antigen processing. Proc 
Natl Acad Sci U S A 2005, 102(14):5144-5149. 
26. Jarosinski KW, Hunt HD, Osterrieder N: Down-regulation of MHC class I 
by the Marek's disease virus (MDV) UL49.5 gene product mildly affects 
virulence in a haplotype-specific fashion. Virology 2010, 405(2):457-463. 
27. Davison TF, Nair V: Marek's disease : an evolving problem. Amsterdam ; 
Boston: Elsevier; 2004. 
28. Burnside J, Bernberg E, Anderson A, Lu C, Meyers BC, Green PJ, Jain N, 
Isaacs G, Morgan RW: Marek's disease virus encodes MicroRNAs that 
map to meq and the latency-associated transcript. J Virol 2006, 
80(17):8778-8786. 
29. Delecluse HJ, Hammerschmidt W: Status of Marek's disease virus in 
established lymphoma cell lines: herpesvirus integration is common. J 
Virol 1993, 67(1):82-92. 
30. Delecluse HJ, Schuller S, Hammerschmidt W: Latent Marek's disease virus 
can be activated from its chromosomally integrated state in herpesvirus-





31. Bumstead N, Sillibourne J, Rennie M, Ross N, Davison F: Quantification of 
Marek's disease virus in chicken lymphocytes using the polymerase chain 
reaction with fluorescence detection. J Virol Methods 1997, 65(1):75-81. 
32. Suchodolski PF, Izumiya Y, Lupiani B, Ajithdoss DK, Lee LF, Kung HJ, 
Reddy SM: Both homo and heterodimers of Marek's disease virus 
encoded Meq protein contribute to transformation of lymphocytes in 
chickens. Virology 2010, 399(2):312-321. 
33. Levy AM, Gilad O, Xia L, Izumiya Y, Choi J, Tsalenko A, Yakhini Z, Witter 
R, Lee L, Cardona CJ et al: Marek's disease virus Meq transforms chicken 
cells via the v-Jun transcriptional cascade: a converging transforming 
pathway for avian oncoviruses. Proc Natl Acad Sci U S A 2005, 
102(41):14831-14836. 
34. Huguier S, Baguet J, Perez S, van Dam H, Castellazzi M: Transcription 
factor ATF2 cooperates with v-Jun to promote growth factor-
independent proliferation in vitro and tumor formation in vivo. Mol Cell 
Biol 1998, 18(12):7020-7029. 
35. Levy AM, Izumiya Y, Brunovskis P, Xia L, Parcells MS, Reddy SM, Lee L, 
Chen HW, Kung HJ: Characterization of the chromosomal binding sites 
and dimerization partners of the viral oncoprotein Meq in Marek's 
disease virus-transformed T cells. J Virol 2003, 77(23):12841-12851. 
36. Liu HC, Cheng HH, Tirunagaru V, Sofer L, Burnside J: A strategy to 
identify positional candidate genes conferring Marek's disease resistance 
by integrating DNA microarrays and genetic mapping. Anim Genet 2001, 
32(6):351-359. 
37. Heidari M, Huebner M, Kireev D, Silva RF: Transcriptional profiling of 
Marek's disease virus genes during cytolytic and latent infection. Virus 
Genes 2008, 36(2):383-392. 
38. Yu Y, Luo J, Mitra A, Chang S, Tian F, Zhang H, Yuan P, Zhou H, Song J: 
Temporal transcriptome changes induced by MDV in Marek's disease-
resistant and -susceptible inbred chickens. BMC Genomics 2011, 12:501. 
39. Venugopal K, Payne LN: Molecular pathogenesis of Marek's disease-
recent developments. Avian Pathol 1995, 24(4):597-609. 
40. Burgess SC, Young JR, Baaten BJ, Hunt L, Ross LN, Parcells MS, Kumar 
PM, Tregaskes CA, Lee LF, Davison TF: Marek's disease is a natural 
model for lymphomas overexpressing Hodgkin's disease antigen (CD30). 
Proc Natl Acad Sci U S A 2004, 101(38):13879-13884. 
41. Xing Z, Schat KA: Expression of cytokine genes in Marek's disease virus-
infected chickens and chicken embryo fibroblast cultures. Immunology 
2000, 100(1):70-76. 
42. Thanthrige-Don N, Read LR, Abdul-Careem MF, Mohammadi H, Mallick AI, 
Sharif S: Marek's disease virus influences the expression of genes 
associated with IFN-gamma-inducible MHC class II expression. Viral 
Immunol 2010, 23(2):227-232. 
43. Rath NC, Parcells MS, Xie H, Santin E: Characterization of a 
spontaneously transformed chicken mononuclear cell line. Vet Immunol 





44. Abdul-Careem MF, Haq K, Shanmuganathan S, Read LR, Schat KA, Heidari 
M, Sharif S: Induction of innate host responses in the lungs of chickens 
following infection with a very virulent strain of Marek's disease virus. 
Virology 2009, 393(2):250-257. 
45. Kodama H, Mikami T, Inoue M, Izawa H: Inhibitory effects of 
macrophages against Marek's disease virus plaque formation in chicken 
kidney cell cultures. J Natl Cancer Inst 1979, 63(5):1267-1271. 
46. Haffer K, Sevoian M, Wilder M: The role of the macrophages in Marek's 
disease: in vitro and in vivo studies. Int J Cancer 1979, 23(5):648-656. 
47. Lee LF, Witter RL: Humoral immune responses to inactivated oil-
emulsified Marek's disease vaccine. Avian Dis 1991, 35(3):452-459. 
48. Omar AR, Schat KA: Syngeneic Marek's disease virus (MDV)-specific cell-
mediated immune responses against immediate early, late, and unique 
MDV proteins. Virology 1996, 222(1):87-99. 
49. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL: Baculovirus expressed 
herpes simplex virus type 1 glycoprotein C protects mice from lethal 
HSV-1 infection. Antiviral Res 1992, 18(3-4):291-302. 
50. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL: Expression of herpes 
simplex virus type 1 glycoprotein I in baculovirus: preliminary 
biochemical characterization and protection studies. J Virol 1992, 
66(4):2505-2509. 
51. Gavora JS, Grunder AA, Spencer JL, Gowe RS, Robertson A, Speckmann 
GW: An assessment of effects of vaccination on genetic resistance to 
Marek's disease. Poult Sci 1974, 53(3):889-897. 
52. von Krosigk CM, McClary CF, Vielitz E, Zander DV: Selection for 
resistance to Marek's disease and its expected effects on other important 
traits in white leghorn strain crosses. Avian Dis 1972, 16(1):11-19. 
53. Hepkema BG, Blankert JJ, Albers GA, Tilanus MG, Egberts E, van der Zijpp 
AJ, Hensen EJ: Mapping of susceptibility to Marek's disease within the 
major histocompatibility (B) complex by refined typing of White Leghorn 
chickens. Anim Genet 1993, 24(4):283-287. 
54. Briles WE, Briles RW, Taffs RE, Stone HA: Resistance to a malignant 
lymphoma in chickens is mapped to subregion of major 
histocompatibility (B) complex. Science 1983, 219(4587):977-979. 
55. Hartmann W: Evaluation of "major genes" affecting disease resistance in 
poultry in respect to their potential for commercial breeding. Prog Clin 
Biol Res 1989, 307:221-231. 
56. Bacon LD, Hunt HD, Cheng HH: A review of the development of chicken 
lines to resolve genes determining resistance to diseases. Poult Sci 2000, 
79(8):1082-1093. 
57. Gallatin WM, Longenecker BM: Expression of genetic resistance to an 
oncogenic herpesvirus at the target cell level. Nature 1979, 280(5723):587-
589. 
58. Powell PC, Lee LF, Mustill BM, Rennie M: The mechanism of genetic 






59. Kuhnlein U, Ni L, Weigend S, Gavora JS, Fairfull W, Zadworny D: DNA 
polymorphisms in the chicken growth hormone gene: response to 
selection for disease resistance and association with egg production. Anim 
Genet 1997, 28(2):116-123. 
60. Heidari M, Sarson AJ, Huebner M, Sharif S, Kireev D, Zhou H: Marek's 
disease virus-induced immunosuppression: array analysis of chicken 
immune response gene expression profiling. Viral Immunol 2010, 
23(3):309-319. 
61. Chen C, Li H, Xie Q, Shang H, Ji J, Bai S, Cao Y, Ma Y, Bi Y: 
Transcriptional profiling of host gene expression in chicken liver tissues 
infected with oncogenic Marek's disease virus. J Gen Virol 2011, 92(Pt 
12):2724-2733. 
62. Kano R, Konnai S, Onuma M, Ohashi K: Microarray analysis of host 
immune responses to Marek's disease virus infection in vaccinated 
chickens. J Vet Med Sci 2009, 71(5):603-610. 
63. Sarson AJ, Parvizi P, Lepp D, Quinton M, Sharif S: Transcriptional analysis 
of host responses to Marek's disease virus infection in genetically 
resistant and susceptible chickens. Anim Genet 2008, 39(3):232-240. 
64. Sarson AJ, Abdul-Careem MF, Zhou H, Sharif S: Transcriptional analysis 
of host responses to Marek's disease viral infection. Viral Immunol 2006, 
19(4):747-758. 
65. Kaiser P, Underwood G, Davison F: Differential cytokine responses 
following Marek's disease virus infection of chickens differing in 
resistance to Marek's disease. J Virol 2003, 77(1):762-768. 
66. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nat Cell 
Biol 2009, 11(3):228-234. 
67. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN: MicroRNA 
genes are transcribed by RNA polymerase II. Embo J 2004, 23(20):4051-
4060. 
68. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang 
BT, Kim VN: Molecular basis for the recognition of primary microRNAs 
by the Drosha-DGCR8 complex. Cell 2006, 125(5):887-901. 
69. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. 
Cell 2004, 116(2):281-297. 
70. Luciano DJ, Mirsky H, Vendetti NJ, Maas S: RNA editing of a miRNA 
precursor. Rna 2004, 10(8):1174-1177. 
71. Yang W, Chendrimada TP, Wang Q, Higuchi M, Seeburg PH, Shiekhattar R, 
Nishikura K: Modulation of microRNA processing and expression 
through RNA editing by ADAR deaminases. Nat Struct Mol Biol 2006, 
13(1):13-21. 
72. Blow MJ, Grocock RJ, van Dongen S, Enright AJ, Dicks E, Futreal PA, 
Wooster R, Stratton MR: RNA editing of human microRNAs. Genome Biol 
2006, 7(4):R27. 






74. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD: Asymmetry 
in the assembly of the RNAi enzyme complex. Cell 2003, 115(2):199-208. 
75. Khvorova A, Reynolds A, Jayasena SD: Functional siRNAs and miRNAs 
exhibit strand bias. Cell 2003, 115(2):209-216. 
76. He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene 
regulation. Nat Rev Genet 2004, 5(7):522-531. 
77. Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals. Nat Rev 
Mol Cell Biol 2009, 10(2):126-139. 
78. Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA 
biogenesis, function and decay. Nat Rev Genet, 11(9):597-610. 
79. Chuang JC, Jones PA: Epigenetics and microRNAs. Pediatr Res 2007, 61(5 
Pt 2):24R-29R. 
80. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L: Crystal structure of 
Argonaute and its implications for RISC slicer activity. Science 2004, 
305(5689):1434-1437. 
81. Diederichs S, Haber DA: Dual role for argonautes in microRNA 
processing and posttranscriptional regulation of microRNA expression. 
Cell 2007, 131(6):1097-1108. 
82. Brodersen P, Voinnet O: Revisiting the principles of microRNA target 
recognition and mode of action. Nat Rev Mol Cell Biol 2009, 10(2):141-148. 
83. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of 
mammalian microRNA targets. Cell 2003, 115(7):787-798. 
84. Stark A, Brennecke J, Russell RB, Cohen SM: Identification of Drosophila 
MicroRNA targets. PLoS Biol 2003, 1(3):E60. 
85. Yekta S, Shih IH, Bartel DP: MicroRNA-directed cleavage of HOXB8 
mRNA. Science 2004, 304(5670):594-596. 
86. Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs 
predominantly act to decrease target mRNA levels. Nature, 
466(7308):835-840. 
87. Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, Van Dongen S, Inoue K, 
Enright AJ, Schier AF: Zebrafish MiR-430 promotes deadenylation and 
clearance of maternal mRNAs. Science 2006, 312(5770):75-79. 
88. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R: MicroRNA-dependent 
localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 
2005, 7(7):719-723. 
89. Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: 
microRNAs can up-regulate translation. Science 2007, 318(5858):1931-
1934. 
90. Vasudevan S, Tong Y, Steitz JA: Cell-cycle control of microRNA-mediated 
translation regulation. Cell Cycle 2008, 7(11):1545-1549. 
91. Lytle JR, Yario TA, Steitz JA: Target mRNAs are repressed as efficiently 
by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl 
Acad Sci U S A 2007, 104(23):9667-9672. 
92. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R: miR-148 targets 
human DNMT3b protein coding region. Rna 2008, 14(5):872-877. 





database of experimentally supported animal microRNA targets. Rna 
2006, 12(2):192-197. 
94. Xiao C, Rajewsky K: MicroRNA control in the immune system: basic 
principles. Cell 2009, 136(1):26-36. 
95. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic 
lineage differentiation. Science 2004, 303(5654):83-86. 
96. Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, 
Jensen K, Cobb BS, Merkenschlager M, Rajewsky N et al: Dicer ablation 
affects antibody diversity and cell survival in the B lymphocyte lineage. 
Cell 2008, 132(5):860-874. 
97. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, 
Newman J, Bronson RT, Crowley D, Stone JR et al: Targeted deletion 
reveals essential and overlapping functions of the miR-17 through 92 
family of miRNA clusters. Cell 2008, 132(5):875-886. 
98. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD: 
MicroRNAs: new regulators of immune cell development and function. 
Nat Immunol 2008, 9(8):839-845. 
99. Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA, Manjunath 
N: miRNA profiling of naive, effector and memory CD8 T cells. PLoS One 
2007, 2(10):e1020. 
100. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, 
Soutschek J, Skare P et al: miR-181a is an intrinsic modulator of T cell 
sensitivity and selection. Cell 2007, 129(1):147-161. 
101. Liston A, Lu LF, O'Carroll D, Tarakhovsky A, Rudensky AY: Dicer-
dependent microRNA pathway safeguards regulatory T cell function. J 
Exp Med 2008, 205(9):1993-2004. 
102. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev 
Cancer 2006, 6(11):857-866. 
103. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, 
Iorio M, Roldo C, Ferracin M et al: A microRNA expression signature of 
human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 
2006, 103(7):2257-2261. 
104. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, 
Schmittgen TD, Patel T: Involvement of human micro-RNA in growth and 
response to chemotherapy in human cholangiocarcinoma cell lines. 
Gastroenterology 2006, 130(7):2113-2129. 
105. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic 
factor in human glioblastoma cells. Cancer Res 2005, 65(14):6029-6033. 
106. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, 
Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 
microRNA family. Cell 2005, 120(5):635-647. 
107. Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ: The temporal 
patterning microRNA let-7 regulates several transcription factors at the 
larval to adult transition in C. elegans. Dev Cell 2005, 8(3):321-330. 
108. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, 





polycistron as a potential human oncogene. Nature 2005, 435(7043):828-
833. 
109. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-
regulated microRNAs modulate E2F1 expression. Nature 2005, 
435(7043):839-843. 
110. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P, 
Barton G, Jiao LR, Wait R, Waxman J et al: The estrogen receptor-alpha-
induced microRNA signature regulates itself and its transcriptional 
response. Proc Natl Acad Sci U S A 2009, 106(37):15732-15737. 
111. Brodersen P, Voinnet O: The diversity of RNA silencing pathways in 
plants. Trends Genet 2006, 22(5):268-280. 
112. Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, Kang YJ, Jiang Z, Du 
X, Cook R et al: Hypersusceptibility to vesicular stomatitis virus infection 
in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. 
Immunity 2007, 27(1):123-134. 
113. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David 
M: Interferon modulation of cellular microRNAs as an antiviral 
mechanism. Nature 2007, 449(7164):919-922. 
114. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, 
Saib A, Voinnet O: A cellular microRNA mediates antiviral defense in 
human cells. Science 2005, 308(5721):557-560. 
115. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, 
Verlinghieri G, Zhang H: Cellular microRNAs contribute to HIV-1 latency 
in resting primary CD4+ T lymphocytes. Nat Med 2007, 13(10):1241-1247. 
116. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grasser FA, 
van Dyk LF, Ho CK, Shuman S, Chien M et al: Identification of microRNAs 
of the herpesvirus family. Nat Methods 2005, 2(4):269-276. 
117. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright 
AJ, Marks D, Sander C et al: Identification of virus-encoded microRNAs. 
Science 2004, 304(5671):734-736. 
118. Ghosh Z, Mallick B, Chakrabarti J: Cellular versus viral microRNAs in 
host-virus interaction. Nucleic Acids Res 2009, 37(4):1035-1048. 
119. Burnside J, Ouyang M, Anderson A, Bernberg E, Lu C, Meyers BC, Green PJ, 
Markis M, Isaacs G, Huang E et al: Deep sequencing of chicken 
microRNAs. BMC Genomics 2008, 9:185. 
120. Yao Y, Zhao Y, Xu H, Smith LP, Lawrie CH, Watson M, Nair V: MicroRNA 
profile of Marek's disease virus-transformed T-cell line MSB-1: 
predominance of virus-encoded microRNAs. J Virol 2008, 82(8):4007-
4015. 
121. Zhao Y, Yao Y, Xu H, Lambeth L, Smith LP, Kgosana L, Wang X, Nair V: A 
functional MicroRNA-155 ortholog encoded by the oncogenic Marek's 
disease virus. J Virol 2009, 83(1):489-492. 
122. Zhao Y, Xu H, Yao Y, Smith LP, Kgosana L, Green J, Petherbridge L, 
Baigent SJ, Nair V: Critical role of the virus-encoded microRNA-155 






123. Muylkens B, Coupeau D, Dambrine G, Trapp S, Rasschaert D: Marek's 
disease virus microRNA designated Mdv1-pre-miR-M4 targets both 
cellular and viral genes. Arch Virol 2010, 155(11):1823-1837. 
124. Xu S, Xue C, Li J, Bi Y, Cao Y: Marek's disease virus type 1 microRNA 
miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of 
the transforming growth factor beta signal pathway. J Virol 2010, 
85(1):276-285. 
125. Hicks JA, Trakooljul N, Liu HC: Discovery of chicken microRNAs 
associated with lipogenesis and cell proliferation. Physiol Genomics 2009. 
126. Hicks JA, Tembhurne PA, Liu HC: Identification of microRNA in the 
developing chick immune organs. Immunogenetics 2009, 61(3):231-240. 
127. Trakooljul N, Hicks JA, Liu HC: Characterization of miR-10a mediated 
gene regulation in avian splenocytes. Gene 2012, 500(1):107-114. 
128. Guillon-Munos A, Dambrine G, Richerioux N, Coupeau D, Muylkens B, 
Rasschaert D: The chicken miR-150 targets the avian orthologue of the 
functional zebrafish MYB 3'UTR target site. BMC Mol Biol 2010, 11:67. 
129. Lambeth LS, Yao Y, Smith LP, Zhao Y, Nair V: MicroRNAs 221 and 222 
target p27Kip1 in Marek's disease virus-transformed tumour cell line 
MSB-1. J Gen Virol 2009, 90(Pt 5):1164-1171. 
130. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, 
Nery JR, Lee L, Ye Z, Ngo QM et al: Human DNA methylomes at base 
resolution show widespread epigenomic differences. Nature 2009, 
462(7271):315-322. 
131. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, 
Gehrke C: Amount and distribution of 5-methylcytosine in human DNA 
from different types of tissues of cells. Nucleic Acids Res 1982, 10(8):2709-
2721. 
132. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J 
Mol Biol 1987, 196(2):261-282. 
133. Lin IG, Tomzynski TJ, Ou Q, Hsieh CL: Modulation of DNA binding 
protein affinity directly affects target site demethylation. Mol Cell Biol 
2000, 20(7):2343-2349. 
134. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber 
J, Helin K: TET1 and hydroxymethylcytosine in transcription and DNA 
methylation fidelity. Nature 2010, 473(7347):343-348. 
135. Wu SC, Zhang Y: Active DNA demethylation: many roads lead to Rome. 
Nat Rev Mol Cell Biol 2010, 11(9):607-620. 
136. Lehnertz B, Ueda Y, Derijck AA, Braunschweig U, Perez-Burgos L, Kubicek 
S, Chen T, Li E, Jenuwein T, Peters AH: Suv39h-mediated histone H3 
lysine 9 methylation directs DNA methylation to major satellite repeats at 
pericentric heterochromatin. Curr Biol 2003, 13(14):1192-1200. 
137. Brinkman AB, Gu H, Bartels SJ, Zhang Y, Matarese F, Simmer F, Marks H, 
Bock C, Gnirke A, Meissner A et al: Sequential ChIP-bisulfite sequencing 
enables direct genome-scale investigation of chromatin and DNA 
methylation cross-talk. Genome Res 2012. 





Eynde A, Bernard D, Vanderwinden JM et al: The Polycomb group protein 
EZH2 directly controls DNA methylation. Nature 2006, 439(7078):871-
874. 
139. Kawasaki H, Taira K: Induction of DNA methylation and gene silencing by 
short interfering RNAs in human cells. Nature 2004, 431(7005):211-217. 
140. Waterland RA, Jirtle RL: Transposable elements: targets for early 
nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003, 
23(15):5293-5300. 
141. Jirtle RL, Skinner MK: Environmental epigenomics and disease 
susceptibility. Nat Rev Genet 2007, 8(4):253-262. 
142. Anway MD, Cupp AS, Uzumcu M, Skinner MK: Epigenetic 
transgenerational actions of endocrine disruptors and male fertility. 
Science 2005, 308(5727):1466-1469. 
143. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: 
Transcriptional repression by the methyl-CpG-binding protein MeCP2 
involves a histone deacetylase complex. Nature 1998, 393(6683):386-389. 
144. Bell AC, West AG, Felsenfeld G: The protein CTCF is required for the 
enhancer blocking activity of vertebrate insulators. Cell 1999, 98(3):387-
396. 
145. Heindel JJ, McAllister KA, Worth L, Jr., Tyson FL: Environmental 
epigenomics, imprinting and disease susceptibility. Epigenetics 2006, 
1(1):1-6. 
146. Bibikova M, Chudin E, Wu B, Zhou L, Garcia EW, Liu Y, Shin S, Plaia TW, 
Auerbach JM, Arking DE et al: Human embryonic stem cells have a unique 
epigenetic signature. Genome Res 2006, 16(9):1075-1083. 
147. Danbara M, Kameyama K, Higashihara M, Takagaki Y: DNA methylation 
dominates transcriptional silencing of Pax5 in terminally differentiated B 
cell lines. Mol Immunol 2002, 38(15):1161-1166. 
148. Richardson B: DNA methylation and autoimmune disease. Clin Immunol 
2003, 109(1):72-79. 
149. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, 
Rodriguez-Ubreva J, Berdasco M, Fraga MF, O'Hanlon TP, Rider LG et al: 
Changes in the pattern of DNA methylation associate with twin 
discordance in systemic lupus erythematosus. Genome Res 2012, 
20(2):170-179. 
150. Schwartz DA: The importance of gene-environment interactions and 
exposure assessment in understanding human diseases. J Expo Sci Environ 
Epidemiol 2006, 16(6):474-476. 
151. Meshorer E, Misteli T: Chromatin in pluripotent embryonic stem cells and 
differentiation. Nat Rev Mol Cell Biol 2006, 7(7):540-546. 
152. Bollati V, Schwartz J, Wright R, Litonjua A, Tarantini L, Suh H, Sparrow D, 
Vokonas P, Baccarelli A: Decline in genomic DNA methylation through 
aging in a cohort of elderly subjects. Mech Ageing Dev 2009, 130(4):234-
239. 
153. Rakyan VK, Down TA, Balding DJ, Beck S: Epigenome-wide association 





154. Bobetsis YA, Barros SP, Lin DM, Weidman JR, Dolinoy DC, Jirtle RL, 
Boggess KA, Beck JD, Offenbacher S: Bacterial infection promotes DNA 
hypermethylation. J Dent Res 2007, 86(2):169-174. 
155. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ: 
Epstein-barr virus latency in B cells leads to epigenetic repression and 
CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 2009, 
5(6):e1000492. 
156. Kalla M, Gobel C, Hammerschmidt W: The lytic phase of epstein-barr 
virus requires a viral genome with 5-methylcytosine residues in CpG 
sites. J Virol 2012, 86(1):447-458. 
157. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos 
PV: Features of mammalian microRNA promoters emerge from 
polymerase II chromatin immunoprecipitation data. PLoS One 2009, 
4(4):e5279. 
158. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, Zhang X, Song 
JS, Fisher DE: Chromatin structure analyses identify miRNA promoters. 
Genes Dev 2008, 22(22):3172-3183. 
159. Han L, Witmer PD, Casey E, Valle D, Sukumar S: DNA methylation 
regulates MicroRNA expression. Cancer Biol Ther 2007, 6(8):1284-1288. 
160. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA: 
Specific activation of microRNA-127 with downregulation of the proto-
oncogene BCL6 by chromatin-modifying drugs in human cancer cells. 
Cancer Cell 2006, 9(6):435-443. 
161. Weber B, Stresemann C, Brueckner B, Lyko F: Methylation of human 
microRNA genes in normal and neoplastic cells. Cell Cycle 2007, 
6(9):1001-1005. 
162. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder 
H, Costinean S, Fernandez-Cymering C et al: MicroRNA-29 family reverts 
aberrant methylation in lung cancer by targeting DNA 
methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007, 
104(40):15805-15810. 
163. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, 
Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ et al: A 
microRNA DNA methylation signature for human cancer metastasis. 
Proc Natl Acad Sci U S A 2008, 105(36):13556-13561. 
164. Lujambio A, Esteller M: How epigenetics can explain human metastasis: a 
new role for microRNAs. Cell Cycle 2009, 8(3):377-382. 
165. Lindsay MA: microRNAs and the immune response. Trends Immunol 2008, 
29(7):343-351. 
166. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-
Cordero A, Ebert BL, Mak RH, Ferrando AA et al: MicroRNA expression 
profiles classify human cancers. Nature 2005, 435(7043):834-838. 
167. Davison TF, Nair V: Marek's disease : an evolving problem. Amsterdam ; 
Boston: Elsevier; 2004. 
168. Abdul-Careem MF, Hunter BD, Nagy E, Read LR, Sanei B, Spencer JL, 





chemistry for monitoring Marek's disease virus genome load in feather 
tips. J Virol Methods 2006, 133(1):34-40. 
169. Zehner ZE, Paterson BM: Characterization of the chicken vimentin gene: 
single copy gene producing multiple mRNAs. Proc Natl Acad Sci U S A 
1983, 80(4):911-915. 
170. Smyth GK: Linear models and empirical bayes methods for assessing 
differential expression in microarray experiments. Stat Appl Genet Mol 
Biol 2004, 3:Article3. 
171. Smyth GK, Speed T: Normalization of cDNA microarray data. Methods 
2003, 31(4):265-273. 
172. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and 
display of genome-wide expression patterns. Proc Natl Acad Sci U S A 
1998, 95(25):14863-14868. 
173. Lee LF, Powell PC, Rennie M, Ross LJ, Payne LN: Nature of genetic 
resistance to Marek's disease in chickens. J Natl Cancer Inst 1981, 
66(4):789-796. 
174. Burgess SC, Davison TF: Identification of the neoplastically transformed 
cells in Marek's disease herpesvirus-induced lymphomas: recognition by 
the monoclonal antibody AV37. J Virol 2002, 76(14):7276-7292. 
175. Persengiev SP, Green MR: The role of ATF/CREB family members in cell 
growth, survival and apoptosis. Apoptosis 2003, 8(3):225-228. 
176. Liu H, Kohane IS: Tissue and process specific microRNA-mRNA co-
expression in mammalian development and malignancy. PLoS One 2009, 
4(5):e5436. 
177. Sayed D, Abdellatif M: MicroRNAs in development and disease. Physiol 
Rev 2011, 91(3):827-887. 
178. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, 
Bartel DP: The widespread impact of mammalian MicroRNAs on mRNA 
repression and evolution. Science 2005, 310(5755):1817-1821. 
179. Shkumatava A, Stark A, Sive H, Bartel DP: Coherent but overlapping 
expression of microRNAs and their targets during vertebrate 
development. Genes Dev 2009, 23(4):466-481. 
180. Bhoumik A, Ronai Z: ATF2: a transcription factor that elicits oncogenic 
or tumor suppressor activities. Cell Cycle 2008, 7(15):2341-2345. 
181. Bhoumik A, Gangi L, Ronai Z: Inhibition of melanoma growth and 
metastasis by ATF2-derived peptides. Cancer Res 2004, 64(22):8222-8230. 
182. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang 
J, Yu J, Muthusamy N et al: MicroRNA-29b induces global DNA 
hypomethylation and tumor suppressor gene reexpression in acute 
myeloid leukemia by targeting directly DNMT3A and 3B and indirectly 
DNMT1. Blood 2009, 113(25):6411-6418. 
183. Braconi C, Huang N, Patel T: MicroRNA-dependent regulation of DNA 
methyltransferase-1 and tumor suppressor gene expression by 
interleukin-6 in human malignant cholangiocytes. Hepatology 2010, 
51(3):881-890. 





interaction: a new role for microRNAs. Retrovirology 2006, 3:68. 
185. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, Junemann C, 
Niepmann M: microRNA-122 stimulates translation of hepatitis C virus 
RNA. Embo J 2008, 27(24):3300-3310. 
186. Roberts AP, Lewis AP, Jopling CL: miR-122 activates hepatitis C virus 
translation by a specialized mechanism requiring particular RNA 
components. Nucleic Acids Res 2011, 39(17):7716-7729. 
187. Yao Y, Zhao Y, Smith LP, Lawrie CH, Saunders NJ, Watson M, Nair V: 
Differential expression of microRNAs in Marek's disease virus-
transformed T-lymphoma cell lines. J Gen Virol 2009, 90(Pt 7):1551-1559. 
188. Chen M, Payne WS, Hunt H, Zhang H, Holmen SL, Dodgson JB: Inhibition 
of Marek's disease virus replication by retroviral vector-based RNA 
interference. Virology 2008, 377(2):265-272. 
189. Li SD, Chono S, Huang L: Efficient oncogene silencing and metastasis 
inhibition via systemic delivery of siRNA. Mol Ther 2008, 16(5):942-946. 
190. ter Brake O, Berkhout B: A novel approach for inhibition of HIV-1 by 
RNA interference: counteracting viral escape with a second generation of 
siRNAs. J RNAi Gene Silencing 2005, 1(2):56-65. 
191. ter Brake O, t Hooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B: 
Lentiviral vector design for multiple shRNA expression and durable 
HIV-1 inhibition. Mol Ther 2008, 16(3):557-564. 
192. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-
Sundaram S, Huang C, Shankar S, Jing X, Iyer M et al: Deep sequencing 
reveals distinct patterns of DNA methylation in prostate cancer. Genome 
Res 2011, 21(7):1028-1041. 
193. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 
2004, 4(2):143-153. 
194. Brown AC, Nair V, Allday MJ: Epigenetic regulation of the latency-
associated region of Marek's disease virus in tumor-derived T-cell lines 
and primary lymphoma. J Virol 2011, 86(3):1683-1695. 
195. Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, Gu H, Jager N, 
Gnirke A, Stunnenberg HG, Meissner A: Quantitative comparison of 
genome-wide DNA methylation mapping technologies. Nat Biotechnol 
2010, 28(10):1106-1114. 
196. Edwards JR, O'Donnell AH, Rollins RA, Peckham HE, Lee C, Milekic MH, 
Chanrion B, Fu Y, Su T, Hibshoosh H et al: Chromatin and sequence 
features that define the fine and gross structure of genomic methylation 
patterns. Genome Res 2010, 20(7):972-980. 
197. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, 
Jones PA: The human DNA methyltransferases (DNMTs) 1, 3a and 3b: 
coordinate mRNA expression in normal tissues and overexpression in 
tumors. Nucleic Acids Res 1999, 27(11):2291-2298. 
198. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-
methylcytosine content in human colonic neoplasia. Cancer Res 1988, 
48(5):1159-1161. 





Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal 
hematopoiesis and in acute and chronic myelogenous leukemia. Blood 
2001, 97(5):1172-1179. 
200. Leonard S, Wei W, Anderton J, Vockerodt M, Rowe M, Murray PG, 
Woodman CB: Epigenetic and transcriptional changes which follow 
Epstein-Barr virus infection of germinal center B cells and their 
relevance to the pathogenesis of Hodgkin's lymphoma. J Virol 2011, 
85(18):9568-9577. 
201. Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S: Co-operation and 
communication between the human maintenance and de novo DNA 
(cytosine-5) methyltransferases. Embo J 2002, 21(15):4183-4195. 
202. Ostler KR, Davis EM, Payne SL, Gosalia BB, Exposito-Cespedes J, Le Beau 
MM, Godley LA: Cancer cells express aberrant DNMT3B transcripts 
encoding truncated proteins. Oncogene 2007, 26(38):5553-5563. 
203. Li Q, Li N, Hu X, Li J, Du Z, Chen L, Yin G, Duan J, Zhang H, Zhao Y et al: 
Genome-wide mapping of DNA methylation in chicken. PLoS One 2011, 
6(5):e19428. 
204. Laird PW: Principles and challenges of genomewide DNA methylation 
analysis. Nat Rev Genet 2010, 11(3):191-203. 
205. Singh H: Teeing up transcription on CpG islands. Cell 2009, 138(1):14-16. 
206. Feschotte C: Transposable elements and the evolution of regulatory 
networks. Nat Rev Genet 2008, 9(5):397-405. 
207. Jordan IK, Rogozin IB, Glazko GV, Koonin EV: Origin of a substantial 
fraction of human regulatory sequences from transposable elements. 
Trends Genet 2003, 19(2):68-72. 
208. Huda A, Jordan IK: Epigenetic regulation of Mammalian genomes by 
transposable elements. Ann N Y Acad Sci 2009, 1178:276-284. 
209. Slotkin RK, Martienssen R: Transposable elements and the epigenetic 
regulation of the genome. Nat Rev Genet 2007, 8(4):272-285. 
210. Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159. 
211. Consortium ICGS: Sequence and comparative analysis of the chicken 
genome provide unique perspectives on vertebrate evolution. Nature 2004, 
432(7018):695-716. 
212. Lee SH, Eldi P, Cho SY, Rangasamy D: Control of chicken CR1 
retrotransposons is independent of Dicer-mediated RNA interference 
pathway. BMC Biol 2009, 7:53. 
213. Liu HC, Kung HJ, Fulton JE, Morgan RW, Cheng HH: Growth hormone 
interacts with the Marek's disease virus SORF2 protein and is associated 
with disease resistance in chicken. Proc Natl Acad Sci U S A 2001, 
98(16):9203-9208. 
214. Duncan MC, Peifer M: Regulating polarity by directing traffic: Cdc42 
prevents adherens junctions from crumblin' aPart. J Cell Biol 2008, 
183(6):971-974. 
215. Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent 
bystander to major culprit. Nat Rev Cancer 2002, 2(4):301-310. 





Khondoker M, Dickinson P, Sing G, Rodriguez-Martin S et al: Host defense 
against viral infection involves interferon mediated down-regulation of 
sterol biosynthesis. PLoS Biol 2011, 9(3):e1000598. 
217. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat 
Rev Cancer 2011, 11(2):85-95. 
218. Lucas A, Dai E, Liu LY, Nation PN: Atherosclerosis in Marek's disease 
virus infected hypercholesterolemic roosters is reduced by HMGCoA 
reductase and ACE inhibitor therapy. Cardiovasc Res 1998, 38(1):237-
246. 
219. Fabricant CG, Fabricant J, Minick CR, Litrenta MM: Herpesvirus-induced 
atherosclerosis in chickens. Fed Proc 1983, 42(8):2476-2479. 
220. Fynan EF, Ewert DL, Block TM: Latency and reactivation of Marek's 
disease virus in B lymphocytes transformed by avian leukosis virus. J Gen 
Virol 1993, 74 ( Pt 10):2163-2170. 
221. Smith CA, Roeszler KN, Ohnesorg T, Cummins DM, Farlie PG, Doran TJ, 
Sinclair AH: The avian Z-linked gene DMRT1 is required for male sex 
determination in the chicken. Nature 2009, 461(7261):267-271. 
222. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin 
RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. 
Genes Dev 2002, 16(8):948-958. 
223. Rapp JC, Harvey AJ, Speksnijder GL, Hu W, Ivarie R: Biologically active 
human interferon alpha-2b produced in the egg white of transgenic hens. 
Transgenic Res 2003, 12(5):569-575. 
224. Bosselman RA, Hsu RY, Boggs T, Hu S, Bruszewski J, Ou S, Kozar L, 
Martin F, Green C, Jacobsen F et al: Germline transmission of exogenous 
genes in the chicken. Science 1989, 243(4890):533-535. 
225. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D: Germline transmission 
and tissue-specific expression of transgenes delivered by lentiviral 
vectors. Science 2002, 295(5556):868-872. 
226. Kim J, Kollhoff A, Bergmann A, Stubbs L: Methylation-sensitive binding of 
transcription factor YY1 to an insulator sequence within the paternally 
expressed imprinted gene, Peg3. Hum Mol Genet 2003, 12(3):233-245. 
227. Hodges E, Molaro A, Dos Santos CO, Thekkat P, Song Q, Uren PJ, Park J, 
Butler J, Rafii S, McCombie WR et al: Directional DNA methylation 
changes and complex intermediate states accompany lineage specificity in 
the adult hematopoietic compartment. Mol Cell 2011, 44(1):17-28. 
228. Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, Klug M, 
Dietmaier W, Thiede C, Holler E, Andreesen R et al: General transcription 
factor binding at CpG islands in normal cells correlates with resistance to 
de novo DNA methylation in cancer cells. Cancer Res 2010, 70(4):1398-
1407. 
229. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, 
Winget M, Yasui Y: Phases of biomarker development for early detection 
of cancer. J Natl Cancer Inst 2001, 93(14):1054-1061. 
230. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW: DNA 






231. Anglim PP, Alonzo TA, Laird-Offringa IA: DNA methylation-based 
biomarkers for early detection of non-small cell lung cancer: an update. 
Mol Cancer 2008, 7:81. 
 
 
